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ABSTRACT 
Antigens encountered via mucosal surfaces may specifically reduce systemic 
immune responses. Oral tolerance, the phenomenon of specific immunological 
unresponsiveness induced by feeding antigen has previously been demonstrated 
for food proteins such as ovalbumin (OVA) and target antigens in experimental 
models of autoimmune diseases. The inhalation of antigens has also been 
revealed as a potentially tolerogenic route. This thesis investigates mucosa! 
routes to induce immunological tolerance in two models. 1.) Oral tolerance to 
OVA, 2.) The effect of oral and intranasal administration of myelin basic protein 
(MBP) and MBP-peptides in a mouse model of experimental autoimmune 
encephalomyelitis (EAE). 
In the Balb / c mouse model of oral tolerance to OVA, feeding 20 mg OVA 
prior to priming with OVA or the major immunogenic, I-Ad-restricted peptide 
323-339 of OVA reduced specific in vitro lymphocyte proliferation in response to 
OVA or OVA 323-339 by 40-80 %. Transfer of spleen cells or serum from OVA-
fed donors under conditions previously shown to suppress delayed-type 
hypersensitivity responses in recipients, or oral administration of OVA 323-339 
alone could not substitute for direct feeding of whole OVA to achieve this effect. 
The inhibition of specific IgGl and IgG2a antibody levels argued against 
immune deviation towards T helper type 2 responses as a relevant mechanism in 
this model. 
In the H-2u mouse model of EAE, the dominant T cell response is directed to 
the acetylated N-terminal peptide Acl-9 or Acl-11 of MBP. Analogues of this 
peptide with alanine or tyrosine at position 4 bind to the I-Au MHC class II 
molecule with higher affinity than the original peptide with lysine at this 
position, with a hierarchy of affinity Acl-9 [4Y]>>[4A]>[4K]. In contrast to oral 
tolerance to OVA, there was no evidence for oral tolerance in the H-2u mouse 
model of EAE when either whole porcine MBP, mouse myelin, or Acl-11[4K] or 
[4A] were fed. Abrogation of in vitro T cell proliferation and EAE after oral 
administration of repeated high doses of the 4Y peptide showed, however, that 
in principal, encephalitogenic T cells could be targetted by peptide feeding. 
Unlike oral administration, a single intranasal 100 µg dose of Acl-9 (or Acl-
11) or the 4A and 4Y analogues inhibited EAE induced with Acl-9 alone or 
whole myelin, showing a positive correlation between peptide-I-Au affinity and 
the degree of protection. These data were consistent with a direct epitope-
specific mechanism favoured by high avidity T cell receptor-MHC class II-
peptide complexes, independently of (CDS+) T suppressor cells. Although 
inhalation of Acl-9 and its analogues also protected against whole myelin-
induced EAE, co-immunization experiments using Ac1-9 and the I-EU-restricted 
encephalitogenic peptide 35-47 of MBP provided no evidence for bystander 
suppression. Intranasally administered peptides could also downregulate the 
functions of encephalitogenic T cells after the induction of EAE, albeit in a yet 
unpredictable manner which appeared to depend on the state of T cell 
activation. 
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CHAPTERl 
Introduction 
1.1 SOME PRINCIPLES OF IMMUNE RESPONSES - AN 
OVERVIEW 
1.1.1 The Role Of The Immune System: Discriminating Between 
The Innocuous And The Detrimental 
All biological processes have evolved to secure the survival of the species and 
maintain the integrity of the individual. Organisms are constantly changing and 
reacting according to inherent patterns and in response to an environment that 
may be both hospitable and hostile. The cells and molecules of the immune 
system pay a major contribution to preserve an individual's integrity in the light 
of continuous internal changes and external challenges. 
The concept of individual integrity was put forward by Eli Metchnikoff from 
the embryologist's point of view, emphasizing the role of the phagocyte to 
"harmonize potentially discordant cellular elements during development" 
(Tauber, 1994). The protective role of phagocytes against pathogens was 
subsequently included in a concept of immunity encompassing both cellular and 
humoral elements. However, as discussed by Tauber, while Metchnikoff's 
concept emphasized integration, the terminology adapted in subsequent years 
stressed the confrontation between the individual and environmental pathogens 
culminating in "self-non self" discrimination, one of the most common phrases 
to characterize the immune system. 
Self-nonself discrimination accounts for the majority of components that 
immune responses should either spare or attack. However, many substances 
defy this strict categorisation. Some self proteins are only temporarily expressed 
and may appear as rare and foreign as non-self compounds from the immune 
system's point of view. Heterotrophic forms of life require the regular uptake of 
foreign matter without inflicting inflammatory reactions against dietary 
components. On the other hand, immune responses against malignant 
transformations of self are desirable. Therefore, to account for the dynamics of 
self, the interplay between non-self and self during metabolism and the 
occasional conversion from harmless self into malignant self, it is perhaps 
appropriate to describe the competence of the immune system more generally as 
being able to distinguish between innocuous and detrimental agents. 
1.1.2 Innate And Acquired Immunity 
The skin and mucosa! surfaces serve as physical barriers to block the entry of 
pathogens into the body. Mechanical and chemical factors such as cilial 
movement and bactericidal components of secreted body fluids contribute to 
this first line of defence. However, pathogens that manage to defy these 
obstacles and penetrate a host encounter the complex network of co-operating 
cells and molecules that constitute the immune system. Some 'innate" immune 
effector mechanisms combat infections without the requirement for specific 
induction. Phagocytes (polymorphonuclear neutrophils and macrophages), 
eosinophils and natural killer (NK) cells recognize common glycoprotein and 
glycolipid structures on the surface of bacteria, parasites or virally infected cells 
(reviewed in Sastry & Ezekowitz, 1993; Yokoyama, 1993). They destroy 
pathogens by a wide range of toxic (oxygen) metabolites, oxygen-independent 
bactericidal and bacteriostatic factors and proteolytic enzymes. Most of these 
factors are stored in granules ready to be released, either intracellularly upon 
contact with phagocytosed microbes or extracellularly as a defence against 
larger parasites. NK cells may initiate programmed cell death (apoptosis) of 
virally infected cells or destroy such cells by membranolysis following the 
formation of transmembrane pores lined with NK-derived perforin molecules 
(reviewed in Berke, 1994) 
The complement system provides an important humoral defence mechanism. 
This names a series of serum proteins organized as an enzyme cascade where 
one reaction is catalyzed by the product of the preceding reaction allowing for a 
rapid and highly amplified :response to an initial trigger stimulus. The 
complement pathway can be activated directly by some microbes. (alternative 
pathway) or mediated by antibodies (classical pathway). Both routes merge after 
the formation of the central molecule C3b. Subsequent products of this pathway 
(C5-C9) associate with membrane-bound C3b and form a transmembrane 
channel through the lipid bilayer, frequently leading to cell lysis (reviewed in 
Tomlinson, 1993). 
Effector mechanisms of innate immunity follow the same reaction patterns 
with every infection. In contrast, for T and B lymphocytes, a first contact with an 
infectious agent (primary response) induces significant physiological changes 
which enable these lymphocytes to respond much faster to a subsequent 
challenge with the same agent (secondary or memory response). This concept of 
acquired memory requires lymphocytes to specifically recognize characteristic 
features beyond those common hallmarks of pathogens that initiate innate 
immune responses. These individual units of specific lymphocyte recognition, 
the antigens, bind to receptors exposed on the surface of T and B lymphocytes. 
They are unique to each lymphocyte (or each clone derived from one 
lymphocyte) with each receptor being specific for a small part of a particular 
antigen- the antigenic determinant or epitope. If different antigens share very 
similar epitopes, these may be recognized by the same antigen receptor: this 
receptor is then cross-reactive with two or more antigens. 
Although T and B cells fulfil different functions, their membrane-bound 
antigen receptors are similarly organized. They are composed of relatively 
constant parts forming the overall structure of the molecule and highly variable 
regions that mediate antigen-specific ligation. Each type of receptor is closely 
associated with several peptide chains that bear more prominent cytoplasmic 
domains and link the message of ligand-receptor interactions to intracellular 
biochemical signalling cascades. These receptor-mediated signals are critical for 
the development of immature and the functional state of mature lymphocytes 
(reviewed in Borst et al, 1993). 
1.1.3 Antigen Recognition By B Cells 
The antigen receptor of B lymphocytes consists of membrane bound 
immunoglobulin (mlg) and noncovalently associated transmembrane chains (lg-
a, lg-~) that together with the transmembrane part of mlg mediate signal 
transduction (reviewed in Cambier et al, 1994). Cognate receptor ligation selects 
a B cell to proliferate, differentiate and to secrete soluble forms of 
immunoglobulin (slg, antibodies) of the same epitope specificity. 
The basic structure of immunoglobulins is a four-peptide unit composed of 
two identical heavy chains and two identical light chains held together by 
interchain disulphide bonds. Each peptide chain is compactly folded into 
characteristic globular (lg) domains. The amino-termini of both heavy and light 
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chains contribute to the formation of the antigen binding site. They display 
considerable sequence variability whereas the remaining parts of the chains are 
relatively constant. Within each variable part some residues display even greater 
variability and define hypervariable regions which determine the epitope 
specificity of an immunoglobulin molecule. 
Binding of an antigen to the combining site is mediated by the formation of 
multiple non-covalent interactions which are critically dependent on short 
distance. This requirement is met when the antigen fits tightly into the 
combining site. The affinity of antigen-antibody binding is a means to express 
how well an antigen-antibody fit is achieved, that is how specific this interaction 
is (reviewed in Amzel & Poljak, 1979). 
1.1.4 Antigen Recognition By T Cells 
The T cell receptor (TCR) is a non-covalently formed heterodimer consisting 
of one ex. and one ~ chain (or y and 8 chains for some T cells). These chains 
contain a short cytoplasmic tail, a transmembrane segment and towards the 
extracellular space one lg-like and one variable domain. The variable domains of 
both TCR ex. and ~ chains together contribute to the antigen combining site. The 
TCR forms a complex with a number of small proteins of prominent cytoplasmic 
regions involved in signal transduction. These are chains of the CD3 complex 
(y,8,e) and homodimers/heterodimers of ~ and ~11, respectively (reviewed in 
Janeway, 1993). 
In contrast to immunoglobulins that can bind to epitopes as part of the native 
three-dimensional structure of the intact antigen, the TCR recognizes a 
bimolecular complex composed of one small antigenic peptide bound to a 
molecule of the major histocompatibility complex (MHC) on the surface of an 
antigen presenting cell (APC). APC's (dendritic cells, marophages, B cells) 
process antigenic peptides intracellularly either from exogenous and membrane 
bound proteins or from endogenously synthesized and cytosolic proteins. Along 
this processing pathway antigenic peptide associates with MHC molecules upon 
which the MHC-peptide complex is transported to and expressed on the cell 
surface. Since the association with peptide stabilizes the MHC molecule, most 
surface MHC products bind intracellularly processed peptide (Sadegh-Nasseri & 
Germain, 1991). However, there are also "empty" MHC molecules on the cell 
surface w hich allow for binding of naturally occurring extracellular or 
experimentally added pep tides (Germain & Hendrix, 1991). Furthermore, 
although many peptides form highly stable MHC complexes, others bind to 
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products of the MHC with lower affinity and may be replaced by free exogenous 
peptide at the cell surface (Lanzavecchia, Reid, & Watts, 1992; Fairchild et al, 
1993). 
There are two classes of MHC molecules. Class I MHC proteins are encoded 
by three separate genetic loci, H-2K, H-2D and H-2L in the mouse and HLA-A, 
HLA-B, and HLA-C in humans (reviewed in Guillemot et al, 1988). Each of these 
loci encodes a single polypeptide chain (the heavy chain) which, when inserted 
into the plasma membrane displays a short carboxy-terminal cytoplasmic tail 
followed by the transmembrane segment and a large extracellular part which is 
folded into three globular domains (al-a3). They are non-covalently associated 
with a small non-MHC encoded protein, ~2 microglobulin whose structure, like 
the a3 domain, resembles that of a single immunoglobulin domain. 
The class II MHC proteins are heterodimers composed of two non-covalently 
bonded polypeptide chains, a and ~' usually expressed from the same gene 
locus, either H2-A or H2-E (in mice) for which the products are referred to as I-A 
and I-E, respectively. In humans the equivalent loci are HLA- DP, DQ, and DR 
(reviewed in Guillemot et al, 1988). The large extracellular part of each a and~ 
chain is folded into two globular domains, with the membrane proximal a2 and 
~2 domains displaying the characteristic immunoglobulin fold. 
In spite of their different subunit composition, the four globular extracellular 
domains characteristic for both class I and class II MHC protein complexes form 
homologous three-dimensional structures. Accordingly, both classes of MHC 
molecules bind peptides in a principally similar fashion. The two most 
membrane distal domains, al/a2 for class I and al /~1 for class II molecules 
contribute to the peptide binding groove composed of strands of antiparallel ~-
sheets forming the floor, and antiparallel a- helical regions as the sides. For 
class I molecules the boundaries at both ends of the groove restrict the length of 
peptides that can associate with class I to eight or nine amino acids, whereas the 
more open""ended sites of class II products permit binding of longer peptides, 
commonly of 13-17 amino acids. The actual specificity of peptide binding, 
similar to antigen-antibody interactions, is determined by non-covalent bonds 
mediated by charged groups, hydrogen bo~ds, Van-der \vaals forces and 
hydrophobic interactions. However, binding of peptide to MHC molecules is far 
less stringent than antigen recognition by specific B-and T cell receptors. A 
limited number of highly polymorphic residues within the binding groove 
determines the nature of peptides that can form thermodynamically favourable 
and hence stable interactions with one particular MHC allele. Certain peptide 
motifs specified by one or more key residues determine the physicochemical 
properties ( size, charge, hydrophobicity) that are best suited to interact with 
prominent polymorphic residues characteristic for one particular MHC allele 
(reviewed in Rotzschke & Falk, 1994). 
Generally, peptides that bind to class I or class II molecules are derived from 
different sources of proteins. For class I, these are usually endosomal self-, viral-, 
or cytosolic proteins. Binding of peptides to MHC class I molecules occurs in the 
endoplasmic reticulum (ER). The nascent polypeptide chain of endogenous self 
or viral proteins may be directly inserted into the ER during proteins synthesis. 
Alternatively, a complex of proteases, the proteasome, generates peptides from 
proteins in the cytosol (reviewed in Goldberg, 1992) followed by peptide 
targeting and transport into the ER by transporter molecules (reviewed in 
Momburg, Neefjes, & Hammerling, 1994). At this early stage of intracellular 
MHC molecule trafficking, binding of peptides to MHC class II products is 
prevented by the invariant chain, a polypeptide that closely binds to and thereby 
stabilizes class II molecules in the ER and Golgi compartments. While post-Golgi 
vesicles containing MHC class I-peptide complexes are directly transported to 
the cell surface, vesicles enclosing free class II molecules fuse with acidic 
endosomal compartments most of which will include free peptides, lysosomal 
degradation products of previously endocytosed extracellular or membrane-
bound proteins. The low pH of this compartment favours proteolytic 
degradation of the invariant chain from the a~ class II heterodimer and its 
exchange with endosomal peptides, which become subsequently expressed at 
the cell surface, available for T cell recognition (reviewed in Germain & 
Margulies, 1993). Therefore, in contrast to antigen recognition by B cells which is 
sufficiently characterized by the bimolecular antigen-immunoglobulin complex, 
cognate T cell-antigen interactions are based on the trimolecular complex of 
TCR-MHC-peptide depending on two variables: the affinity of peptide for the 
MHC (class I or II) molecule and the affinity of the TCR for the MHC-peptide 
complex. 
There a,re, however, exceptions to this rule of TCR recognition of 
'conventional' antigens. Superantigens, for example endogenous mouse 
mammary tumour virus and some exogenous bacterial toxins may associate 
directly with extracellular MHC domains rather than being processed and 
presented within the peptide binding groove. As a consequence, the mode of 
antigen recognition by the TCR is also different and largely governed by the 
variable part of the ~ chain (V~) alone (reviewed in Marrack et al, 1993). Since 
many T cells specific for a variety of different conventional antigens may 
nevertheless share the same V~, superantigens can mediate polyclonal T cell-
antigen interactions, in sharp contrast to generally uniclonal T cell recognition of 
individual types of MHC-peptide complexes. 
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1.1.5 Developing And Co-ordinating Immune Responses 
1.1.5 i Generation of antigen-receptor diversity 
The problem of generating specific recognition sites for a virtually unlimited 
number of epitopes from a limited number of antigen receptor genes and their 
alleles is solved by the unique mechanism of gene rearrangement at early stages 
of Band T cell development (reviewed in Blackwell & Alt, 1988; Davis, 1988). 
Multiple clusters of gene segments code for the variable (V) and constant (C) 
regions of antigen receptors. These genes enclose additional segments encoding 
the joining (J) region and, in the case of the immunoglobulin heavy chains and 
the TCR ~ chain also diversity (D) regions. Within the embryonic germ line DNA 
of B and T cell precursors these gene segments are separated by long intervening 
nucleotide sequences which become enzymatically excised when a V gene is 
translocated to lie next to a J (or previously combined JD) segment, generating 
VJ-intron-C or VJD-intron-C of B or T cell DNA. This VJ or VJD segment will 
determine the epitope specificity of the successfully rearranged and transcribed 
antigen-receptor gene product. The intron between VJ(D) and C is excised prior 
to transcription of the functional antigen-receptor molecule. 
Theoretically, the number of different antigen-receptors that can be generated 
by this mechanism is given by the product of the number of V, J, D, and C 
segments. Although a diploid set of these genes is available, after the successful 
rearrangement of one set of genes, the corresponding allelic genomic sections are 
inactivated (allelic exclusion), thereby ensuring unique antigen specificity for 
each individual lymphocyte. However, at the nucleotide level, additional 
diversity can be achieved by somatic mutation, some variation in the exact site of 
the V-J-D _ join('hot spots'), and somatic hypermutation as a peculiar 
phenomenon during the maturation of a B cell response. Further diversity of the 
TCR repertoire arises from the insertion of nucleotides at the N region of the D 
and J segments (reviewed in Blackwell & Alt, 1988; Davies, 1988). At the protein 
level, the antigen-receptor monomers may form different combinations of the 
complete multimeric antigen-receptor. 
1.1.5 ii The role of APC's and coreceptors 
While the antigen receptors confer specificity a multitude of other surface 
molecules expressed on lymphocytes and APC's are crucially important for the 
development and regulation of lymphocytes. Receptor-coreceptor interactions 
between these cells not only increase the degree of physical intercellular 
adhesion; their cytoplasmic domains are often integral parts of signalling 
pathways, thereby regulating intracellular biochemical events. 
The variable capacity of different types of APC's to induce T cell activation is 
largely based on their ability to provide costimulatory signals mediated by such 
coreceptors. Among those, the receptor/ counterreceptor pair B7 / CD28 (or 
B7 /CTLA-4) provides a critical costimulatory signal for the activation of naive 
(antigen-inexperienced) T cells (reviewed in Schwartz, 1992). Furthermore, the 
functions of MHC molecules extend beyond mere peptide presentation. Their 
cytoplasmic tails are involved in intracellular signalling events that induce and 
upregulate the expression of costimulatory molecules (reviewed in Wade et al, 
1993). Thanks to their high levels of surface MHC class II and their ability to 
constitutively express B7, dendritic cells (DC) are the primary APC for the 
activation of naive T cells. Other APC's such as macrophages can be induced by 
IFNy to upregulate levels of class II MHC and to express B7. Primed B cells also 
function as APC and can provide costimulation upon activation. Their antigen 
receptor enables them to take up antigen specifically and therefore more 
efficiently than other types of APC's. In turn, coreceptor signals and T cell-
derived lymphokines (T cell "help") govern further B cell functions . Apart from 
B7 /CD28, a whole range of other surface molecules such as LFA-1/ICAM-1, 
CD40/CD40L, CD2/CD58 or CD59 and others contribute to intercellular 
adhesion and intracellular signalling (reviewed in Clark & Ledbetter, 1994). 
1.1.5 iii Intracellular signalling events 
The coreceptors that become most closely associated with the TCR/CD3-
MHC-peptide complex are CD4 and CD8 which are alternatively expressed on 
the surfac~ of mature T lymphocytes. CD8 associates with MHC class I 
molecules whereas CD4 binds to MHC class II molecules. These interactions 
therefore specify two classes of T cells with respect to the source of antigenic 
peptides they encounter: CD4-positive T cells generally are directed to class II 
MHC molecules in combination with peptides captured in acidic endosomal 
compartments (although there may be exceptions), whereas T lymphocytes 
expressing the CD8 receptor are destined to encounter peptides largely derived 
from endogenous- or cytosolic proteins. 
T cell activation initiates at least three inter-linked second messenger 
pathways that are tightly controlled by Ca2+_ dependent reactions and 
phosphorylation / dephosphorylation of certain key regulatory enzymes. These 
control mechanisms constitute complex positive and negative feedback loops 
ensuring appropriate and prompt reactions by either rapid signal amplification 
or downregulation. Tyrosine kinases of the src and 70kd family which are 
associated with the cytoplasmic domains of both CD4 and CD8, and chains of 
the TCR/CD3 complex respectively, act coordinately to recruit by tyrosine 
phosphorylation a complex of molecules that may specifically interact with the 
phophorylated form of the cytoplasmic receptor domains and couple the TCR to 
downstream intracellular events. Although the precise sequence of subsequent 
events is yet poorly defined they involve further kinases and phosphatases 
which are themselves regulated by phosphorylation and/ or Ca2+ (reviewed in 
Janeway, 1993). Recent evidence suggests that the src tyrosine kinases which 
initiate this cascade are themselves subject to regulation by CD45, an abundant 
leukocyte surface protein with tyrosine phosphatase activity (reviewed in 
Trowbridge & Thomas, 1994). 
Phospholipase Cyl is another key enzyme triggering early events of T cell 
activation. It may bind to the tyrosine-phosphorylated cytoplasmic domains of 
the TCR upon which it is itself phosphorylated, thereby increasing its affinity for 
its substrate phosphatidyl inositol-bisphosphate (PIP2). Breakdown of PIP2 
generates diacylglycerol (DAG) and inositol-triphosphate (IP3), two central 
mediators of subsequent intracellular signalling. IP3 releases Ca2+ from 
intracellular stores. Together, DAG and Ca2+ activate protein kinase C (PKC) 
which in turn mediates the activation and translocation of nuclear factors. The 
central role of Ca2+ in the regulation of both PKC and src/70kd-initiated 
signalling pathways demands a tight control over intracellular calcium levels. 
This is largely achieved by the metabolism of IP3. Removal of IP3 not only 
prevents further release of Ca2+ from intracellular stores but, furthermore, other 
inositol-phosphate metabolites such as IP 4 are actively engaged in replenishing 
these stores (reviewed in Berridge, 1993). 
In addition to the downregulation of positive signals, TCR ligation also 
initiates negative regulation mediated by the serine-threonine protein kinase 
cAKl, an enzyme that is functionally dependent on cyclic adenosine 
monophosphate (cAMP). cAKl co-localizes with the TCR/CD3 complex upon 
TCR ligation and may establish an inhibitory signalling pathway that interferes 
with protein phosphorylation by TCR/CD3-associated tyrosine kinases 
(Skalhegg et al, 1994). 
Among the first proteins expressed as a result T cell signalling are the 
interleukin-2 receptor and interleukin-2 (IL-2). IL-2 is a crucial autocrine growth 
factor for the proliferation and differentiation of all T lymphocytes. However, 
engagement of the TCR/CD4 or CD8 complex with peptide-MHC alone is not 
sufficient to initiate T cell activation. As mentioned above, synergy with 
costimulatory molecules is required for IL-2 production in a primary immune 
response. 
The events following specific B cell receptor (BCR) ligation appear to include 
very similar mechanisms outlined above for TCR ligation-mediated intracellular 
signalling cascades (reviewed in Borst, 1993; Cambier et al, 1994). Homologous 
to signal transduction via TCR-CD3 and CD4/CD8, the Iga and Igp chains 
together with coreceptors including CD22 and CD19/CD21 mediate proximal 
activation of protein tyrosine kinases such as src and lyn, GTP-binding proteins 
(p2iras), more distal serine/threonine kinases all which by various diverging 
biochemical cascades serve to convert the message of BCR ligation into gene 
transcription. 
1.1.5 iv Regulation of effector functions 
The variable nature of pathogenic insults requires selective acquisition of 
those effector functions that exactly meet the needs of the infected organism to 
successfully combat the intruder. There is no general rule to attribute a 
particular immune response to one particular pathogen. Rather, the route of 
entry, the tissue or cell type that become infected and whether or not the 
immune system has encountered the pathogen before, together with the actual 
antigenic "make up" of the infectious agent, determine the nature of the immune 
response. However, for immune responses against any given infection, it is often 
appropriate to be dominated by either antibody- or cell mediated mechanisms. 
At the effector stage, many features of innate and acquired immunity converge. 
The effector functions of antibody molecules are mediated by the constant Fe 
("fraction crystalizable")domains of the heavy chain. These enable antigen-
antibody complexes to activate complement by the "classical" pathway thereby 
attacking infectious agents that fail to activate complement directly. The Fe 
portion also specifically binds to Fe receptors on the surface of effector cells thus 
targeting and enhancing phagocytosis of (antibody-complexed) bacteria. 
Furthermore, antibodies that bind to pathogen-derived antigens expressed on 
the surface of infected cells may trigger cytotoxic mechanisms by which effector 
cells are targeted to the antibody-coated cell via their Fe receptors in order to kill 
the target directly (antibody dependent cell mediated cytotoxicity, ADCC). 
T cell mediated immune responses are involved when infectious particles 
gain access to MHC class I and/or class II processing pathways. Cytotoxic cells 
(Tc or CTL) specific for these MHC-peptide complexes may destroy the infected 
target cell directly by two mechanisms that are also characteristic of NK cells: by 
10 
necrosis (membranolysis) probably mediated by perforin lined transmembrane 
pores leading to osmotic lysis or by apoptosis ( reviewed in Berke, 1994). Tc cells 
are usually CDS-positive and MHC class I-restricted. However, CD4-positive T 
cells can also acquire a cytotoxic phenotype. Another mechanism mediated by 
CD4 + T cells is delayed type hypersensitivity (DTH). Here, the interaction of 
APCs (presumably mainly or exclusively macrophages) presenting antigen to 
primed CD4+ T cells culminates in an inflammatory response: Cytokines are 
released that further attract and activate macrophages to release lysosomal 
enzymes and reactive oxygen metabolites. 
Most of these effector functions require primed lymphocytes, those that have 
already encountered antigen before (memory cells). A first confrontation with 
(T-dependent) antigens induces CD4+ T helper (TH) cells to control the 
development of subsequent immune responses. T helper functions are mainly 
governed by cytokines. This has been particularly well described for the murine 
immune system. Here, two populations of TH cells, THl and TH2 control the 
nature of the immune response by secreting characteristic and mutually 
antagonistic sets of cytokines. THl cells produce IL-2 and IFNy whereas IL-4, IL-
5, IL-6 and IL-10 are characteristic of TH2 cells. Both types of TH cells can 
produce IL-3, tumour necrosis factor a. (TNFa.) and granular macrophage colony 
stimulating factor (GM-CSF). This distinction based on lymphokines 
corresponds to distinct functional phenotypes (reviewed in Mosmann & 
Coffman, 1989). THl cells appear to mediate DTH reactions and activation of 
CTL whereas TH2 type' lymphokines favour antibody-mediated effector 
mechanisms. 
With respect to T helper functions for B cells these lymphokines control the 
mechanism by which the VDJ segment of the immunoglobulin heavy chain is 
linked to one of several constant region genes for the expression of the soluble 
immunoglobulin molecule (class switching). While the rearranged VDJ segment 
define antigen specificity, the constant regions mediate different effector 
functions and define the immunoglobulin isotype. Different isotypes vary in 
their ability for ADCC, complement fixation, and they may selectively bind to 
different types of Fe receptors (reviewed in Greenwood & Clark, 1993; Morrison, 
Canfield & Tao, 1993). The process of class switching thus allows the same 
antigen specificity to be combined with various different effector functions to 
adapt to changing host requirements as an immune response evolves. For 
instance, in the mouse, IL-4 (from TH2 cells) selectively induces switching to the 
£ and yl loci whereas THl type IFNy inhibits IL-4 induced switching and causes 
switching to "(2.a . IgGl and IgE levels become elevated during nematode 
infections. They bind well to Fe receptors on monocytes and mast cells and are 
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therefore efficient mediators of ADCC (reviewed in Snapper & Mond, 1993). 
Some bacterial antigens such as lipopolysaccharide (LPS) may crosslink mig 
non-specifically and activate B cells independently of T cell help. However, T-
independent antigens usually only trigger IgM production and lack the ability to 
induce class switching or affinity maturation of an antibody response. 
THl and TH2 cells do not constitute fixed pre-formed sets of lymphocytes, 
but appear to emerge from a common, relatively unspecialized THO phenotype. 
The differentiation into either THl or TH2 cells appears to depend on the 
cytokine environment in which a T helper cell first encounters antigen. In the 
presence of IL-4 T cells also produce IL-4 upon restimulation whereas the 
development into THl effectors is inhibited by IL-4. Conversely, in the absence 
of IL-4, an IFNy-producing T cell phenotype develops (reviewed in Seder & 
Paul, 1994). A certain cytokine environment is often created by the infectious 
agent itself and effector cells of innate immunity. IFNy-secreting NK cells and 
IL-12 produced by Listeria-infected macrophages synergized to induce a THl-
type response against bacterial infection (Hsieh et al, 1993). Experimental 
Leishmania major infection in mice induceddistinct T cell functions 
corresponding to either a THl or a TH2 phenotype which could be correlated 
with either recovery and survival or a lethal infection, respectively (Scott et al, 
1988; Heinzel et al, 1989). In contrast, immunity against helminth worms such as 
schistosomes was dominated by IgE-mediated ADCC. Here, one egg 
component, a glycoprotein appeared to induce B cells to proliferate and to 
secrete IL-10 (Velupillai & Harn, 1994). 
1.1.6 The Need For Immunological Tolerance 
Most effector functions culminate in inflammatory responses which, besides 
destroying the pathogen, often also cause some local tissue injury. Since effector 
mechanisms are tightly controlled and rapidly downregulated after the 
successful removal of the pathogenic insult, this is usually an acceptable price to 
pay. However, immune responses can only b~ constructive if the destructive 
forces are exclusively directed against hazardous agents. Since the vast majority 
of MHC molecules contain peptides derived from the organism's own proteins 
(self-peptides) this seems not a trivial problem. In order to meet the requirement 
for selective immunity, T lymphocytes need to interpret TCR-MHC-peptide 
ligation in different ways so as to direct effector functions against detrimental 
while tolerating innocuous antigens. 
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Immunological tolerance can be induced in both B and T lymphocytes. 
However, for all T-dependent antigens (to which all antigens studied in this 
thesis belong), tolerance in the T cell compartment will also abrogate B cell-
mediated responses to these antigens. The next section discusses various 
strategies by which T cell tolerance is achieved. 
1.2 IMMUNOLOGICAL TOLERANCE 
1.2.1 Modes Of Tolerance Induction 
One way to avoid destructive immune reactions against innocuous agents is 
the elimination of T lymphocytes bearing specific receptors for such antigens. 
Alternatively, T cells may be rendered unable to convert the message of cognate 
TCR-peptide- MHC ligation into activating biochemical signals; they are said to 
be anergic. Among mature lymphocytes, regulatory networks in which some 
(suppressor) T lymphocytes modulate the functions of other T cells also play a 
significant role. 
All three mechanisms, deletion ,anergy and suppression have been 
demonstrated for the control of mature lymphocytes in the periphery. The 
education of immature lymphocytes follows a rigorous regime mainly leading to 
deletion of T lymphocyte precursors that fail to withstand certain selective 
pressures. The central organ for the education of immature T lymphocytes is the 
thymus. To account for the different developmental stages of T lymphocytes at 
the time of tolerance induction and the central role of the thymus, rules that 
govern T cell tolerance are conveniently discussed as central (thymic) and 
peripheral tolerance. 
1.2.2 Central Tolerance 
Early T lymphocyte precursors that enter the thymus express neither TCR 
nor CD4/CD8. As they traverse the thymus they either die or differentiate under 
various selective pressures (reviewed in Robey & Fowlkes, 1994). Thymocytes 
develop into early double positive cells with low levels of TCR, at which stage 
they are positively selected for their ability to bind to self-MHC-peptide 
complexes (MHC restriction), while all other thymocytes are programmed to die. 
Furthermore, T cells commit themselves to one lineage defined by the CD4 and 
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CDS coreceptors. Consequently, T cells that bind to peptide-MHC class I 
complexes only express CDS and, conversely, specific interactions of the TCR 
with MHC class II and peptide are associated with surface expression of CD4. 
During the subsequent stage of negative selection a high proportion of 
lymphocytes is deleted upon cognate MHC-peptide interactions. 
Negative selection in the thymus eliminates a high proportion of self-reactive 
T lymphocytes and therefore pays a major contribution to self tolerance. 
However, most self and nonself proteins are too similar in sequence to allow for 
a self-nonself discrimination based on qualitative differences between proteins 
by either APC's or T cells. Rather, the nature of peptides that can be processed 
and presented is determined by constraints imposed by the MHC peptide 
binding groove, protease specificities and (for class I molecules) transporter 
molecules (Driscoll et al, 1993; Powis et al, 1992). Therefore, self-reactive T cells 
are not negatively selected for the recognition of "self" as a qualitative entity per 
se but because they do not normally encounter "nonself" in the neonatal thymus. 
Or, to phrase this differently: because the majority of innocuous antigens are 
indeed self proteins, the thymus as a specialized organ of densely packed 
complexes of self MHC molecules and representative self peptides guarantees 
the deletion of those self-reactive immature T cells which, as mature T cells in 
the periphery could be expected to induce fatal autoimmune responses. 
The apparent paradox as to how recognition of self_ MHC-self peptide 
complexes direct T cell survival during positive selection and at later stages 
induce programmed cell death (apoptosis) has been an enigma for a long time. 
Clearly, two requirements for thymocyte selection have to be met. 1). The 
neonatal thymus expresses only self peptides. Obviously, however, the deletion 
of all self-reactive T cells would thwart the purpose of the immune system. 
Therefore, negative selection should only delete thymocytes with specificity for 
those self-peptides that could potentially induce detrimental T cell-mediated 
reactions in the periphery. 2). Although T cells can only be positively selected by 
self peptides, they need to recognize pathogenic antigens not previously 
expressed in the thymus. This requires positively selected T lymphocytes with 
specificity for "self" to be sufficiently cross-reactive with "nonself". Or- more 
pointedly- in order to combat pathogens while sparing innocuous self, T cells 
have to respond to certain peripheral antigens with considerably greater 
efficiency than to those antigens that they were originally selected for. 
To explain the paradox that self MHC-self peptide complexes induce both 
positive and negative selection, several mechanisms have been proposed. 
Different thymic tissues and types of APC were suspected to selectively mediate 
either positive or negative selection. However, numerous studies demonstrated 
14 
that thymocyte selection was not crucially dependent on intrinsic properties of 
different types of APC's. When antigen presentation by endogenous thymic 
tissue was abrogated, different lines of fibroblasts could sufficiently reconstitute 
positive selection, both with respect to MHC restriction and peptide-specific 
selection (reviewed in Pawlowski & Staerz, 1994). It also became clear that APC 
from many different sources including professional peripheral APC's could 
induce deletion of maturing T lymphocytes (Matzinger & Guerder, 1989). 
Furthermore, thymus grafting experiments with chimeric recipients suggested 
that , although different thymic tissues might display and therefore induce 
tolerance to different peptides, there was no evidence for one type of thymic 
tissue being able to positively but not negatively select (Bonomo & Matzinger, 
1993). 
The evidence against the significance of distinct intrinsic properties of APC' s 
in thymocyte selection lead to the conclusion that T lymphocytes themselves 
determine the outcome of TCR ligation with peptide-MHC complexes. These 
models propose that positive and negative selection can be sufficiently explained 
solely on the basis of different avidity interactions between maturing T 
lymphocytes and thymic APC's. Cognate, yet low avidity ligation would rescue 
thymocytes from apoptosis and enable the progress of development. 
Subsequently, T cells capable of forming high avidity interactions would be 
deleted (Pircher et al, 1991). The overall avidity of T cell-APC interactions is a 
function of both ligand-receptor affinities and concentrations. If the avidity 
model were valid, then manipulating any of these variables should influence the 
outcome of thymic selection. 
Several recent reports are consistent with the avidity model of thymocyte 
maturation. In these studies the differentiation of thymocytes bearing transgenic 
TCR specific for a model peptide was monitored in fetal thymic organ cultures. 
The sensitivity of thymocyte responses to exogenous peptides was sufficiently 
increased by using mutants with defects in MHC complex formation with 
endogenous peptides, either due to ~2M or peptide transporter (TAPl) 
deficiencies. With these methods it was possible to demonstrate that different 
concentrations of the same peptide (1Q-6M versus 1Q-12M) could induce either 
negative or positive selection with ~2M- APC's (Sebzda et al, 1994). When 
peptide was added to TAP1+ and TAP1- cultures, negative selection required 
higher peptide concentrations with TAP- than with TAP+ APC's (Ashton-
Rickardt et al, 1994). Essentially the same message arose from experiments with 
another peptide in ~2M- versus ~2M+ cultures (Hogquist et al, 1994). These 
findings suggested that the summations of TCR-MHC-peptide interactions 
determine the outcome of T cell differentiation in agreement with the avidity 
model. Another report proposed that the expression of coreceptors that 
contribute to the overall T cell- APC avidity may also determine the outcome of 
T cell selection. An increase in the surface expression of CD8 induced negative 
selection while moderate ·, to low levels of surface CD8 allowed for positive 
selection of T cells specific for the same peptide (Robey et al, 1992). 
1.2.3 Properties Of Peripheral T Lymphocytes 
The evidence in favour of the avidity model for thymic selection allows one 
to predict the properties of T cells that escape thymic deletion and are released 
into the periphery. Generally, they can be expected to form low avidity TCR-self 
MHC-self peptide interactions, either due to low intrinsic ligand-receptor 
affinities or because the concentrations of interacting molecules are low, in 
particular the concentration of peptides available for presentation. 
1.2.3 i Dominant, subdominant, and cryptic epitopes 
The rules that govern antigen handling by APC's restrict the number of 
peptides that can be processed and presented. In consequence, these peptides 
dominate T cell responsesto any given antigen. Other peptides may also be 
presented, albeit less efficiently. These constitute minor or subdominant 
antigenic determinants. In more exteme cases, antigenic peptides are presented 
with such low efficiency that T cell responses to these cryptic epitopes are 
virtually undetectable upon challenge with the intact antigen except at very high 
concentrations. Experimentally, a hierarchy of dominance among several 
epitopes can be assessed by priming and restimulating T lymphocytes with the 
whole protein or synthetic peptides representing different regions of the 
complete sequence. If peptide-primed T cells can be restimulated with the intact 
antigen, then this peptide necessarily contains at least one of the naturally 
processed epitopes. Cryptic peptides may elicit vigorous T cell responses to 
themselves but cannot be recalled after priming or restimulation with the intact 
protein (reviewed in Ametani et al, 1989). The ability to elicit strong immune 
responses to cryptic and minor epitopes with these peptides alone also suggests 
that a hierarchy of dominance among epitopes is determined by the APC rather 
than the lack of specific TCRs. The avidity model of thymic T cell differentiation 
therefore predicts that clonal deletion eliminates self-reactive T cells specific for 
dominant epitopes and permits the maturation of T cells specific for minor or 
cryptic self epitopes. Before the avidity model had gained further support, this 
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idea was formulated as a "threshold escape hypothesis" by which autoreactive T 
cells specific for dominant self epitopes would be deleted while allowing the 
escape of T cells specific for minor or cryptic epitopes (Gammon, Sercarz & 
Benichou, 1991). 
1.2.3 ii Low affinity peptides 
Epitope subdominance as defined above is not a prerequisite for the escape 
from central tolerance induction. In a mouse model of an experimental 
autoimmune demyelinating disease (which is also the subject of this thesis) the 
dominant peripheral T cell response is directed against a peptide of mouse 
myelin basic protein that forms extremely unstable complexes with its specific 
MHC class II restriction element. The authors propose that the very low affinity 
interactions between peptide and MHC molecules prevent thymic deletion 
(Fairchild et al, 1993). Here, the "threshold escape" is defined by the low affinity 
of ligand- MHC interactions rather than by the low concentrations of cryptic or 
subdominant peptide ligands. However, both cases amount to the same net 
result, namely low concentrations of TCR-MHC-peptide complexes at any given 
time thereby reducing the overall avidity below a critical threshold for thymic 
deletion. 
1.2.4 Peripheral Tolerance 
1.2.4 i Positive correlation between epitope dominance and peripheral 
tolerance 
The existence of peripheral peptides which were not available for thymic 
presentation requires that immunological tolerance can also be induced in 
mature thymic emigrants. Peripheral tolerance is established and maintained by 
various (not mutually exclusive) mechanisms such as deletion, anergy, and 
suppression depending on the model and experimental conditions. For some 
phenomena of peripheral tolerance that are sufficiently explained on the basis of 
direct T cell-APC interactions (i.e. without the need for suppressor cells), there 
appears to be a parallel with central tolerance. Adult mice rendered tolerant to 
hen egg lysozyme (HEL) failed to respond to whole HEL or immunodominant 
HEL peptides, while T cell activation with subdominant epitopes was still 
possible. These findings suggested that those epitopes that dominated T cell 
activation were also dominant in tolerance induction. Epitopes that failed to 
activate T cells efficiently would also be poor tolerogens (Gammon & Sercarz, 
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1989). A transgenic mouse model of endogenously expressed HEL confirmed 
these observations that central and peripheral tolerance were more easily 
achieved with the dominant HEL epitope. However, within the hierarchy of 
dominance of three HEL peptides (108-116>>1-18>74-96), tolerance to the 
subdominant epitopes was also observed in mice expressing high serum levels 
of endogenous HEL. The positive correlation between epitope dominance and 
tolerogenicity on the one hand and levels of peripheral HEL required to enable 
the tolerogenicity of subdominant epitopes on the other hand suggested that the 
actual number of specific peptide-MHC complexes displayed on APC was 
decisive (Cibotti et al, 1992). It is therefore conceivable that high avidity TCR-
MHC-peptide interactions also determine peripheral tolerance in some models. 
In these studies T cell tolerance to HEL was assessed by the ability of primed 
lymphocytes to mount specific proliferative responses in vitro. This method 
allowed the analysis of the relative significance of individual epitopes in detail. 
It did not, however, distinguish between anergy and deletion since lower levels 
of proliferation may reflect an overall reduction in the number of responder cells 
or the inability of anergic T cells to proliferate in response to an antigenic 
stimulus. Due to the low numbers of precursor T lymphocytes with specificity to 
any one conventional antigen in a physiological T cell repertoire (about 1/105), it 
is usually impossible to follow the fate of individual T cell clonesto distinguish 
between deletion and anergy. 
1.2.4 ii Deletion and anergy through activation 
The limitations set by low T cell precursor frequencies were circumvented in 
models utilizing transgenic TCR or superantigens. Studies on mouse models 
with transgenic TCR specific for the male H-Y antigen (Rocha & von Boehmer, 
1991) or the superantigen Mlsa (Webb, Morris, & Sprent, 1990) showed that the 
constant confrontation of self-reactive T cells with high densities of specific 
antigen in the periphery evoked a characteristic kinetic pattern of rapid in vivo 
expansion followed by a steep decline. Furthermore, the remaining H-Y - or 
Mlsa-specific peripheral T cells were unresponsive to subsequent antigenic 
stimulation in vitro, and they did not proliferate in vivo after secondary transfer. 
This process was progressive and could be correlated with the downregulation 
of TCR and CD8 on the T cell surface (Webb, Morris, & Sprent, 1990) . The same 
sequence of events of tolerance through activation was also observed in 
transgenic models using more conventional antigens such as viral peptides 
(Mamalaki et al, 1993; Moskophidis et al, 1993). The mechanism of tolerance in 
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these studies was interpreted as clonal exhaustion of T cells as a result of long-
term exposure to antigen. 
This sequence of proliferation, deletion and irreversible anergy of remaining 
T cells is not a universal mechanism of peripheral tolerance. Deletion may be 
observed without prior proliferation (McCormack et al, 1993; Waanders et al, 
1993). Furthermore, when the peripheral concentrations of self-antigen were 
lower such as in heterozygous mice expressing only about half the amounts of a 
specific Mls superantigen, clonal deletion of Mls-reactive T cell clones was 
incomplete, and clonal anergy of the remaining responder T cells was reversible 
in hosts that lacked the particular superantigen altogether (Ramsdell & Fowkes, 
1992). The ability to reverse anergy in the absence of antigen was confirmed for 
T cell clones specific for the male antigen H-Y upon transfer into female 
recipients (Rocha, Tanchot & von Boehmer, 1993). When the level of peripheral 
antigen expression was under the control of an inducible promoter, T cell 
tolerance as assessed by the downregulation of TCR surface expression was 
partial at low and complete at high antigen concentrations (Ferber et al, 1994). 
These studies highlighted the importance of the antigen dose in determining the 
mode of peripheral tolerance induction. 
1.2.4 iii The role of APC's in peripheral tolerance 
Numerous reports highlight the significance of different APC's or different 
physiological states of the same APC for peripheral tolerance. Furthermore, the 
nature of the antigen and the route of antigen administration may determine the 
outcome of immune responses . Some phenomena of peripheral 
nonresponsiveness can be explained by antigen presentation in the absence of 
costimulation or by selective induction of TH2 cells that subsequently inhibit the 
induction of a THl type response. All these factors may be closely inter-linked: 
t he route of antigen administration may determine the type of APC that will be 
confronted with the antigen, and APC's may differ in their ability to provide 
costimulation or preferentially induce either THl or TH2 type responses. 
Anergy in the absence of costimulatonJ signals 
An early explanation for clonal anergy has been the presentation of antigen in 
the absence of costimulatory signals. Antigen presentation by fixed 
(physiologically inactivated) APC's in vitro resulted in functional inactivation of 
T cell clones as shown for proliferation and IL-2 production. However, the 
addition of normal allogeneic APC's, themselves incapable of presenting 
antigen, abolished this effect. Experiments in which semipermeable membranes 
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separated fixed and unfixed APC's demonstrated that soluble mediators were 
not responsible for this phenomenon (reviewed in Mueller, Jenkins, & Schwartz, 
1989). Thus, it appeared that the quality and quantity of physical contacts 
between APC's and T cells beyond those mediated by the MHC restriction 
element constituted critical parameters for the modulation of T cell activity. The 
lack of costimulation seemed not only to prevent the induction of effector 
mechanisms but to actively induce negative regulation that compromised 
subsequent T cell functions in the presence of costimulatory signals. Studies on 
an autoimmune disease model (experimental autoimmune encephalomyelitis, 
EAE) appeared to confirm the significance of lacking costimulatory signal for 
tolerance induction in vivo. Here, intravenous administration of 
encephalitogenic peptide coupled to fixed splenocytes protected animals from 
disease (Pope, Paterson & Miller, 1992; Tan, Kennedy, & Miller, 1992). Likewise, 
mice treated with encephalitogenic peptide coupled to soluble MHC class II 
molecules were also protected against EAE. (Sharma et al, 1991). 
While isolated MHC-peptide complexes and the fixation of APC's are 
experimental manipulations to deprive T cells of costimulation, APC's that are 
devoid of essential coreceptors under physiological conditions might "naturally'' 
inhibit those immune responses that are critically dependent on coreceptor-
mediated signals. In search for a candidate APC that induces tolerance in vivo, 
the B cell became the focus of attention for a series of studies. Much of the T cell-
B cell cross-talk depends on the activation state of both types of lymphocytes 
since several coreceptors are not expressed on resting or naive B and T cells. 
While dendritic cells can prime naive T cells, B cells can only stimulate T cells 
during a secondary response (Ronchese & Hausmann, 1993). One study 
investigated the responses of naive and memory T cells from female donors to 
resting and activated B cells presenting the male-specific antigen H-Y. Both 
resting and LPS-activated B cells were tolerogenic for naive T cells whereas 
memory T _cells were stimulated even when the B cells were not previously 
activated (Fuchs & Matzinger, 1992). When antigen was specifically targetted to 
B cells by anti -IgD, T cell functions such as in vitro proliferation, IL-2 
production and TH-dependant antibody production were diminished, if the 
tolerizing protocol was applied before or at the time of the antigenic challenge 
(Eynon & Parker, 1993). The tolerogenic potential of B cells was also explored in 
a rat model of EAE demonstrating protection from EAE when an 
encephalitogenic peptide was linked to anti-IgD for B cell targetting (Day et al, 
1992). Taken together, these results suggested that the outcome of the T cell- B 
cell dialogue was critically dependent on the T cell' s history and emphasized the 
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competence of B cells to induce antigen-specific tolerance in naive T 
lymphocytes. 
Differential requirements for tolerance induction in TH1/TH2 subset 
A number of reports showed that antagonistic cytokines characteristic of THl 
or TH2 responses could guide T cell functions towards either activation or 
tolerance. Beyond the failure to provide costimulation under some conditions, 
the tolerogenic effect of B cells as APC's was also attributed to a preferential 
induction of TH2 responses accompanied by selective inhibition of THl cells. In 
one report, the authors speculated that the combination of impaired in vitro THl 
responses (proliferation, IL-2, IFNy, and serum IgG2a) and increased levels of IL-
4 after intraperitoneal injection of human gamma globulin(HGG) might have 
originated from Fe-Fe-receptor mediated antigen targetting to B cells. (De Wit et 
al, 1992). Other studies examined the requirements for tolerance induction with 
established THl and TH2 clones in vitro. Chemical fixation of APC's only 
rendered a THl clone unable to proliferate in response to an antigenic stimulus 
while the proliferative response of a TH2 clone was unaffected. However, clones 
of both TH subsets were unable to provide B cell help for antibody production 
(Gilbert, Hoang, & Weigle, 1990). When the significance of different APC's for 
selective T cell activation was addressed, TH2 clones seemed to proliferate 
preferentially in response to B cells as APC's whereas a THl clone was optimally 
activated by plastic adherent splenocytes, mostly macrophages and dendritic 
cells (Gajewski et al, 1991). To pursue the question of differential TH1/TH2 
regulation further, the lymphokine profiles of THO, THI and TH2 clones were 
examined in vitro in response to treatment with anti-CD3 as a protocol for 
anergy induction. This method selectively inhibited THl functions such as IL-2 
production and cytolytic activity while anergy could not be induced in TH2 
clones. Significantly, the THO clones which exhibited a mixed cytokine profile 
(IL-2, IL-4, IL-5) prior to the incubation with anti-CD3 specifically lost the ability 
to exert THI type functions while retaining a TH2 phenotype (Gajewski et al, 
1994). Together, these results suggest that Thl and Th2 type responses follow 
different rules both for specific activation and tolerance induction. 
However, the evidence for differential induction of anergy in TH subsets in 
vitro remains spurious for the in vivo situation. In one study, inactivated 
Theiler's virus coupled to fixed splenocytes and injected i.v. selectively inhibited 
THl but not TH2 responses as assessed by DTH, proliferation, lymphokine 
production, and the secretion of characteristic immunoglobulin isotypes. These 
findings suggested that lack of costimulation selectively inhibited THI responses 
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and were interpreted as "split tolerance" (Peterson et al, 1993). However, it may 
be difficult to rigorously prove in vivo whether selective downregulation of one 
type of TH response (here THl) was due to selective anergy induction in THl 
cells thereby permitting an antagonistic TH2 response to prevail or, 
alternatively, whether it resulted from selective activation of TH2 responses 
which further inhibited THl-mediated functions. In some cases, all mechanisms 
might play a role, but the relative significance of each, i.e. selective anergy, 
selective activation, and antagonistic regulation may be difficult to assess. 
Many findings reviewed above can be accounted for by T cell anergy as a 
direct consequence of interactions between T cells and peptide-MHC complexes 
under conditions that fail to provide certain costimulatory signals. However, 
differential TH1/TH2 regulation may bridge two major mechanisms of 
peripheral tolerance, anergy and suppression. A particular method of antigen 
administration that preferentially induces anergy in- or selectively activates a 
subpopulation of T cells, may permit the outgrowth of those T cells which 
subsequently downregulate or suppress the antagonistic T cell subset. Under 
some conditions these regulatory functions of T cells may pay a more significant 
contribution to peripheral tolerance than anergy; and in some models, tolerance 
may largely or exclusively be induced by the action of regulator or suppressor 
cells. 
1.2.4 iv The role of suppressor cells 
Experimentally induced suppressor cells 
The significance of active regulatory mechanisms mediated by suppressor 
cells has been studied in a variety of cell transfer systems, often with models of 
experimental autoimmune diseases, in which lymphocyte populations from 
tolerized donors were examined for their capacity to protect recipients from 
disease induction. In a murine model of thyroiditis, intravenous injection of the 
target antigen thyroglobulin (MTg) rendered mice unable to mount anti-MTg 
antibody responses upon subsequent challenge with MTg and LPS (for B cell 
activation). This state of tolerance could be transferred to naive recipients with 
splenocytes from tolerized donors. Selective depletion of lymphocyte subsets 
revealed that CD4 + T cells were responsible for tolerance and tolerance transfer 
in this model (Parish, Roitt, & Cooke, 1988). A role for suppressor cells was also 
shown for other strategies of tolerance induction such as oral administration of 
antigen. In these studies, resistance to experimental autoimmune diseases could 
be adoptively transferred with lymphocytes from donors that had been fed with 
the respective target antigens. For the Lewis rat model of EAE, the relevant 
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suppressor cells were CDS-positive (Lider et al, 1989) while protection from 
experimental autoimmune uveoretinitis could be transferred with lymphocytes 
from rats that had been fed with a peptide known to be recognized by CD4+ T 
cells (Gregerson, Obritsch, & Donoso, 1993). 
Antigen-specific suppressor cells can also be induced when T cells encounter 
antigen in the presence of antibodies that block the CD4 or CD8 coreceptors. For 
a mouse model of transplantation tolerance Qin et al reported that donor CD4+ 
T cells tolerized with antigen (skin graft) and non depleting CD4/CD8 
antibodies not only prevented skin graft rejection in naive recipients but also 
endowed the recipient's T cells with the capacity to transfer tolerance themselves 
to a second group of recipients, a phenomenon named "infectious tolerance" 
(Qin et al, 1993). The ability to provoke active suppressor mechanisms by 
targetting coreceptor with monoclonal antibodies was also shown for the mouse 
model of thyroiditis. (Hutchings et al, 1993). 
Evidence for naturally occurring regulator cells 
Several studies demonstrate that suppressor cells are not confined to 
tolerance induced by experimental manipulations but also appear to 
contribute to immune regulation under physiological conditions. Fowell and 
Mason showed that thymectomy and irradiation of a normally non-diabetic rat 
strain was sufficient to induce cell-mediated autoimmune diabetes. However, 
diabetes could be prevented by transferring T cells from_ syngeneic healthy 
donors, thus attesting the significance of cells within an intact immune system to 
control potentially autoreactive T cells. A detailed analysis of the T cell 
phenotype required to replenish the ability to resist diabetes revealed that only 
non-activated CD45 RC low CD4+ T cells were protective upon transfer. 
Although this phenotype applies to both memory T cells and recent thymic 
migrants, the latter were not required to transfer protection (Fowell & Mason, 
1993). 
Experimental autoimmune encephalomyelitis (EAE) represents an attractive 
model to study the role of regulator cells. In the acute model of EAE in the Lewis 
rat, a phase of inflammatory reactions in the CNS and limb paralysis is followed 
by spontaneous recovery after which animals are refractory to further disease 
induction. In rat and mouse models of EAE, protection from further phases of 
disease was found to be associated with post-recovery CD4+ T cells which upon 
transfer protected recipients against EAE (Welch, Holda, & Swanborg, 1980; 
Kumar & Sercarz, 1993). In vitro studies on these T suppressor cells showed that 
they proliferated in response to irradiated effector cells or a synthetic peptide 
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covering a likely effector TCR V~ chain determinant. The mechanism as to how 
Ts cells downregulate effector cells in vivo has not been resolved. However, 
when stimulated with T cell effector determinants in vitro, these regulator cells 
were shown to release IL-4 (Karpus, Gould & Swanborg, 1992). In another study, 
their suppressive effect on IFNy-production by T cells specific for the 
encephalitogenic antigen was inhibitable with antibodies to O·a..ns(o,...,.,~ ,~&.<)Hi 
factor-B (TGF-B), a cytokine known for its anti-inflammatory action (Karpus & 
Swanborg, 1991). Other experiments in which mice were depleted of cos+ T 
cells (Jiang, Zhang & Pernis, 1992) or where the CDS gene was non-functional 
(Koh et al, 1992) suggested that cos+ T cells did not influence the recovery 
phase but conferred resistance to a second induction of disease. In another 
study, the transfer of an MBP- specific encephalitogenic cell line (Q4) directly 
after birth prior to the expression of MBP lead to a loss of resistance to repeated 
EAE induction in adults. In this Lewis rat model of EAE the resistance to a 
second challenge with activated Q4 cells was mediated by cos+ T cells that 
proliferated in vitro in response to irradiated Q4. This population of cos+ T 
cells was missing in mice neonatally treated with Q4 cells (Qin, Sun, & Wekerle, 
1992). 
In summary, selective pressures in the thymus and the periphery favour the 
inactivation of T cells forming high avidity TCR-MHC-peptide complexes by 
anergy and deletion. Different requirements for the activation of antagonistic T 
cell subsets and other regulatory or suppressor cells establish homeostatic 
control mechanisms which together with the inherent avidity and signalling 
threshold constraints on T cell activation serve to preserve the integrity of the 
immune system. However, the ability to induce autoimmune disease in 
experimental models and the occurrence of autoimmunity and allergies in 
humans demonstrate that this balance can be perturbed to an extent at which it 
can no longer re-adjust itself. The challenge to immunology is then to educate 
the immune system according to its own rules, to exploit the knowledge about 
mechanisms of peripheral tolerance to divert lymphocyte functions from 
erroneously attacking innocuous antigens into a, normal state of tolerance. 
1.3 BREAKING OF TOLERANCE AND IMMUNE 
INTERVENTION 
1.3.1 How Peripheral Tolerance Can Be Broken 
Various experimental manipulations enable T cells to break the rules that 
govern the maintenance of peripheral tolerance. A common protocol for priming 
THl type responses is to administer antigen subcutaneously in complete 
Freund's adjuvant (CFA), a mixture of oil and mycobacterial antigens mimicking 
a pathogenic insult. By this method, T cell mediated experimental autoimmune 
diseases can be induced with self antigen/CFA in susceptible animals. Antigen 
is retained at the site of injection and slowly released to draining lymph nodes 
where NK cells appear to initially set the scene by IFNy production, presumably 
in response to the mycobacterial particles. This attracts and activates 
macrophages after which IL-2 producing T cells can be demonstrated by 
immunohistochemistry (Bogen, Fogelman, & Abbas, 1993). Autoreactive T cells 
are therefore driven to recognize antigen presented in the presence of 
costimulatory signals such as provided by activated macrophages within a 
lymphokine environment that favours inflammatory effector functions. 
T cells which fell below the avidity threshold for negative selection in the 
thymus may nevertheless mediate high avidity interactions in the periphery 
under certain conditions. Immunization with a single peptide in CFA bypasses 
the need for antigen processing thereby enabling T cells to respond to 
subdominant or cryptic autoantigenic epitope. Significantly, peptide 
immunization also seems to drive immune responses to the whole protein to 
which animals initially failed to respond as shown for cytochrome c in the 
mouse (Mamula, 1993). Presumably, as a secondary effect to peptide priming, B 
cells specific for the cyt 81-104 peptide also bound and processed whole mouse 
cytochrome c and subsequently presented other cyt peptides. A similar 
observation was made in a mouse model of EAE where immunization with the 
disease-inducing agent myelin basic protein (MBP) initially only evoked T cell 
responses to the dominant N- terminal epitope of MBP (Acl-11) whereas after 40 
days responses to subdominant were also evidenced, . a phenomenon termed 
epitope spreading (Lehmann et al, 1992). Spreading of the immune response to 
subdominant and cryptic epitopes was also observed when the dominant 
epitope alone was used for priming, suggesting subsequent waves of priming by 
endogenous MBP. 
As discussed for thymic selection, the TCR repertoire has to display some 
degree of degeneracy with respect to antigen specificity to allow for the 
recognition of antigens not presented during positive selection. For the H-2u-
restricted TCR specific for Acl-11 of MBP, Gautam et al have shown that a 
polyalanine analogue of this peptide containing only five native residues was 
sufficient to activate a specific T cell° hybridoma in vitro and to induce EAE in 
vivo (Gautam et al, 1992a). Wraith et al demonstrated in the same model that 
one of two peptide residues that serve as TCR determinants could be replaced 
by a number of alternative amino acids without abrogating TCR recognition 
(Wraith, Bruun, & Fairchild, 1992). A drawback of TCR crossreactivity is 
therefore the potential of self-reactive T cells to be activated by microbial or viral 
peptides that fulfil the same minimal requirements for TCR recognition as the 
self peptides. Furthermore, tissue injury may lead to the release and presentation 
of high amounts of previously sequestered antigens which, in combination with 
local inflammatory responses may suffice to activate autoreactive T cells. 
The induction of autoimmune diseases with activated T cell clones bypasses 
the control mechanisms that might otherwise have prevented the induction of 
those cells. In a transgenic mouse model of EAE, some animals spontaneously 
developed autoimmune disease (Goverman et al, 1993). Presumably, in this 
situation the non-physiologically large number of self-reactive T cells defies 
most physiological control mechanisms. 
1.3.2. Strategies For Immune Intervention 
Autoimmunity, allergies, and organ transplant rejection represent areas for 
which the ultimate goal is to reverse detrimental immune responses towards 
tolerance to innocuous self and non-self antigens. Therapeutic approaches to 
ameliorate these conditions still rely heavily on the application of various non-
specific immunosuppressive drugs (Thomson, Woo, & Cooper, 1992) which can 
be severely toxic and may compromise normal effector functions involved in 
immune surveillance and protective immunity (Bach, 1991). Other strategies in 
animal models aimed to prevent the access of autoreactive effector T cells to the 
target tissue by blocking surface molecules required for adhesion and 
transendothelial migration (reviewed in Cooke & Wraith, 1993). However, 
preventing the riot does not necessarily appease the aggressor. Thus, 
management of undesirable immune reactions would be greatly improved if T 
cells could be targetted more specifically. In models of EAE with restricted 
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effector TCR chain usage, attempts have been made to induce regulator cells 
against effector T cells by TCR vaccination. As mentioned before, such regulator 
or suppressor cells may be involved in recovery from and further resistance to 
acute forms of EAE. However, while TCR vaccination conferred protection in 
one study (Gaur et al, 1993), it enhanced disease in other cases (Desquenne-Clark 
et al, 1991). Another approach has been the blockade of MHC molecules with 
peptides that associate with the same restriction element as the target peptide 
thereby competing for binding and preventing ligation with the self-reactive 
TCR. (Gautam et al, 1992b; Hurtenbach et al, 1993). A common drawback in 
those systems is, however, that blocking is not permanent and may require 
continuous treatment. 
The knowledge of antagonistic TH1/TH2 functions and its control by distinct 
sets of cytokines has encouraged attempts to selectively block or enhance 
immune responses by the administration of cytokines, anti-cytokine antibodies 
or soluble cytokine receptors (reviewed in Cooke & Wraith, 1993; Lanzavecchia, 
1993). While this strategy was successful in some models, it may prove difficult 
where tissues are not easily accessible by soluble therapeutic agents or in 
situations where cytokine regulation does not fall into clear-cut TH1/TH2 
categories. 
The most specific strategy for immune intervention is to target the TCR with 
its own ligand, the MHC-peptide complex. One approach suggested by a 
number of recent studies could involve alterations of critical peptide residues in 
such a way that it engages in the trimolecular MHC-peptide-TCR complex 
without eliciting T cell responses (antagonism) or where the altered peptide 
ligand triggers some but not all signals required for T cell activation (partial 
agonism). These observations revealed that ligation of the TCR by peptide-MHC 
is not an all- or- none event but that different intracellular signalling pathways 
connected to the TCR/ CD3 and CD4- or CD8 corn plex can be triggered 
selectively depending on the nature of the peptide ligand (reviewed in Fairchild 
et al, 1994; Sette et al, 1994). Furthermore (and somewhat homologous to the 
significance of coreceptor-mediated costimulatory signals), a partial agonist may 
not only fail to activate a T cell but render it anergic to subsequent stimulation 
with the natural ligand (Sloan-Lancaster, Evavold, & Allen, 1993). 
The application of peptide antagonists or partial agonists requires in depth 
knowledge of critical residues and relevant substitutions. However, the 
numerous strategies to induce peripheral tolerance outlined earlier clearly reveal 
that T cell responses can also be downregulated by their natural ligand under 
appropriate conditions. Generally, in those studies, soluble protein antigens 
injected intravenously or intraperitoneally induced T cell nonresponsiveness. 
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Antigen administered in incomplete Freund's adjuvant (IFA) that lacks 
mycobacterial particles and therefore does not provoke inflammatory responses, 
may also induce specific T cell tolerance (Smilek et al, 1991; Gaur et al, 1992). 
While these approaches employ somewhat artificial routes of antigen 
administration, antigen uptake through mucosal surfaces represents a major 
natural route by which the immune system is constantly challenged with foreign 
antigens. Some of these antigens may be detrimental, but the majority is 
innocuous. In the case of food proteins that pass the mucosa of the small 
intestine, antigens provide essential metabolites against which aggressive 
immune responses would be devastating. Local inflammatory allergic responses 
to certain food substances or inhaled antigens are the exception to the rule that 
antigens encountered via mucosal surfaces are generally tolerized by the 
immune system. Oral tolerance, the phenomenon of specific immunological 
unresponsiveness induced by feeding antigen, has been known for a long time 
and studied with dietary proteins (reviewed by Mowat, 1987) as well as 
potential self-antigens (reviewed by Thompson & Staines, 1990). More recently, 
antigen inhalation was also shown to downregulate specific immune responses 
(reviewed in Holt & McMenamin, 1989). 
The prospect of antigen-specific immune intervention by natural routes is 
intriguing and has already encouraged clinical trials for oral tolerance in human 
autoimmune or inflammatory conditions (Weiner et al, 1993; Trentham et al, 
1993). However, a thorough understanding of the mechanisms that mediate 
immunological tolerance to antigens taken up through the gut and the 
respiratory tract not only provide a close insight into immune regulation in 
general; it is also a prerequisite for safe and successful clinical applications. This 
thesis aims to contribute to the understanding of oral tolerance and to examine 
the potential to inhibit T cell-mediated autoimmune responses by antigen 
administered through the respiratory tract. In both situations, antigen is 
confronted with lymphoid cells and structures which are peculiar to the gut or 
the respiratory tract. However, both routes are also sites where antigen may be 
efficiently absorbed into the systemic circulation., When considering phenomena 
of oral- and inhalation tolerance the question therefore arises as to which extent 
the impact of fed or inhaled antigens on systemic immune responses can be 
accounted for by mechanisms of peripheral tolerance in general (such as induced 
by the intravenous or intraperitoneal route) and to which extent by regulatory 
mechanisms that are unique to mucosal-associated lymphoid elements. 
Furthermore, the lymphoid tissue associated with the small intestine and the 
respiratory tract bear both striking similarities and obvious differences. It will 
therefore be interesting to compare the impact on immune responses by antigen 
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administered through both routes. Before the issues addressed in this thesis are 
introduced in more detail, an overview of the lymphoid tissues and cells in the 
small intestine and the respiratory tract is included to aid further discussion. 
1.4 LYMPHOID TISSUES AND ·ANTIGEN HANDLING IN THE 
SMALL INTESTINE AND THE RESPIRATORY TRACT 
1.4.1 Histologic Organisation And Cell Types Of The Small 
Intestine 
The lining of the intestinal wall is thrown into large elevations (plicae 
circularis) that include mucosa and submucosa. The surface is studded with 
fingershaped mucosal projections, the villi. These contain a core of highly 
cellular, loose connective tissue, the lamina propria, covered by a simple 
columnar epithelium. The intestinal glands or crypts of Lieberkuhn form simple 
tubular structures with pore-like openings between the bases of the villi 
(Rhodin,1974; Weiss & Greep, 1977). 
1.4.1 i Villi and crypts 
The absorptive cell with its highly differentiated structure (microvilli) is 
characteristic of the villi whereas within the crypts, relatively undifferentiated, 
frequently dividing columnar cells prevail. Other cell types include: goblet cells 
which produce the pre-epithelial mucus. Several types of endocrine cells 
produce hormones including serotonin, gastrin, secretin (a glucagon-like 
hormone), and possibly noradrenalin and cholecystokinin (reviewed in 
O'Dorisio, 1986; Freier & Lebenthal, 1989). Paneth cells in the crypts secrete 
peptidases and lysozyme. M (microfold) cells are characteristic of the epithelial 
area covering Peyer's Patches and are probably specialized in antigen sampling. 
Intraepithelial lymphocytes are mainly T cells of which 80-90% are cos+ 
(reviewed in Pabst, 1987). 
1.4.1 ii Lamina propria 
The lamina propria contains large numbers of lymphocytes, granulocytes, 
macrophages, and plasma cells. The majority of lymphocytes are CD4+ T cells. 
Mature small B cells are relatively rare, but plasma cells are present in large 
numbers, most of which are IgA positive (80%) followed by IgM+ and IgG+ B 
cells (reviewed in Pabst, 1987). 
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1.4.1 iiiPeyer's Patches (PP) 
PP constitute the lymphoid organ of the intestinal wall. They are covered by 
a distinct PP-associated dome epithelium ("dome", because the follicles cause 
the epithelium to bulge into the lumen like the vault of a church). This dome 
epithelium is devoid of the crypt/villi structure. M cells are distributed evenly 
over the higher regions of the dome representing about 15% of the total cell 
population. The absence of goblet cells renders the dome area a mucus-free zone 
and therefore a weak point in the intestinal barrier. Of great functional 
importance is the ability of M cells to transport large molecules and particles as 
shown for India ink, horse radish peroxidase and others. M cells transport but 
do not seem to degrade antigen. The basement membrane of the dome shows a 
typical porosity, thereby enabling macrophages and other cells from the lamina 
propria to interact with M cells, possibly by taking up particles and molecules 
transported by M cells. 
PP consist of four compartments defined by different structural elements and 
functions: upon antigenic stimulation germinal centres comprising the B cell 
areas develop within the lymphoid follicles. Most B lymphocytes differentiate 
into IgA plasma cells. Processes of I-A-positive follicular dendritic cells are 
prominent in germinal centres, and some T cells are also present. Small mature (mainly B) lymphocytes surround the follicles forming the corona. Specialized 
venules with a high cobble stone type epithelium are cha.racteristic of the 
interfollicular area. Lymphocytes emigrate from the blood and enter the PP via 
these postcapillary venules (PCV). Migration patterns of lymphocytes are 
directed by homing receptors, and some lymphocytes specifically home to the 
gut. The interfollicular area contains mainly T lymphocytes, the majority of them 
belonging to the CD4 positive lineage. Processes of I-A-positive dendritic cells 
are found throughout this area, sending branches between T cells. The dome 
area underneath the epithelium contains a mixture of B-and T lymphocytes, 
plasma cells and macrophages (reviewed in Pabst, 1987; Kawanishi, 1989; 
Nagura, 1988). 
1.4.2 Antigen Presentation 
The apparently intimate contact between dendritic cells and M cells in the 
interfollicular area suggests that dendritic cells may take up antigen transported 
by M cellsand present it to T cells in the interfollicular area. Within germinal 
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centres of PP, I-A positive follicular dendritic cells trap and present antigen to B 
cells (reviewed in Kawanishi, 1989; Nagura, 1988). 
It has been reported that IFNy-induced I-A-positive gut epithelial cells can 
replace macrophages or dendritic cells as APC in mixed lymphocyte reactions 
(Mayer & Shlien, 1987). In these experiments, the epithelial cells seemed to 
selectively stimulate CDS+ T cells. Since a high proportion of intraepithelial cells 
are CDS+, it is conceivable that they might also be relevant as APC in vivo. In 
another study, intestinal epithelial cells were found to inhibit in vitro 
lymphocyte proliferation, an effect which was reversible with a blocker of 
prostaglandin synthesis or exogenous IL-2 (Santos et al, 1990). 
1.4.3 Lymphocyte Trafficking 
Two pools of small recirculating lymphocytes have been described, one 
migrating mostly through peripheral lymph nodes and others mainly through 
gut-associated lymphoid tissue (GALT). Lymphocytes which derived from the 
gut or mesenteric lymph nodes showed a preference for migration to other 
organs lined with mucous membranes such as the bronchial tract, salivary-, 
lacrimal- and mammary glands. These observations gave rise to the concept of 
mucosa-associated lymphoid tissue (MALT). 
PP lack an afferent lymph supply so that lymphocytes ·may only enter PP 
from the mucosa! circulation via PCV. Antigen-primed lymphocytes exit 
through the lymphatics to mesenteric lymph nodes, the thoracic duct, spleen, 
and finally lodge in the lamina propria. Alternatively, some lymphocytes may 
home directly from the mesenteric lymph nodes to PP without entering the 
thoracic duct and passing through the spleen (reviewed in Kawanishi, 1989). 
1.4.4 The Gut Epithelium- An Extrathymic Place Of T Cell 
Differentiation 
Recent studies revealed a function of the gut epithelium as a thymus-
independent site of T cell development. Phenotype analysis of intraepithelial 
lymphocytes (IEL) showed a distribution of 10% CD4+TCRa~+ cells and 80% 
CDS+ T cells which bear either TCRa~ (70%) or TCRy8 (30%) chains. Some of the 
TCRa~CD8+ cells and all of the TCRy 8 cells expressed homodimeric CDS 
molecules composed of two alpha chains instead of the a~ heterodimer. 
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Homodimeric CD8aa+ T cells were not detectable in any other peripheral 
lymphoid tissues or the thymus (Guy-Grand et al, 1991; Rocha, Vassalli, & Guy-
Grand, 1991). The development of these TCRyo cells (which were either double 
negative or expressfCD8aa) was independent of the thymus and also followed 
different rules for development. In MHC class I or class II knockout mice, 
TCRa~ IEL were missing while the population of TCRyo+ cells was even 
increased, suggesting that classical MHC molecules were not involved in the 
selection of TCRyo+ cells (Schleussner & Ceredig, 1993). Disrupting the gene for 
the ~ chain abrogated normal development of T cells in the thymus. Among IEL, 
all thymus dependent T cells were missing while the development of all TCRyo 
cells and the small population of TCRa~+CD4-CD8~- cells was unaffected 
(Malissen et al, 1993). Furthermore, thymic dependent T cells specific for a Mis 
superantigen or the male-specific H-Y antigen were deleted in the thymus in 
animal expressing these antigens while, in contrast, the antigen appeared to be 
required for the maturation of thymus independent IEL. In female mice, all H-Y-
specific thymus independent cells were double negative and lacked granules 
while in male mice the same population expressed high levels of TCR and CDS. 
Although these T cells could mediate primary cytotoxic responses in vitro, there 
were no lesions or other signs of autoimmune reactions in vivo (Rocha, Vassalli, 
& Guy-Grand, 1991; Rocha, von Boehmer, & Guy-Grand, 1992). 
The antigens recognized by TCRyo cells have not been clearly defined. 
However, in agreement with yo T cell selection in the absence of classical MHC 
molecules, antigen recognition by mature yo T cells was also shown to be 
independent of MHC class I or II molecules. Disrupting conventional MHC-
antigen presentation had no effect on the stimulation of yo T cells while 
abrogating all TCRa~ cell-mediated responses in vitro. Instead, antigen 
recognition by a yo T cell line correlated with the expression of the nonclassical 
MHC molecule TL (Schild et al, 1994). The authors suggest that the structural 
similarities ·l?etween immunoglobulins and yo TCR imply similar modes of 
antigen recognition independent of specialized APC. 
1.4.5 Structure Of The Respiratory Tract 
The respiratory system consists of portions anterior and posterior to the 
pharynx where respiratory and digestive tracts cross. The anterior respiratory 
tract includes nostrils, nasal cavity, and pharyngeal tract. The posterior tract 
consists of larynx, trachea, bronchi, and lungs. The trachea extends from the 
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narrow end of the larynx into the thoracic cavity where it branches into left and 
right bronchi. Large primary bronchi lead into the left and right lung, where 
they branch repeatedly, diminishing in size with each division. As the tubes 
become smaller their walls become thinner. The terminal bronchioles branch into 
several alveolar ducts leading into .alveolar sacs, each composed of several 
alveoli. These structures have very thin walls invested with fine dose-meshed 
networks of large thin-walled capillaries (reviewed in Hummel, Richardson, & 
Fekete, 1966). 
1.4.6 Routes followed by Antigen In The Respiratory Tract 
1.4.6 i Role of particle size 
A number of mechanisms protect the lung from inhaled antigenic material. In 
the upper respiratory tract, the first barrier is a layer of mucous and the action of 
cilia. The deposition of inhaled particles within the respiratory tract depends to a 
large extent on their size. Several studies suggested that the majority of droplet 
particles greater than 12µm in diameter were retained in the nose, whereas those 
of 4µm in diameter were deposited in the nose, bronchi and bronchioles. Smaller 
particles of 0.8-1.6 µm in diameter were partly retained in the alveoli or breathed 
out again (reviewed in Yoffey & Courtice, 1970). 
1.4.6 ii Absorption into lymphatics and circulation 
Within the nasopharynx, the submucosa underlying the epithelium is rich in 
lymphatic vessels from which the lymph drains into the deep cervical 
lymphatics. To ascertain the pathway of antigenic material, substances of 
varying molecular weight and size were applied to the nasal mucosa. Small 
molecules such as water and some salts or dyes were mainly absorbed into 
blood capillaries and to a lesser extent into lymphatic vessels. Dyes such as 
trypan blue and Evans blue with a molecular weight of about 1000 rapidly 
entered the cervical lymph when applied in solution to the nasal mucosa. In 
several studies intranasally administered molecules up to the size of ovalbumin 
passed into the lymph (reviewed in Yoffey & Courtice, 1970). When fluorescent 
-or radiolabelled bovine serum albumin (BSA) was administered as an aerosol 
with droplet sizes around 2µm or 7 µm in diameter, fluorescent deposits lined 
the whole of the respiratory tract of rabbits, including finely dispersed granules 
in alveolar ducts and sacs (Willoughby &Willoughby, 1977). Kinetic experiments 
with radiolabelled BSA in the same study demonstrated that the majority of the 
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label (about 70%) was found in the stomach and subsequently in the serum and 
urine. At any time, even after repeated aerosol exposure, the proportion of total 
label in the lung did not exceed 4% suggesting that there was no pulmonary 
sequestration of soluble protein. When BSA was administered directly through 
the nostrils rather than in an aerosolized form, it also entered the circulation, 
apparently as intact molecules rather than degradation (non-TCA precipitable) 
products. 
Soluble proteins thus appear to be readily absorbed into the rich network of 
lymphatic-and blood vessels surrounding the whole of the respiratory tract. In 
contrast, studies with carbon particles and fluorescent microspheres showed that 
particulate antigens did not readily penetrate the mucosa and epithelium. 
Instead, the alveolar macrophage (AM) as the prominent cell in the lower 
respiratory tract phagocytosed particles and carried them to the draining 
(tracheobranchial) lymph nodes (Harmsen et al, 1985). In contrast to their 
efficient handling of particulate antigen, AM were defective in stimulating 
specific in vitro T cell proliferative responses to soluble antigens, in striking 
contrast to splenic and peritoneal macrophages (Ullrich & Herscowitz, 1980). 
While this study suggested an inherent difference in antigen handling by AM 
rather than active suppression, it has also been reported in support of AM-
mediated inhibition that lymphocyte responses to mitogens were substantially 
improved after depletion of AM (reviewed in Lawrence, 1988). Recent work by 
Holt et al showed that the inhibitory effect of AM on mitogen -induced T cell 
proliferation could be abrogated by granulocyte/macrophage colony-
stimulating factor, GM-CSP (Bilyk & Holt, 1993). 
1.4.7 Lymphoid Tissues 
Antigen in the respiratory tract may be drained to several lymph nodes. In 
the mouse, these are the superficial- and deep cervicals and the mediastinal 
lymph nodes (reviewed in Hummel, Richardson, & Fekete, 1966). 
The bronchus- associated lymphoid tissue (BAL T) is morphologically very 
similar to Peyer's Patches (PP) of GALT (Bienenstock, Johston, & Perey, 1973). It 
lies within the lamina propria of large bronchi near bifurcations. BAL T is 
covered by a specialized flattened epithelium which, like M cells of PP, is devoid 
of mucous and cilia. There is evidence that these specialized epithelial M cells 
can pinocytose and transport soluble and particulate antigens across the 
bronchial mucosa. Similar epithelial cells also cover smaller lymphoid 
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aggregated in the more distal bronchioles. However, unlike in PP, no prominent 
germinal centres were identified in BALT (reviewed in Gil & Daniele, 1988). The 
cell population in BALT contains both T and B cells although the relative 
proportions of both types of lymphocytes vary among different reports 
(reviewed in Lawrence, 1988). By microscopy, the epithelium overlying BALT 
was heavily infiltrated with lymphocytes, but only few plasma cells were 
detected (Bienenstock, Johston, & Perey, 1973). When the cellular components of 
bronchial lavage were analyzed, the lung parenchyma also contained 
lymphocytes of which a high proportion (about 65%) were T cells. 
1.5 DOWNREGULATION OF SYSTEMIC IMMUNE RESPONSES 
BY ORAL AND INTRANASAL ANTIGEN ADMINISTRATION 
1.5.1 Oral Tolerance 
The term "oral tolerance" describes the state of specific immunological 
nonresponsiveness induced by oral or intragastric administration of antigen. The 
phenomenon of oral tolerance has been known for a long time. Wells showed in 
1911 that feeding guinea pigs rendered them refractory to anaphylactic reactions 
against dietary proteins (Wells, 1911). For the last two decades, Ovalbumin 
(OVA) has served as a popular model protein for numerous studies addressing 
the mechanism of oral tolerance (reviewed in Mowat, 1987). The potential of 
orally administered antigens to downregulate systemic immune responses has 
also been widely explored with target antigens in experimental models of 
autoimmune inflammatory diseases such as experimental autoimmune 
uveoretinitis (EAU), arthritis (EAA), and encephalomyelitis (EAE, reviewed in 
Thompson ~ Staines, 1990; Weiner et al, 1994). Oral tolerance w as shown to 
affect T cell mediated effector functions such as DTH and pathological signs of 
inflammatory reactions. Antibody levels were also reduced, although hapten-
carrier experiments suggested that this was due to a lack of T cell help rather 
than by direct B cell tolerance (Hanson et al, 1977; Richman et al, 1978; Titus & 
Chiller, 1981). 
In many models, two major mechanisms, T cell mediated suppression and 
anergy have both been implicated in oral tolerance. In the OVA mouse model, 
numerous reports showed that tolerance was transferrable to naive recipients 
with splenocytes from OVA-fed donors (Miller & Hanson, 1979; Mowat, 1986; 
Lamont et al, 1988). Adoptive transfer of tolerance was also achieved with cos+ 
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T cells from Peyer's patches (Ishii et al, 1993). Transfer of tolerance was not 
confined to cellular elements but was also demonstrated with serum collected 
from donors one hour after OVA feeding (Strobel et al, 1983; Peng, Turner & 
Strobel, 1990). However, when T cell responses such as proliferation and IL-2 
production were examined in vitro, there was no evidence for suppression. 
Rather, the results were consistent with T cell anergy (Richman et al, 1978; 
Melamed & Friedman, 1993). Oral tolerance in the Lewis rat model of EAE has 
been induced by feeding the target protein myelin basic protein (MBP). The 
suppressive effect of oral antigen administration in this model was attributed to 
the anti-inflammatory cytokine transforming growth factor-~ (TGF-~) released 
by cos+ T cells upon stimulation with the same antigen that had previously 
been fed. The release of TGF-~ appeared to be inducible by a non-
encephalitogenic but not by the encephalitogenic MBP fragment. In these studies 
the action of cos+ T suppressor cells was also assessed by the ability of TGF-~ 
to non-specifically reduce immune responses to a second antigen in a bystander 
fashion (Miller, Lider & Weiner, 1991; Miller et al, 1992a). However, in other 
studies on the same model, albeit under different experimental conditions, there 
was no evidence for suppression upon cell transfer whereas diminished in vitro 
T cell responses from MBP-fed rats were consistent with T cell anergy (Whitacre 
et al, 1991). Studies on oral tolerance in a Lewis rat model of EAU emphasized 
the dose dependence of fed antigen to induce modes of oral tolerance that were 
consistent with either suppression of anergy. While low do_se feeding revealed 
hallmarks of suppression such as the ability to adoptively transfer tolerance and 
to induce bystander inhibition to other (not previously fed) epitopes, high dose 
feeding appeared to induce a strictly epitope-specific and non-transferrable form 
of tolerance. The mechanisms of suppression in this model were not resolved. 
However, the finding that a disease -inducing peptide known to activate CD4+ T 
cells was able to induce suppression suggested that the suppressor cells 
belonged tc;, the CD4 rather than the CD8 lineage (Gregerson, Obritsch, & 
Donoso, 1993). The dose of intragastrically applied antigen may not only dictate 
the mechanism of oral tolerance but also decide between tolerance induction 
versus priming of an immune response. In the OVA mouse model, different oral 
doses of OVA induced either tolerance or supported T cell priming while some 
amounts of fed protein had no apparent effect on a subsequent challenge 
(Lamont, Mowat, & Parrott, 1989). These findings therefore suggest that the 
in tragastric route of antigen administration does not necessarily provide a 
default mechanisms for tolerance induction. The evidence from various models 
of oral tolerance also reveals a broad spectrum rather than a universal 
mechanisms of tolerance induced by feeding antigen. 
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1.5.2 Downregulation Of Immune Responses By Protein Inhalation 
While oral tolerance boasts a long history of investigation, antigen inhalation 
represents a more recent approach to modulate systemic immune responses in 
an antigen-specific manner. The problems faced by the immune system are, 
however, very similar. Like the gastrointestinal tract, the respiratory tract is in 
constant contact with numerous antigenic particles of which only a minority is 
potentially pathogenic. The similarities between GALT and BALT suggest that 
the task of selectively attacking potentially detrimental while sparing innocuous 
agents might be solved in a similar fashion. Since IgE-mediated activation of 
mast cells constitutes the major hazard in allergies to airborne particles, a series 
of studies focussed on aerosol- induced tolerance with emphasis on the IgE 
isotype (reviewed in Holt & McMenamin, 1989). A recent report showed that 
exposure of rats to aerosolized OVA induced a complex mechanism of tolerance 
whereby IFNy producing cos+ T cells abrogated a transient C04+-mediated 
OVA-specific IgE response. This was interpreted as a cos+ T cell mediated 
deviation from a C04 + T cell -induced TH2 response. In this model the tolerant 
state was transferrable to naive animals with cos+ T cells (McMenamin & Holt, 
1993). Other studies addressed the role of APC's in the induction of inhalation 
tolerance. Early reports already mentioned the inhibitory effect of alveolar 
macrophages (AM) on T cell proliferation (reviewed in Lawrence, 1988). More 
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recently, the immunosuppressive capacity of AMswas shown to be abrogated by 
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GM-CSF, (Bilyk & Holt, 1993). Furthermore, AMsalso appeared to suppress the 
ability of pulmonary dendritic cells to activate T cells (Holt et al, 1993). In a 
mouse model of allergy to house dust mite antigens, inhalation of a single 
peptide representing a dominant CD4 + T cell epitope diminished in vitro IL-2 
production as well as in vitro antibody secretion by spleen cells from primed 
mice, suggesting a cos+ T cell-independent mechanism of suppression (Hoyne 
et al, 1993). However, antigen inhalation has not yet been widely investigated as 
a strategy for tolerance induction in inflammatory autoimmune diseases. One 
report mentioned the amelioration of EAE by MBP inhalation in Lewis rats, but 
no data was provided or referred to (Weiner et al, 1991). One study 
demonstrated that nasal administration of retinal antigens suppressed EAU in 
Lewis rats (Dick et al, 1993). To our knowledge, this has been the only evidence 
that antigen inhalation could abrogate inflammatory autoimmune responses 
apart from the work presented in this thesis. 
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1.5.3 Aim Of This Thesis 
This project explores antigen administration via the gastrointestinal- and the 
respiratory tract as a potential means to specifically downregulate systemic T 
cell-dependent immune responses to soluble antigens. Previously published 
work has provided evidence for both anergy and suppression. In an attempt to 
distinguish between these two mechanisms, the experiments presented in this 
thesis concentrate on the significance of individual epitopes. An engagement of 
cos+ T suppressor cells implies that distinct epitopes are required for 
suppression ( MHC class I-restricted) of a MHC class II-restricted immune 
response. As shown for the Lewis rat model of EAE, only a non-encephalitogenic 
peptide could induce cos+ T cells to release TGF-J3 (Miller et al, 1993). A MHC 
class II restricted epitopes may either induce co4+ T cell-mediated regulation or 
more directly T cell anergy. In the first case, we may be able to demonstrate 
bystander suppression if C04 + Ts cells also operate by the release of inhibitory 
(possibly TH2 type) lymphokines. In the latter case we expect a strictly epitope-
specific phenomenon which presumably requires relatively high doses of fed or 
inhaled antigen. Furthermore, if our observations are consistent with anergy 
rather than suppression, then, similarly to the HEL model of peripheral 
tolerance, we may be able to demonstrate a higher degree of downregulation if 
the overall avidity of TCR-peptide-MHC interactions is increased. This project 
.features experiments on tolerance induction in two models, the H-2d mouse 
model of oral tolerance to OVA and the H-2u mouse model of EAE . 
1.5.3 i Oral tolerance to OVA 
Previous :work addressed the effects of orally administered whole OVA on T 
cell-mediated immune responses upon challenge with the intact OVA molecule. 
The OVA peptide 323-339 was identified as a major epitope for I-Ad-restricted 
co4+ OVA-specific T cells (Shimonkevitz et al, 1984). For this thesis, OVA 323-
339 is used as a tool to investigate in some more detail which epitopes of OVA 
are effective and which epitopes are affected. If the induction of cos+ T 
suppressor cells . is a prerequisite for oral tolerance to OVA, then oral 
administration of OVA but not OVA 323-339 will be effective. Furthermore, 
cos+ T cells induced by antigen feeding may have to encounter their specific 
epitope again at the time of immunization in which case feeding OVA would 
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downregulate immune responses after priming with OVA but not with OVA 
323-339. 
In the light of reports emphasizing the role of B cells as an APC to either 
anergize naive T cells or deviate an immune response towards the TH2 
spectrum, the PP and the spleen as. rich sources of B cells may represent 
lymphoid organs for the preferential downregulation of food antigen-specific 
TH1 responses, either by direct anergy or TH2 deviation. This possibility will be 
addressed by an isotype-specific analysis of OVA-specific IgG. Furthermore, if 
TH2 cells play a role, they may be considered as suppressor cells for TH1 
responses with the potential to downregulate responses to a second antigen in a 
bystander fashion. 
The ability to transfer tolerance with serum from OVA-fed mice revealed a 
peripheral component which -at least in recipients- operates independently of 
the gut. Apart from a yet unidentified tolerogenic factor, whole immunogenic 
OVA which resembled the native form of the molecule was also detectable in the 
serum (Peng, Turner, & Strobel, 1990). This project includes experiments to 
examine both the tolerogenic and antigenic properties of serum from OVA-fed 
mice. 
1.5.3 ii Studies on oral-and inhalation tolerance in the H-2u mouse model of 
EAE 
Experimental autoimmune encephalomyelitis (EAE) represents an instructive 
model for acute inflammatory autoimmune disease, and in certain cases displays 
a chronic-relapsing course similar to multiple sclerosis in humans. Although 
originally induced with whole brain and spinal cord material, it became clear 
that CD4 + T cell dependent immune reactions directed against myelin proteins 
played a critical role. In many models of EAE, myelin basic protein (MBP) and 
proteolipid protein (PLP) are the major target antigens. EAE is inducible by 
immunizing susceptible animals with myelin antigens in CPA or by directly 
transferring specifically activated CD4+ T cells (reviewed in Wraith, 1992). In the 
H-2u mouse model of EAE the dominant I-Au?estricted T cell response is 
directed to the acetylated N-terminal nonapeptide of MBP (Acl-9) which on its 
own is sufficient to induce EAE (Zamvil et al, 1986). The interactions of this 
peptide both with its specific TCR and with the I-Au restriction element have 
been analyzed in detail (Wraith et al, 1989; Wraith, Bruun, & Fairchild, 1992). 
Glutamine at position 3 and proline at position 6 serve as determinants for TCR 
recognition, whereas lysine 4 and arginine 5 are involved in binding to the I-Au 
molecule (Gautam et al, 1992a). In previous studies, analogues of Acl-9 (or Acl-
11) with alanine or tyrosine at position 4 were shown to bind to the I-Au 
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molecule with higher affinity than the original peptide with lysine at position 4. 
Although competitive binding studies revealed an at least 10-fold higher affinity 
of 4A over 4K for I-Au, only the 4Y analogue remained stably bound to I-Au for 
at least 4 hours (Wraith et al, 1989; Fairchild et al, 1993). A recent report features 
a model of Acl-9 complexed to the peptide binding groove of the I-Au molecule, 
showing that the phenyl ring of tyrosine fits optimally into a single predominant 
hydrophobic pocket within the binding groove (Fairchild et al, 1994). Thus, a 
hierarchy of MHC binding affinity was defined as Acl-11 (or Acl-9) 
[4Y]>>[4A]>[4K]. We have applied this well characterized MBP epitope to study 
the effect of peptide feeding and inhalation on the course of EAE. This model 
permits the modulation of the MHC-peptide-TCR avidity based on a hierarchy 
of affinity. Therefore, if direct MHC-peptide-TCR interactions are critical, then 
the higher affinity analogues of Acl-9 may be more potent tolerogens when 
administered intragastrically or through the respiratory tract. Furthermore, 
although Acl-9 is the dominant encephalitogenic epitope in this model, the I-Eu-
restricted peptide 35-47 of MBP represents a subdominant epitope upon 
immunization with whole MBP (Zamvil et al, 1988). This peptide will be used to 
address the significance of epitope dominance for the induction of tolerance. 
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CHAPTER2 
Materials And Methods 
2.1 LIST OF MATERIALS AND SUPPLIERS 
Item 
acetone 
adjuvant complete Freund (CFA) 
albumin, bovine, fraction V 
albumin, chicken egg (ovalbumin) 
gradeV 
ammonia solution (35 % NH3) 
ammonium sulphate 
Benzotriazole-1-yl-oxy-tris-
pyrrolidino-phosphonium 
hexafluorophosphate (PyBOB) 
chloroform 
citric acid 
di-sodium hydrogen orthophosphate 
diatomaceous earth 
dichloromethane (DCM) 
diethylether 
diisopropyle~hylamine 
dimethylaminopyridine (DMAP) 
dimethylformamide (DMF) 
filter mats, for use with cell harvesters 
gamma globulins, human: from Cohn 
fraction II, III (HGG) 
Supplier 
FISONS, Loughborough, England 
DIFCO, Detroit Michigan, USA 
SIGMA, Poole, Dorset, England 
SIGMA, Poole, Dorset, England 
BDH, Poole England 
BDH, Poole England 
N ovabiochem, Nottingham, UK 
FISONS, Loughborough, England 
FISONS, Loughborough, England 
BDH, Poole England 
SIGMA, Poole, Dorset, England 
Sigma-Aldrich, Gillingham, Dorset, 
England 
BDH, Poole England 
SIGMA, Poole, Dorset, England 
Novabiochem, Nottingham, UK 
Sigma-Aldrich, Gillingham, Dorset, 
England 
SKATRON, LTD, Newmarket, Suffolk, 
England 
SIGMA, Poole, Dorset, England 
goat anti-mouse IgG (y-chain-specific), SIGMA, Poole, Dorset, England 
peroxidase conjugate 
goat anti-mouse IgG2a (gamma chain) sera-lab, Crawley Down, Sussex, 
England 
goat anti-mouse IgM (µ- chain SIGMA, Poole, Dorset, England 
specific), peroxidase conjugate 
'I 
hydrochloric acid (HCl), 36% w/w 
hydroxybenzotriazole (HOBT) 
Iscove's Modified Dulbecco's Medium (IMDM) 
L-amino acids for peptide synthesis 
Liquid scintillation cocktail OptiPhase · 
'HiSafe2' 
M tuberculosis H37 RA 
methanol 
Novachrome 600 dye 
NovaSyn KA resin 
N ovaSyn KR resin 
o-phenylenediamine dihydrochloride (ODP) 
pertussis toxin 
phenol 
phosphate buffered saline (PBS) 
Dulbeccos w/o calcium and 
magnesium, w / o sodium bicarbonate 
piperidine 
polyoxyethylene-sorbitan 
monolaurate (Tween 20) 
propanol 
rat anti-mouse IgGl: Biotin 
sample bags, for use with 1205 
Beta plate 
streptavidin-horseradish peroxidase 
sulphuric acid, about 98% 
trifl uoroacetic acid(TF A) 
trypan blue 
trypsin inhibitor, from soybean 
trypsin- chymotrypsin inhibitor, from 
soybean 
tuberculin PPD, bovine 
[Methyl-3H] Thymidine 
May & Baker LTD, Dagenham, 
England 
Novabiochem, Nottingham, UK 
GIBCO BRL, Paisley, Scotland 
Novabiochem, Nottingham, UK 
Wallac, Turku, Finland 
made by FISONS, Loughborough, 
England 
DIFCO, Detroit Michigan, USA 
FISONS, Loughborough, England 
Novabiochem, Nottingham, UK 
Novabiochem, Nottingham, UK 
Novabiochem, Nottingham, UK 
SIGMA, Poole, Dorset, England 
Porton products, Salisbury, UK 
BDH, Poole England 
GIBCO BRL, Paisley, Scotland 
Aldrich Chemical Co LTD, 
Gillingham, Dorset, England 
SIGMA, Poole, Dorset, England 
Hayman Limited, Whitham, Essex, 
England 
serotec, Kidlington, Oxford, England 
WALLAC, Oy Turku, Finland 
Amersham, Little Chalfant, UK 
BDH, Poole England 
Aldrich Chemical Co LTD, 
Gillingham, Dorset, England 
SIGMA, Poole, Dorset, England 
SIGMA, Poole, Dorset, England 
SIGMA, Poole, Dorset, England 
Central Veterinary Laboratory, 
Weybridge, England 
Amersham; Little Chalfon t, UK 
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2.2 PREPARATION OF ANTIGENS 
2.2.1 Purification Of Myelin Basic Protein Form Pig Spinal Cords 
(Pig MBP) 
MBP was prepared from pig spinal cords according to the procedures of 
Eylar, Kniskern, & Jackson (Eylar, Kniskern, & Jackson, 1974). Spinal cords were 
obtained from a local slaughter house and either immediately used or kept at-80 
oc. For all procedures only ice cold reagents were used. Samples were 
centrifuged at 4 oc and handled in the cold wherever possible. No protease 
inhibitors were added. 
For each preparation of MBP, 50 g pig spinal cord was homogenized with 125 
ml methanol in a Servall Omni-mixer. This homogenate was thoroughly mixed 
with 250 ml chloroform and poured into a separating funnel. When the two 
phases were well separated, the lower lipid extract was discarded while the 
upper phase was mixed with diatomaceous earth to give a rather solid mud pie. 
This mixture was placed in a Buchner funnel on filter paper (Whatman) and 
extensively washed with acetone (approximately 500 ml) to extract residual 
lipids. As much acetone as possible was removed by vacuum pumping after 
which the earth was distributed as a thin layer on a piece of foil and left to dry 
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completely. The dry powder was mixed with 500 ml H20.HCL pH2.l, and 
stirred for approximately 16 hours (overnight). The slurry was filtered to yield a 
clear solution. The pH was raised to 5.5 with NH40H and the cloudy sample 
stirred for 1 hour. The precipitate was spun at 15,000 x g for 20 min in a Sorvall 
RC-5B Superspeed centrifuge (DuPont). To the clear supernatant (typically 300-
400 ml) 354g/l ammonium sulphate were slowly added. This corresponded to 
50% saturation at 40c (Dawson et al, eds., 1969). When all the ammonium 
sulphate was completely dissolved, the pH was adjusted to 6.0 with NH40H, 
and the sample left stirring for about 16 hours (overnight). The precipitate was 
spun for 30 min at 15,000 x g and the superna.tant discarded. The pellet was 
dissolved in 15 ml H20. To this solution, 135 ml acetone and 135 µl 12 N HCL 
were added, and the mixture stirred for 1 hour. The precipitate was spun at 
15,000 x g for 30 min. The pellet was dried on an oil vacuum pump, and then left 
in a fume cupboard until the acetone was fully evaporated. The dried pellet was 
resuspended in 20 ml H20 and dialyzed 2x for 1 day each against 1.5-2 1 H20. 
The sample was frozen on liquid nitrogen and lyophilized on a high vacuum 
pump (EDWARDS) for approximately 30 hours. The yield of MBP from each 
preparation was about 50-100 mg lyophilized powder. The purity of MBP was 
examined by sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS 
PAGE) under reducing conditions, and Coomassie blue staining of gels. The 
MBP preparations (20 µg loaded per lane) showed a single predominant band at 
18.5 kD, corresponding to the previously reported molecular weight of the 
porcine MBP isotype (reviewed in Fritz & Mc Farlin, 1989). A few (4-5) faint 
bands of lower molecular weight probably represented small amounts of 
proteolytic degradation products of MBP (not shown). The identity of the 
purified protein with MBP was confirmed by Western blotting (not shown) 
using the monoclonal antibody clone 12 (kindly provided by Nigel Groome, 
Oxford) that was shown to recognize the epitope 82-87 of intact MBP from a 
variety of species (Hruby et al, 1987). 
2.2.2 Preparation Of Mouse Spinal Cord Homogenate 
Spinal cords were flushed from spines with the help of a water-filled syringe. 
The freshly isolated cords obtained from various strains of inbred mice were 
homogenized with a Dounce homogenizer, frozen at-80 oc and lyophilized. The 
lyophilized powder was stored at 4 oc. 
2.2.3 Serum Samples 
In chapter 3, sera from OVA-fed mice were used as a source of antigen for in 
vivo transfer experiments, and in vitro lymphocyte proliferation assays. Balb/c 
mice were fed 20 mg OVA in 200 µl PBS or 200 µl PBS alone. After 1 hour, mice 
were deeply anaesthetized with ether and bled from the neck vein. Blood 
samples were left to clot at room temperature for approximately 1 /2 hour, and 
then kept on ice for 1 hour. The supernatant was removed from the clot and 
spun at 8,000· x g for 5 min in a minifuge (Biofuge A, Heraeus). The serum was 
either used immediately in all transfer experiments, or stored in small aliquots at 
-80°C for use in cell cultures. For 2 experiments in chapter 3, serum samples 
prepared either from Balb / c or Balb / c SCID mice fed with OVA or PBS under 
the same conditions, were kindly provided by Elizabeth Furrie. 
2.2.4 Fractionation Of Serum Samples 
Sera were prepared from OVA-fed or PBS-fed Balb/c mice as described 
under 2.2.3. For the separation of small molecular weight fragments, sera were 
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diluted 1/10 and spun through lOkD size exclusion filters (Millipore, Ultrafree-
CL low binding series) at 4°C 5000 x g for approximately 40-60 min. in an 
Omnifuge 2.0 RS (Heraeus). To wash filters prior to use, they were filled with 2 
ml PBS and spun at 4°C 5000 x g for 10 min. This was repeated twice. The filters 
were subsequently filled with 2 ml of the diluted serum sample. This was 0.2 ml 
serum plus 1.8 ml PBS for OVA-fed and PBS-fed sera. When sera were spiked 
with OVA, this was 0.2 ml PBS-fed serum, 1.6 ml PBS, and 0.2 ml of a 200 µg/ml 
solution (40 µg) of OVA in PBS to yield a concentration of 20 µg/ml OVA in 10% 
serum. For OVA 323-339, 0.2 ml of PBS-fed serum was mixed with 1.4 ml PBS 
and 0.4 ml of OVA 323-339 at 1.5 mg/ml (600 µg). Serum samples were spun as 
mentioned above until approximately 1.5 ml had passed through the filter. Both 
fractions were further diluted as required for the lymphocyte proliferation assay 
(figure 3.3), and sterilized by filtering through a 0.2 µm filter (sartorius). 
2.2.5. Peptide Synthesis 
2.2.5 i Peptide sequences 
The sequences of peptides used in studies on EAE in chapters 4-6 were 
Acl-11 (or Acl-9), Acetyl-ASQKRPSQR(HG) 
Acl-11 (or Acl-9) [4A], Acetyl-ASQARPSQR(HG) 
Acl-11 (or Acl-9) [4Y], Acetyl-ASQYRPSQR(HG) 
(Acl-11 respresents the sequence of the N-terminus of rat MBP, Acl-9 contains 
the sequence of mouse MBP). 
MBP 35-47, TGILDSIGRFFSG 
The sequence of OVA 323-339 used for chapter 3 was ISQA VHAAHAEINEAGR. 
2.2.5 ii Peptide synthesis 
All peptides were synthesized using Fluorenylmethoxycarbonyl-polyamide 
(Fmoc) chemistry (Atherton & Sheppard, 1985). Peptides of MBP were 
synthesized by David Wraith on a LKB-Biolynx 4175 synthesizer using NovaSyn 
KR resin, or provided by Nigel Groome (Oxford). Synthesis on the KR resin 
yields C-terminal amide peptides which have identical T cell stimulating 
properties when compared with peptides bearing C-terminal carboxyl groups 
(David Wraith, unpublished data). Arginine was side-chain protected with the 
Pentamethylchroman-6-sulfonyl (PMC) group and activated with Benzotriazole-
1-yl-oxy-tris-pyrrolidino-phosphonium hexafluorophosphate (PyBOB) and 
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diisopropylethylamine. Other L-amino acids were purchased in an ester-
activated form, containing appropriate side chain protection groups. Serine was 
added as the Fmoc-oxo-benzotriazine ester. All other amino acids were 
pentafluorophenoxy (OPfp) esters. Coupling of each amino acid was followed 
by counter-ion distribution monitoring (Salisbury et al, 1990) with Novachrome 
600 dye on an ULTROSPEC II spectrophotometer (LKB), and allowed to proceed 
to completion at each step. Peptides were acetylated and subsequently cleaved 
and deblocked with 95% trifluoroacetic acid(TFA), 5% H20 for 2 hours. Peptides 
were precipitated with excess ether and the precipitates washed with ether to 
remove residual TFA. The dry precipitates were dissolved in 25% glacial acetic 
acid, lyophilized, dissolved in PBS, filter-sterilized through a 0.2 µm filter 
(sartorius), and stored at -sooc. 
The peptide OVA 323-339 was synthesized using N ovaSyn KA resin and 
otherwise the same equipment as described above for the synthesis of MBP 
peptides. Prior to coupling of the first residue (arginine), 0.9 g resin were left to 
swell for 1 hour in 5 ml Dimethylformamide (DMF). The resin was then carefully 
mixed with 0.5 ml DMF containing 10.5 mg Dimethylaminopyridine (DMAP, 12 
mg DMAP per mg resin). Fmoc-Arg(MTR)-OPFP (0.25mg) was dissolved in 1 ml 
DMF, mixed with the resin and left at room temperature for 1 hour. The resin 
was washed twice with approximately 10 ml DMF, which was decanted after 
each wash. This coupling step was carried out 4x. The resin was subsequently 
washed 3x with each of DMF, dichloromethane (DCM), propanol, and ether. 
After washing, the resin was dried for 1/2 hour each on a water and an oil 
vacuum pump. 
To estimate the degree of attachment of arginine to the resin, triplicates of 10 
mg dried resin were mixed with 20% piperidine in DMF for 2-3 minutes. After 
the resin was settled, the absorbance of the supernatant was measured at 
290nm.The percentage attachment was read from a standard curve published in 
the Biolynx users manual. The absorbance (1.84) corresponded to 100% coupling 
according to the standard. 
The resin was then loaded onto the column of the peptide synthesizer. For 
each coupling step, an appropriate amount of each amino acid (3 x molar excess) 
was dissolved in 1 ml DMF and added to the loading port together with 0.5 ml 
hydroxybenzotryazol (HOBT) at 108 mg/ml. Immediately after the amino acid-
HOBT solution was applied to the column, 1ml of dye was added, followed by 
0.5-1 ml DMF. After each residue, the loading port was washed with methanol 
and filled with 5 ml DMF. The synthesis was controlled by the ' counter-ion 
distribution' program. 
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After completion of the synthesis, the resin was washed 3x with DCM, 
propanol, and ether, and dried on water and oil vaccuum pumps as before. The 
peptide was then cleaved from the resin by treatment with 95% TFA 5% phenol 
(lg phenol dissolved in 19 ml TFA) for 24 hours, during which the resin was 
occasionally mixed. The resin was spun at 1932 x g for 2 min in an Omnifuge 2.0 
RS (Heraeus), and each of two 10 ml samples of the supernatant slowly pipetted 
to 45 ml ether in plastic tubes (falcon). The precipitate was spun at 1932 x g for 5 
min on an Omnifuge 2.0 RS (Heraeus). The pellet was washed 4x in 15 ml ether 
by vigorous vortexing, and spinning between washing steps at 1932 x g for 5 
min as before. After the final wash, the pellets were dried on vaccuum pumps as 
described before. The dry pellets were dissolved in 25% acetic acid (25 ml per 
pellet), frozen in liquid nitrogen, and subsequently lyophilized for 24 hours. The 
peptide powder was re-dissolved in water and freeze-dried again. The peptide 
thus obtained was either stored as a powder at -2ooc in a dessicator, or 
dissolved in PBS, filter- sterilized through a 0.2 µm filter and stored in small 
aliquots at -sooc. 
The HPLC (Waters 600 E) profile revealed a single peak, and the expected 
amino acid content was confirmed by Len Packman in the department of 
biochemistry, University of Cambridge (not shown). 
2.3 MICE 
Female Balb/c mice were purchased from Tucks (UK). PL/J and BlO.PL mice 
were imported from the Jackson laboratories (USA), and bred under specific 
pathogen-free (SPF) conditions in isolators in the Pathology Department, 
Cambridge University. (PL/J x BlO.PL) Fl mice were also bred in isolators at the 
same location. All strains were housed in a SPF facility at Central Biomedical 
Services, Ne:w Addenbrooke's site, Cambridge. For all experiments, only female 
mice were used between 7-14 weeks of age. Groups for each experiment were 
either of the same age or age-matched. 
2.4 METHODS OF ANTIGEN ADMINISTRATION AND 
ANIMAL PROCEDURES 
2.4.1 Feeding 
Antigens were dissolved in PBS or 0.15 M NaHC03 buffer (pH9). In some 
experiments (chapter 4) trypsin inhibitor or trypsin/ chymotrypsin inhibitor was 
47 
included as indicated in the figure legends. When mouse spinal cord 
homogenate (SCH) was fed, this was suspended in PBS at 10 mg/ml and 
sonicated for 10 min in a Branson 1200 sonicator. Antigen solutions or SCH 
suspension were taken up in a 2 ml glass syringe which was then connected to a 
1.5 x 22 G dosing cannula with a rounded tip. For feeding, the cannula was 
carefully inserted approximately 3 cm down into the oesophagus and the 
required volume of antigen solution (200-500 µ1) released from the syringe. 
2.4.2 Inhalation 
Mice were lightly anaesthetized with ether and laid on their backs. A 25 µl 
droplet of peptide solution (100 µg) or 25 µl PBS was pipetted on top of their 
nostrils which was rapidly inhaled as mice regained consciousness. 
2.4.3 Immunization 
Proteins or peptides were dissolved in PBS. A suspension of H37 RA in PBS 
was prepared to further enrich complete Freund's adjuvant (CFA) with 
mycobacterial antigen. A mixture of antigen solution and H37 RA suspension 
was then emulsified with an equal volume of CFA by repeated passage through 
a narrow metal connector between two glass syringes. For priming with SCH, 
the adjuvant was sonicated for 10 min in a Branson 1200 sonicator prior to 
passage through the syringes. The quality of the adjuvant was tested by 
dripping a small amount onto a water surface. 
Each mouse was injected with the required dose of antigen in a total volume 
of 100 µl emulsion subcutaneously at the base of the tail. The doses per mouse 
were 100 µg OVA, or 50 µg OVA 323-339 in chapter 3, and 50 µg Acl-9 (Acl-11), 
50 µg MBP 35-47, 1 mg pig MBP, or 1 mg SCH in chapters 4-6. The amounts of 
H37 RA added to CFA were 100 µg per mouse in all experiments of chapter 3, 
400 µg for all studies on EAE in chapters 4-6, and 200 µg for lymphocyte 
proliferation assays included in chapters 4 and 5. 
2.4.4 Induction of EAE 
PL/J, BlO.PL or (PL/J x BlO.PL) Fl mice were primed with encephalitogenic 
antigens in PBS/CFA subcutaneously at the base of the tail as described under 
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2.4.3. On the day of immunization and 2 days later, mice were also injected 
intraperitoneally with 200 ng pertussis toxin in 500 µl PBS. Mice were monitored 
daily for disease and signs of paralysis analyzed as discussed below. 
2.4.5. Transfer Of Spleen Cells 
Balb/c mice were fed with OVA or PBS as described under 2.4.1. One week 
later, spleens were aseptically removed, taken up in either ice cold PBS or 
IMDM, and single cell suspensions prepared by disrupting spleens with the 
rubber end of a syringe plunger through a stainless steel wire mesh. Splenocytes 
in PBS (0.5 ml per spleen) were immediately injected i.p. (see legend to figure 
3.10 a). Prior to i.v. injection (figure 3.10 b), spleen cell suspensions in IMDM 
were spun once for 5 min. at 309 x g 40c in an Omnifuge 2.0 RS (Heraeus), and 
resuspended in fresh serum-free IMDM. A small aliquot (30 µI) of cell 
suspension was mixed with an equal volume of Trypan blue solution and 
counted for live cells excluding small red blood cells. Spleen cell suspensions 
(108 live cells in 0.5 ml IMDM) were immediately injected i.v. as described for 
figure 3.10 b). 
2.5 ANALYSIS OF DATA DERIVED FROM STUDIES ON 
EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS 
2.5.1 Data Presentation And Analysis 
The central questions addressed in chapters 4-6 of this thesis are whether 
antigen feeding or inhalation have any (protective) effect on EAE. One way of 
evaluating disease is based on the severity of limb paralysis. This approach was 
applied to all experiments on EAE presented in this thesis. Paralysis was scored 
with grades ranging from 0-5 defined as follows: 
0 no paralysis 
1 flaccid tail 
2 partial hind limb paralysis and impaired righting reflex 
3 total hind limb paralysis 
4 fore and hind limb paralysis 
5 death or moribund 
Generally, paralysis in EAE progressed from the tail and the hind limbs to 
the front limbs. Very occasionally, an animal displayed signs of front limb 
paralysis before the hind limbs were affected. In this case, partial front limb 
paralysis was also scored as grade 2. 
Additionally, weight loss as a result of inflammatory responses and muscle 
wasting may also be a useful indicator of disease severity. It often precedes the 
signs of paralysis and can therefore be measured to predict the onset of EAE 
(that is the onset of paralysis). This aspect is relevant for experiments presented 
in chapter 6, while the data in chapters 4 and 5 are based on paralysis only. 
The course of EAE in each experiment is presented in a plot of mean grade 
EAE as a function of time. Here, we illustrate the overall severity of disease in a 
group of mice as a whole on individual days. For this, the cumulative disease 
score added from the grades of all mice belonging to a group was divided by the 
number of mice per group. In addition to this approach, there are other 
parameters that utilize data on the manifestation of EAE in individual mice, such 
as the incidence of EAE, the day of onset, and the mean maximal severity. These 
data are presented in a table underneath each plot and subjected to statistical 
analysis. 
The experiments on EAE aimed to investigate whether oral or intranasal 
administration of antigen had a significant effect on disease. A statistical analysis 
usually starts with the formulation of the Null Hypothesis Ho, a hypothesis of 
"no effect". For this project the Null Hypothesis therefore states that feeding or 
inhaling antigen has no effect on EAE. An appropriate statistical test is then 
applied to evaluate whether Ho can be rejected in favour of the alternative 
hypothesis Hl. Hl is the operational statement of our research hypothesis, 
namely that feeding or inhalation of CNS-derived antigens does have an effect 
on EAE. Ho is rejected in favour of Hl if a statistical test yields a value whose 
associated probability p of occurrence under Ho is equal to or less than some 
small probability. That probability is often referred to as the 'level of 
significance'. In many studies including this thesis, a common maximal level of 
significance is set at p=0.05. In other words, if the_probability for Ho being true is 
equal to or less than 5%, this probability is considered sufficiently small to reject 
Ho and accept Hl instead. 
If our alternative hypothesis stated that feeding or inhalation had a protective 
effect, then we would already assume that significant differences between 
controls and treated groups would always reveal less severe disease for treated 
animals. In other words the hypotheses Ho and Hl already have a defined 
direction. If we are so sure that the theory underlying Hl permits only one 
direction, then we will have to consider any opposite effect of treatment, i.e. that 
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feeding or inhalation exacerbates EAE, as a chance effect which cannot be 
indicative of a real difference. In this case we would choose to analyze our data 
with a one-tailed test, since the probability region of the distribution which 
determines the rejection of Ho (region of rejection) e.g.p < 0.05 is entirely at one 
end or tail of this distribution. In contrast, if Ho and Hl are not biased towards a 
certain direction, then a two-tailed test is appropriate for which the region of 
rejection is located at both ends of the distribution while maintaining the overall 
size of this probability region. For instance, if the probability of two selected 
groups belonging to the same population is 5%, a two-tailed test will yield 
p=0.025 at either end of the distribution (Siegel & Castellan, 1988). 
At the beginning of this section, the null hypothesis was stated in general 
terms without implying a direction, namely that feeding or inhaling CNS-
derived antigens has an effect on EAE. Although the term of 'oral tolerance' 
implies a direction, there are numerous examples in the literature to show that 
oral administration of an antigen does not always induce tolerance (discussed in 
chapter 1). Intranasal administration of antigens as a route of tolerance induction 
is far less well characterized than antigen administration by the intragastric 
route. Since published data on oral or inhalation tolerance in the H-2u mouse 
model of EAE were not available, we could not assume that feeding or 
inhalation would be protective under our experimental conditions. We therefore 
avoided including a direction in Ho. Consequently, all data were analyzed by 
two-tailed tests. 
2.5.2 Statistical Tests 
2.5.2. i Incidence of disease 
Here we ·asked whether or not a mouse got EAE during the time of the 
experiment. We only distinguished between sick and healthy, thereby using a 
nominal or categorical scale. We then examined ~hether there was a significant 
difference between any two experimental groups treated in different ways. The 
Fisher exact probability test is a useful technique for analyzing discrete data 
when the two independent samples are relatively small, say between seven and 
10 subjects per group as in most experiments on EAE. To calculate the p value, 
the scores were represented by frequencies in a 2x2 contingency table with the 
column heading indicating the two experimental groups and the row stating the 
two classifications given by the treatment. The test then determines whether the 
two groups differ in the proportions with which they fall into the two 
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classifications. Computation of the test equation provides an exact probability 
value (Siegel & Castellan, 1988). 
2.5.2. ii Median day of onset 
The variable "day of onset" may have any value between the induction of 
EAE on day O and the day on which the experiment is terminated. When all 
animals got EAE, then the differences and distances between any two values 
were clearly defined and fulfilled the characteristics of an interval scale. This 
would have permitted the use of parametric statistical tests such as the t-test 
which are usually more powerful than nonparametric tests. However, animals 
that remained healthy could not be characterized by a meaningful value within 
day O and the end of the experiment. The day of onset in these cases was 
described as '> time of experiment'. This relation no longer fulfilled the 
requirements for an interval scale. We therefore had to lo, ,se some information 
for statistical analysis and apply an ordinal or ranking scale, instead. The 
distribution of the values for the day of onset was described by the median, i.e. 
when the only condition that had to be met was an equal number of scores 
above and below the median value. To evaluate the differences between days of 
onset between any two groups, each value within these groups was given a 
rank, and the significance of the rank sum differences between the groups were 
evaluated by the Mann-Whitney U-test (Campbell, 1974). 
2.5.2. iii Mean maximal EAE 
The grades 0-5 constitute an interval scale. This permitted data analysis by a 
parametric test which focuses on the means of two groups. One standard 
procedure for comparing the means of two groups is Student's t-test. This test is 
based on the assumptions that the two groups have 1) a normal distribution and 
that 2) thei~ variances (square of standard deviations) are the same. The first 
condition could not be tested since it would have required group sizes of at least 
one hundred. Fortunately, however, the t-test is said to be relatively "robust" i.e. 
not much affected by deviations from the normal distribution. From the 
experience of many EAE experiments we know that the grades of severity often 
approximate a "normal" distribution with most animals getting disease scores of 
2 or 3 and some having mild EAE with grade 1 or more extreme grades in the 
other direction of 4 or 5. There were, however, examples where some mice got 
severe EAE of at least grade 3 while the majority of animals remained healthy, 
i.e. was represented by grade 0. In these cases the standard deviations were 
greater than the actual means, so that the application of the t-test was 
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meaningless. In these cases, the values in the tables under "mean maximal EAE" 
are marked by an asterix to indicate this fact. Obviously, for these examples, the 
most meaningful parameter to consider is the incidence of disease. 
In some experiments the data suggested that the variances between groups 
were not equal. In these cases the variance ratio test (F-test) was used to evaluate 
whether the variances between two groups differed significantly at the 5% level 
(p< 0.025 for two-tailed probability analysis). When there was a significant 
difference, the data were analyzed by the Behrens-Fisher test for unequal 
variances instead of Student's t-test. This is indicated in the figures underneath 
the tables. Otherwise the given p values were derived from computation of the 
data according to Student's t-test (Campbell, 1974). 
2.6 EVALUATION OF IMMUNE RESPONSES 
2.6.1 In Vitro Proliferation Assay For Primed Lymph Node T Cells 
This method tests secondary in vitro proliferative responses of lymphocytes 
obtained from lymph nodes draining the site of subcutaneous antigen/ CFA 
injection. Although whole lymph node cells were used rather than purified 
CD4 + T cells, previous reports clearly showed that under the assay conditions 
described below only primed CD4+ T cells may be activated in vitro (Corradin, 
Etlinger, & Chiller, 1977; Schrier et al, 1979; reviewed in Taylor, Thomas, & Mills, 
1987). 
2.6.1 i Preparation of antigens for cell culture 
Antigens were dissolved in PBS to lOx the final concentration, sterilized by 
filtering through a 0.2 µm filter (sartorius), and further diluted in serum free 
IMDM to twice the final concentration required in the assay. Purified protein 
derivative (PPD) of mycobacterium tuberculosis was supplied in 5 ml samples 
which were dialyzed 2x for approximately 12 hours against 500 ml distilled 
water and also filter-sterilized. Aliquots were kept at -80 oc. In all assays, PPD 
was included as a positive control, and added to culture wells at a final 
concentration of 50 µg/ml. Each well contained 100 µl of either the specific test 
antigen, PPD, or IMDM only as a negative control for proliferation in the 
absence of exogenous antigen. 
2.6.1. ii Preparation of lymphocytes 
Mice were primed with antigen in CFA subcutaneously at the base of the tail 
as described under 2.4.5. Ten days later, the draining lymph nodes (inguinal, 
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popliteal and paraaortic) were aseptically removed and taken up in ice cold 
IMDM medium. Single cell suspensions were prepared by disrupting lymph 
nodes with the rubber end of a syringe plunger through a sterile stainless steel 
wire mesh. The cells were spun once for 5 min at 309 x g, 4 oc in an Omnifuge 
2.0 RS (Heraeus), and resuspended in IMDM supplemented with 1 % fresh 
syngeneic normal mouse serum which was prepared with blood samples from 
untreated mice as described under 2.2.3. A small aliquot (30 µl) of cell 
suspension was mixed with an equal volume of Trypan blue solution and 
counted for live cells. Lymphocyte suspensions were then further diluted to a 
densitiy of 8 x 106 live cells/ml and 100 µI of cell suspension, i.e. 8x105 cells/well 
added to 96 well, flat bottomed cell cuture plates (Falcon 3072, Becton 
Dickinson) containing 100 µl of antigen solution. Plates were incubated at 37 oc, 
5% C02 in a LEEC incubator for a total of approximately 90 hours, and pulsed 
with 0.5 µCurie of tritiated thymidine in 25 µl IMDM per well for the last 20 
hours of incubation. The contents of the culture wells was sucked with distilled 
water onto filter mats on a Skatron Combi cell harvester. The dried filters were 
soaked with scintillation fluid, sealed into sample bags, and tritium decay 
counted on a LKB Wallac 1205 betaplate liquid scintillation counter. 
For each experiment, samples were plated in triplicates and the arithmetic 
means of antigen specific proliferative responses illustrated in plots of 3-H 
thymidine uptake against a titration of antigen. The standard deviations of 
triplicates, usually between 10-15% of the means, were omitted from the plots 
for the sake of clarity. The means and standard deviations of control values for 
medium only and PPD are included in the figure legend or stated beside the plot 
symbols. 
2.6.2 Isotype-Spedfic Enzyme-Linked Immunosorbent Assay 
(ELISA) 
2.6.2. i Assay conditions 
Balb/c mice were immunized with OVA (see 2.4.3) and serum samples 
prepared 3 weeks later as described under 2.2.3. The serum was kept at -Booe in 
small aliquots. For ELISA, sera were diluted in PBS. 
Flat-bottomed microtitre plates (Falcon 3912, Becton Dickinson) were coated 
overnight at 40c with 50 µI/well of 1 mg/ml ovalbumin in PBS. Plates were 
washed 2x with PBS and blocked with 200 µI/well of 1 % BSA in PBS for 1-2 
hours at room temperature (RT). After blocking, plates were washed 6x with 
PBS containing 0.05% Tween 20 (PBS/Tween). Between the last 3 washes 
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PBS/Tween was left within the wells for 3-5 minutes. The plates were then 
incubated for 2-3 hours at RT with 50 µI/well of diluted serum samples and a 
titration of a standard for subsequent quantitative analysis of serum antibody 
levels. These standards were either dilutions of a purified anti-OVA IgG (kindly 
provided by Elizabeth Furrie, London) for the analysis of total IgG, IgGl, and 
IgG2a, or, for IgM, a standard serum previously shown to contain appropriate 
amounts of anti-OVA IgM. After washing 6x with PBS/Tween, 50 µl of the 
detection antibody reagent was added to each well and incubated for 1-2 hours 
at RT. The isotype-specific antibody reagents had been tested previously against 
affinity-purified monoclonal antibodies of known isotype (Richard Smith, 
unpublished data). These reagents were prepared as follows: To detect total IgG 
within serum samples, a y-chain specific goat anti-mouse antibody was diluted 
1/5000 in PBS. This antibody was directly conjugated to horse radish peroxidase 
(HRP). An HRP-linked goat anti-mouse IgG2a antibody was diluted 1/100 in 
PBS/1 % BSA. The goat anti-IgM reagent was also directly conjugated to HRP 
and used at 1/1000 dilution in PBS. The rat anti-IgGl antibody was biotin-linked 
and used at 1/50 in PBS/Tween containing 1 % BSA. After incubation, all plates 
were washed 6x with PBS/Tween as before. For the biotin-linked anti-IgGl 
antibody, 50 µl of HRP-streptavidin diluted 1/1000 in PBS/1 % BSA were added 
to each well and incubated for 30-60 min at RT. Plates were washed 6x with 
PBS/Tween as before. All plates were subsequently developed with a substrate 
containing 25 mM citric acid, 25 mM Na2HP04 in H20 and one 4 mg tablet of 0-
phenylenediamine dihydrochloride (ODP) plus 4 µl of 30 % H202 per 10 ml 
substrate solution. The plates were incubated with 100 µI/well of this 
· developing reagent at RT until the colour turned yellow (approximately 5 
minutes). The reaction was stopped by adding 50 µl of lM H2S04 to each well 
and the absorbance measured at 492 nm on a Titertek Multiskan Plus (Flow 
Laboratories). Blank wells contained developing reagent only. The background 
or nonspecific absorbance for other negative controls (sera from untreated 
Balb/c mice or wells containing secondary antibodies without serum samples) 
was negligitble. 
2.6.2. ii Data analysis 
Each plate contained a titration of standard anti-OVA IgG or a standard 
serum from OVA-primed mice, from which the immunoglobulin concentrations 
for all test serum samples assayed on the same plate were read. The relative 
amounts of immunoglobulins in each serum sample were calculated by choosing 
the serum dilution which yielded an absorbance value within the straight line of 
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a semi-logarithmic plot of absorbance at 492nm versus standard IgG or standard 
serum concentration in arbitrary units (for the purified anti- mouse IgG antibody 
standard, the arbitrary units correspond to µg/ml). 
For statistical analysis, the data distribution between the relevant PBS-fed 
and OVA-fed groups were tested for variance differences (F-test) and analyzed 
by either the Behrens-Fisher test or Student's t-test as described under 2.5.2 iii. 
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CHAPTER3 
Oral Tolerance To Ovalbumin 
3.1 INTRODUCTION 
Oral tolerance to Ovalbumin (OVA) has been extensively studied in mouse 
models (reviewed in Mowat, 1987), in particular in Balb/c (H-2<l) and 
(DBA/2xC57BL/6J) Fl (H-2<lxH-2b) strains. Intragastric administration of OVA 
suppressed subsequent specific cellular immune responses such as delayed type 
hypersensitivity (DTH) in vivo (e.g. Miller & Hanson, 1979; Titus & Chiller, 1981; 
Mowat, 1986; Lamont et al, 1988; Ishii et al, 1993) or secondary in vitro 
lymphocyte proliferation and IL-2 secretion (Richman et al, 1978; Miller & 
Hanson, 1979; Melamed & Friedman, 1993 a and 1993 b).The humoral branch of 
the immune system was also affected as assessed by decreased titres of OVA-
specific IgE, IgM, and IgG (Ngan & Kind, 1978; Titus & Chiller, 1981; Mowat et 
al, 1982; Lamont et al, 1988). 
A number of studies showed that specific T suppressor cells accounted for at 
least part of the mechanism underlying the phenomenon of oral tolerance. The 
ability to inhibit OVA-specific DTH- and immunoglobulin responses could be 
transferred to naive recipients with splenocytes from OVA-fed donors (Miller & 
Hanson, 1979; Lamont et al, 1988). More recently, successful transfer of tolerance 
to OVA was also achieved with Peyer' s patch cells for which the tolerogenic 
capacity appeared to be abrogated by prior depletion of cos+ T cells (Ishii et al, 
1993). Furthermore, administration of drugs thought to specifically affect T 
suppressor cells such as cyclophosphamide (CY) or 2-deoxyguanosine (2d Guo) 
prevented the induction of oral tolerance (Mowat et al, 1982; Mowat, 1986; 
Lamont, 1988). However, tolerance by cell transfer was not readily demonstrated 
for in vitro proliferation of lymphocytes from OVA-primed recipients. 
(Challacombe & Tomasi, 1980; Miller & Hanson, 1979). Cell mixing experiments 
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in vitro with lymphocytes from OVA-fed and control animals also failed to 
reveal suppression (Richman et al, 1978; Melamed & Friedman, 1993a). Instead, 
concomitant inhibition of IL-2 production in vitro and diminished expression of 
IL-2 receptors appeared to be indicative of T cell anergy (Melamed & Friedman, 
1993a). 
The evidence in favour of a role for CDs+ T suppressor cells suggests that 
MHC class I-restricted epitopes need to be processed from orally administered 
OVA. On the other hand, the failure to demonstrate the significance of 
suppressor mechanisms for T cell nonresponsiveness in vitro implies that 
suppressor-independent mechanisms also contribute to the phenomenon of oral 
tolerance. The questions addressed in this chapter concern the relevant 
fragments or epitopes of the OVA molecule involved in the induction of oral 
tolerance. An intriguing finding in this respect was the ability to transfer 
tolerance to naive recipients with serum taken from donors one hour after 
feeding OVA. Although the nature of this tolerogenic serum factor was not 
identified, it could be removed by adsorption to a solid-phase anti-ovalbumin 
matrix (Bruce & Ferguson, 1986a). This observation suggested that the 
tolerogenic factor shared at least one B cell epitope with the native OVA 
molecule. On the other hand, analyzing serum samples by ELISA or FPLC gel 
filtration and anion exchange chromatography, Peng et al showed that the 
presence of the tolerogen did not correlate with the presence of intestinally 
absorbed OVA in the serum. The generation of the tolerogen was strictly time 
dependent and required one hour interval between feeding and serum sampling 
whereas a form of OVA indistinguishable from the native molecule was 
detectable as early as 5 min after feeding (Peng, Turner, & Strobel, 1990). 
Transfer of the OVA-derived tolerogenic serum factor fulfilled some but not all 
requirements for tolerance induction since serum recipients displayed impaired 
OVA-specific DTH reactions yet developed normal levels of anti-OVA 
antibodies (Strobel et al, 1983). In the same report, cyclophosphamide abrogated 
specific tolerance induction in recipients of serum from OVA-fed donors. These 
results implied that the tolerogenic serum factor might activate CY-sensitive (T 
suppressor-) cells. The generation of the serum, tolerogen did not require an 
intact intestinal epithelium. Cyclophosphamide which acts on rapidly dividing 
cells such as intestinal enterocytes did not abrogate the generation of the 
tolerogenic factor in serum donors (Strobel et al, 1983). Furthermore, the failure 
to transfer tolerance with the serum from irradiated OVA-fed mice could be 
overcome by reconstituting serum donors with normal spleen cells in spite of a 
severely damaged gut epithelium (Bruce et al, 1987).Another important 
observation was the failure to generate the tolerogenic factor in SCID mice 
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suggesting that immunocompetent cells were critical (Furrie, 1992). The 
evidence for the generation of a yet unidentified tolerogenic factor and the 
presence of whole OVA in the serum upon OVA feeding suggests that the serum 
contains both tolerogenic and immunogenic elements. This project investigates 
both the tolerogenic properties of "OVA-fed" serum in transfer experiments and 
examines its tolerogenic and antigenic properties for OVA-specific T cell 
responses in vitro. 
The OVA peptide 323-339 represents a major epitope for OVA-specific I-Ad-
restricted T cells (Shimonkevitz et al, 1984). It is therefore well suited for studies 
on oral tolerance to OVA in Balbi c mice (H-2d) which are among those strains 
with the most effective suppression of both DTH-and antibody responses 
(Lamont et al, 1988). This peptide is used to investigate to which extent a MHC 
class II-restricted epitope can account for phenomena of oral tolerance. If the 
induction of CDs+ T cell is essential, then feeding OVA but not OVA 323-339 
will induce tolerance. As shown for other models of specific immune 
suppression, these suppressor cells would probably have to be restimulated at 
the time of an antigenic challenge (Miller et al, 1993). In this situation, feeding 
OVA could be expected to downregulate immune responses after immunization 
with whole OVA but not with OVA 323-339. If suppressor cells are induced and 
operate through the release of inhibitory lymphokines, they may also 
downregulate immune responses to a second (not previously fed) antigen in a 
bystander fashion. For this project, cellular immune responses in Balbi c mice 
were examined in an in vitro proliferation assay as a suitable method to analyze 
. the relative significance of different antigenic stimuli. Previous work on 
antibody responses is extended using an isotype-specific ELISA to examine the 
effect of OVA feeding on differential TH1ITH2 lymphokine regulation and T 
helper cell populations. 
3.2 RESULTS 
3.2.1 Antigen-Specificity Of Oral Tolerance To OVA And The 
Question Of Bystander Regulation 
The first experiment tested the antigen-specificity of the effect of orally 
administered OVA on in vitro proliferative responses of OVA-primed 
lymphocytes. Among several suitable control antigens, human gamma globulin 
(HGG) and OVA induced directly comparable levels of proliferation at 
equimolar concentrations in vitro, whereas responses to human serum albumin 
and bovine cytochrome c tended to be weaker (not shown). For the experiment 
suggesting that immunocompetent cells were critical (Furrie, 1992). The 
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in figures 3.1 Balb / c mice were fed 20 mg OVA one week prior to priming with 
either OVA, HGG or both antigens included in the same adjuvant. After 10 days 
lymphocytes were restimulated in vitro with both antigens in separate cultures. 
The data presented in figure 3.1 clearly show that there was no nonspecific 
response of OVA-primed lymphocytes to HGG, and likewise no proliferation of 
HGG-primed cells with OVA, thus excluding the possibility of cross-reactivity 
between these two antigens. Proliferative responses to OVA were strongly 
reduced as a result of prior intragastric administration of OVA. This was true 
whether OVA-fed mice were primed with OVA alone or with a mixture of OVA 
and HGG (figure 3.la). The inhibitory effect of OVA feeding on lymphocyte 
proliferation was antigen specific since feeding OVA did not affect the response 
of HGG-primed lymphocytes to HGG (figure 3.lb). The groups that were co-
immunized with OVA and HGG were included to address the possibility of 
bystander regulation. If intragastric administration of OVA induces regulator 
cells which operate by the release of inhibitory lymphokines, these soluble 
mediators may impair the functions of nearby T cells in an antigen-independent 
bystander fashion. Thus, if a second antigen (HGG) is coinjected with antigen 
that was previously fed (OVA) thereby attracting OVA-and HGG-specific 
lymphocytes to the same microenvironment, some bystander inhibition of the 
proliferative response to HGG may be expected. However, the plots in figure 
3.lb for PBS-fed or OVA-fed and OVA+HGG-primed lymphocytes are virtually 
superimposable. The same results were obtained in a second experiment of this 
kind (not shown). These data demonstrate that feeding a single dose of 20 mg 
OVA one week before immunization with the same antigen lead to a marked 
reduction of specific in vitro proliferative responses to OVA. This effect was 
strictly antigen-specific and also excluded bystander inhibition of the responses 
to a second antigen (HGG) coinjected with OVA. 
3.2.2 Antigenicity Of OVA, OV A323-339 And Serum From OVA-
Fed Mice (Ova-Fed Serum). 
We then attempted to specify relevant antigenic OVA fragments for OVA-
primed lymphocytes. In addition to the previously identified peptide OVA 323-
339 we also considered the serum from OVA-fed mice as a potential source of 
antigenic fragments . It seemed conceivable that the intact OVA present in the 
serum or the toletogenic factor itself may evoke proliferation of OVA-primed 
lymphocytes iri vitro. Since the requirements for eliciting secondary immune 
responses are less stringent than for primary responses<* ), an OVA fragment 
that is tolerogenic for a primary response might nevertheless be able to elicit a 
* :rl(.,.Js ~ hal-2.-i'~ 1 1"lct2.. 
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secondary response. Thus, the purpose of the experiment presented in table 3.1 
was to use the serum from mice that were fed OVA one hour before as a source 
of OVA-derived antigenic fragments to stimulate in vitro proliferation of OVA-
primed lymphocytes. The data shown in table 3.1 clearly reveal the presence of a 
potent antigenic factor in OVA-fed serum. Since proliferation of lymphocytes 
from control mice was negligible and serum from PBS-fed mice did not 
stimulate either control or OVA-primed lymphocytes, this serum factor was 
clearly derived from OVA, and specifically activated OVA-primed cells. 
However, these findings did not yield any information about the nature of 
the antigenic serum factor (SF). Intestinal tryptic digestion of OVA after feeding 
might contribute to the generation of (SF). In this case, not only OVA-primed 
lymphocytes but also lymphocytes from mice immunized with OVA 323-339 
should proliferate in response to OVA-fed serum. To address this question, 
OVA- or OVA 323-339-primed lymphocytes were restimulated in vitro with 
OVA, OVA 323-339 or dilutions of serum from PBS-fed or OVA-fed Balbi c. As 
shown in figures 3.2a and b both groups of lymphocytes, whether primed with 
the whole antigen or the OVA peptide 323-339 proliferated vigorously when 
incubated with either OVA (figure 3.2a) or OVA 323-339 (figure 3.2b). Although 
lymphocytes responded more strongly when restimulated in vitro with the 
homologous antigen, i.e. OVA-primed lymphocytes with OVA and OVA 323-
339-primed cells with this peptide, the results clearly demonstrate that a 
physiologically relevant epitope was generated from OVA that was either 
identical or cross-reactive with OVA 323-339. In contrast, there was no 
proliferation above background when OVA 323-339-primed cells were incubated 
with OVA-fed serum. While OVA-primed cells proliferated strongly when 
restimulated with serum from OVA-fed mice, the dose response curve to the 
OVA-fed serum using OVA 323-339-primed cells was identical with the negative 
controls, i.e. OVA-or OVA 323-339-primed cells incubated with PBS-fed serum. 
These data suggested that OVA 323-339 and SF might represent distinct non-
crossreactive epitopes of OVA. Alternatively, a simpler explanation is based on 
quantitative rather than qualitative differences, namely the much lower 
sensitivity of peptide-primed versus OVA-primed lymphocytes in response to 
whole OVA in vitro (figure 3.2a). It is therefore conceivable that OVA-fed serum 
contained whole OVA at concentrations sufficient to be detected by OVA-
primed but not by peptide-primed cells. 
To distinguish between these possibilities, OVA-fed serum was spun through 
a 10 kD molecular size exclusion filter and the < 10 kD and > 10 kD fractions 
tested against OVA-primed lymphocytes in vitro (figure 3.3). As controls, OVA-
primed cells were restimulated with PBS-fed serum spiked with either OVA or 
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OVA 323-339 (figure 3.3a). To allow for a quantitative estimate, lymphocytes 
were also tested against OVA or OVA 323-339 (figure 3.3b). Figure 3.3a shows 
that all > 10 kD fractions elicited significant proliferation. This was expected 
since the serum samples were not spun to completeness and therefore some < 10 
kD fragments such as OVA 323-339 added to PBS-fed serum were retained in the 
> lOkD fraction. Importantly however, the only < lOkD fraction capable of 
restimulating OVA-primed cells was derived from OVA 323-339-spiked PBS-fed 
serum. The data for the < 10 kD fractions of OVA-spiked PBS-fed serum and 
OVA-fed serum were identical and did not exceed background levels at any of 
the three titration points. These findings did not prove but were consistent with 
the possibility of the serum factor being identical with whole OVA. A 
comparison of the proliferative responses to a titration of OVA in figure 3.3b and 
to serum fractions in figure 3.3a allowed to estimate the amounts of OVA 
present in OVA-fed serum: the response to 10-3.3 (= 0.0005) parts of fractionated 
OVA-fed serum (about 14,000 cpm) was equivalent to OVA between 10-9 Mand 
10-10 M. This implied that neat serum contained between 2x 10-6 Mand 2x 10-7 
MOVA which is about 8-80µg/ml. This is an overestimate since the volume of 
the> 10 kD fraction was reduced by spinning to about 1/4 of its original size 
while OVA was obviously retained. If we correct for this factor then neat OVA-
fed serum contained between 2-20µg/ml OVA. To test whether this method of a 
quantitative estimate was meaningful, the proliferative responses to OVA-
spiked PBS-fed serum were also considered. Before spinning, 10% PBS-fed 
serum was spiked with 20 µg/ml OVA. This was concentrated to about 80 
µg/ml after spinning. Hence there was a final concentration of about 4 µg/ml 
OVA at 10-2.3 parts fractionated serum . The proliferative response after two 
ten-fold dilutions (10 -4.3 parts serum fraction) i.e. at 40 ng/ml OVA reached 
about 17,000 cpm (figure 3.3a). This corresponded to the response to 10-9 M 
OVA (figure 3.3b) which is also 40 ng/ ml OVA. 
In summary, the data presented in this section show that OVA 323-339 
includes a physiologically relevant epitope for freshly isolated OVA-primed 
lymphocytes. Furthermore the serum derived from mice fed with 20 mg OVA 
one hour before is also strongly antigenic for OVA-primed cells. SF probablr 
exceeds a molecular size of 10 kD and may be identical with whole OVA in the 
range of 2-20µg/ml in this experiment. 
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3.2.3 Relative Inhibitory Effects Of OVA Feeding On The 
Proliferation Of OVA-Primed Lymphocytes In Response 
To OVA, OVA 323-339 And OVA-Fed Serum 
Previous results revealed substantially diminished OVA-specific proliferation 
as a consequence of prior oral administration of OVA (figure 3.1). We then 
assessed the relevance of individual OVA-derived epitopes such as OVA 323-339 
and the antigenic component contained within OVA-fed serum for this 
phenomenon. 
To compare the inhibitory effects of OVA feeding on the response to OVA 
323-339 with respect to whole OVA, mice were fed and subsequently primed 
with OVA (figure 3.4). When lymph node cells from OVA-fed mice were 
incubated with either OVA (figure 3.4a) or OVA 323-339 (figure 3.4b) the 
proliferative response to the peptide was reduced to almost the same degree as 
to OVA with cpm values reaching about 50 % of cultures with cells from control 
animals. Thus, feeding OVA affected T cells specific for OVA 323-339. 
In the following experiment shown in figure 3.5, the effect of OVA feeding on 
secondary in vitro activation by either OVA (figure 3.Sa) or OVA-fed serum 
(figure 3.Sb) was compared. In the previous section we have shown that SF may 
be identical with intact OVA. We have not, however, excluded the possibility of 
SF representing an antigenic fragment of OVA with a molecular size bigger than 
10 kD but smaller than the whole OVA molecule. In fact, early experiments 
using 30 kD exclusion filters suggested that SF was smaller than 30 kD (not 
shown). Coomassie blue or silver-stained protein gels revealed that this filter did 
indeed faithfully retain serum proteins with a molecular size larger than 30 kD. 
However, a conclusive analysis was hampered by the finding that the Sigma 
OVA preparation itself contained smaller degradation products which left a 
smear reaching far below the actual 43 kD band for intact OVA on silver stained 
protein gels. (not shown). Thus, the question as to whether SF were a fragment > 
10 kD but smaller than intact OVA and possibly identical with the tolerogenic 
factor remained open. To further address this question, we explored the 
interesting finding that tolerance transfer usually done with serum from OVA-
fed Balbi c mice proved unsuccessful when the serum for transfer was taken 
from OVA-fed SCID mice (Furrie, 1992). Therefore, if the antigenic SF were 
identical with the tolerogenic factor, one would expect OVA-primed 
lymphocytes to fail to respond to serum taken from OVA-fed SCID mice. 
Therefore, OVA-primed lymphocytes from Balb I c mice previously fed OVA or 
PBS were incubated with OVA (figure 3.Sa) or assayed against serum from 
OVA-fed Balbi c, PBS-fed Balbi c and OVA-fed SCID mice (figure 3.Sb). The data 
reveal two important points: f irstly, the proliferative responses to serum from 
OVA-fed Balbi c and OVA-fed SCID mice were identical with all groups of 
lymphocytes. Secondly, the degree of inhibition by prior OVA feeding at 
comparable levels of proliferation (i.e. 5000-25000 cpm) was at least as high with 
OVA-fed serum (figure 3.5b) as with OVA (figure 3.Sa). 
To confirm these observations, the assays described for figures 3.4 and 3.5 
were repeated within the same experiment to allow for direct comparison of all 
three relevant antigenic stimuli, i.e. OVA, OVA 323-339 and SF (figure 3.6). 
Again, OVA-specific lymphocytes strongly proliferated in response to both sera 
from OVA-fed Balbi c or SCID mice in exactly the same way. This finding also 
suggested that the factor responsible for tolerance transfer did not have any 
impact, either stimulatory or inhibitory, on the proliferation of OVA-primed T 
cells under these conditions. As already shown in the previous experiment, 
proliferation of OVA-primed cells taken from orally tolerized mice in response 
to OVA-fed Balblc or Balblc SCID serum was substantially reduced compared 
to controls (figure 3.6c). As expected, OVA-primed cells proliferated strongly 
when activated with both OVA or OVA 323-339, although in molar terms, whole 
antigen added to cultures provided a more 100-1000 times more effective 
antigenic stimulus than the peptide, an observation already described for the 
experiment presented in figure 3.4. Diminished proliferation with lymphocytes 
from OVA-fed mice was observed upon restimulation with both OVA (figure 
3.6a) and OVA 323-339 (figure 3.6b) confirming previous results. 
·3.2.4Proliferative Responses Of OVA 323-339-Primed 
Lymphocytes After Oral Administration Of OVA 
Figures 3.4 and 3.6 showed that oral administration of OVA affected T cells 
specific for OVA 323-339. However, lymphocytes primed with OVA did not 
proliferate as strongly to OVA 323-339 as lymphocytes primed with just this 
peptide (figure 3.2). Therefore, to test the relevance of lymphocytes specific for 
OVA 323-339 in oral tolerance to OVA under more clearly defined conditions, 
mice were fed OVA and subsequently immunized with OVA 323-339 rather than 
OVA (figures 3.7). More importantly, with regard to putative MHC class I-
restricted T suppressor cells, priming with the I-Ad-restricted peptide OVA 323-
339 will reveal whether or not an antigenic challenge with a single MHC class II-
restricted peptide alone is sufficient to demonstrate an inhibitory effect on 
secondary in vitro lymphocyte responses. The data in figure 3.7 clearly 
demonstrate that in two experiments, proliferation of OVA 323-339-primed T 
cells was reduced as a result of OVA feeding. Although the overall degree of 
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reduction after orally administered OVA was higher in experiment 2 than in 
experiment 1 (table underneath legend to figure 3.7), proliferative responses 
appeared to be equally affected whether lymphocytes were restimulated with 
OVA or OVA 323-339. Together with previous results, these data suggest that 
the overall pattern and degree of reduction was very similar whether 
lymphocytes were restimulated in vitro with OVA or OVA 323-339, and equally 
observed when mice were primed with whole OVA or OVA 323-339 alone. 
3.2.5 Relative Inhibitory Effects Of Orally Administered OVA Or 
OVA 323-339 
T cells primed with OVA 323-339 were clearly affected by prior oral 
administration of OVA. We next examined whether oral administration of OVA 
323-339 on its own was sufficient to inhibit lymphocyte proliferation. To address 
this question, Balb / c mice were fed 20mg of OVA or 1 mg of OVA 323-339, an 
approximately equimolar amount to whole antigen. Proliferation was markedly 
diminished both in response to OVA (figure 3.8a) and OVA 323-339 (figure 3.8b) 
when OVA-primed cells were derived from OVA-fed mice. It should be noted, 
though, that the degree of inhibition might be overestimated in this experiment, 
since positive control values were less than half of the other two groups. 
However, oral administration of OVA 323-339 had no effect on secondary in 
vitro responses of OVA-primed lymphocytes, the plots being virtually identical 
with buffer-fed controls and directly comparable control values for medium and 
PPD. It was possible that repeated feeding and an overall higher dose of peptide 
. would be more effective. Therefore, in the next experiment (figure 3.9) 1 mg of 
OVA 323-339 were fed three times 7, 5, and 3 days before priming with OVA. 
Another group of mice was fed approximately 20 mg OVA divided into three 7 
mg doses administered on the same days as peptide. Under these conditions, 
proliferation of lymphocytes from OVA-fed mice was substantially reduced 
whereas the same data plots for lymphocyte proliferation with cells from 
peptide-fed and buffer-fed control mice were almost superimposable, whether 
restimulated with OVA or OVA 323-339. Therefore, even though proliferation of 
OVA 323-339-specific lymphocytes was reduced after oral administration of 
OVA, this effect could not be achieved by feeding this peptide alone. 
3.2.6 Transfer Of Spleen Cells From OVA-Fed Donors And 
Transfer Of OVA-Fed Serum 
We examined whether the in vitro phenomenon of reduced specific 
lymphocyte proliferation could be induced by adoptive transfer of spleen cells 
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and with serum from OVA-fed donors. When spleen cells were taken from 
donors one week after OVA feeding and injected i.p. (figure 3.10a) or i.v. (figure 
3.10b) into naive recipients, this had no effect on the ability of recipient 
lymphocytes to proliferate in response to OVA after priming within 24 or 2 
hours upon transfer. The same results were obtained when serum taken from 
donors that had been fed OVA 1 hour before was transferred i.p. (figure 3.lla) 
or i.v. (figure 3.llb). While proliferative responses with lymphocytes from mice 
that had been fed with OVA directly were clearly reduced compared to PBS-fed 
controls, this effect was not observed upon transfer of OVA-fed serum under the 
same conditions, i.e. one week prior to an antigenic challenge with OVA (figure 
3.11). 
3.2.7 Effect Of OVAFeeding On Specific Immunoglobulin Levels 
In order to examine possible differential inhibition by orally administered 
OVA on T helper subsets, immunoglobulin levels were analyzed for IgG 
isotypes that commonly serve as markers for THl and TH2 type responses, 
IgG2a and IgGl, respectively. For the experiment shown in table 3.2, serum 
samples were taken from OVA-fed and PBS-fed mice three weeks after priming 
with OVA. At this late time point, IgM levels were low in all groups. Although 
IgM concentrations tended to be lower in the OVA-fed groups, the overall levels 
were too low and the variation within groups too high to show significant 
differences. In contrast, the data reveal significantly lower levels of all tested 
gamma immunoglobulins, total IgG, IgG2a, and IgGl in sera from OVA-fed 
mice compared to controls. There was no evidence for IgG2a or IgGl being 
either more or less affected by oral administration of OVA. 
3.3 DISCUSSION 
3.3.1 The Nature Of The OVA-Derived Antigenic Serum Factor 
(Sf) 
3.3.1 i The data are consistent with SF representing a form of intact OVA 
One hour after feeding Balb / c mice with a single dose of 20 mg OVA, their 
serum was highly antigenic for OVA-primed lymphocytes in vitro (table 3.1). 
Although the one hour interval between feeding and serum sampling coincided 
with the time span required to generate the tolerogenic factor in other reports, 
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this serum tolerogen probably did not contribute to the antigenic properties of 
the serum. Other studies showed that OVA-fed serum from SCID mice failed to 
transfer tolerance (Furrie, 1992). However, SCID mouse serum taken one hour 
after OVA feeding stimulated OVA-primed lymphocytes in exactly the same 
way as Balbi c OVA-fed serum (figures 3.5 and 3.6). 
The OVA peptide 323-339 was originally defined by tryptic cleavage 
(Shimonkevitz et al, 1984). Since trypsin is released into the small intestine, it 
seemed possible that this peptide contributed to the antigenic properties of 
OVA-fed serum. However, the lack of T cell activation in vitro with the fraction 
passed through a< lOkD size exclusion filter suggested that molecules in OVA-
fed serum within this size range and below were not antigenic for OVA-specific 
T cells (figure 3.3). Rather, the relative proliferative responses observed in this 
experiment were consistent with SF representing intact OVA in the range of 2-
20µg per ml serum. Other assays in this chapter that include overlapping dose 
responses to OVA and SF allow for additional estimates: In figure 3.5, 25,000 
cpm were obtained with 10-2.3 (= 0.005) parts of OVA-fed serum and with OVA 
concentrations between 10-8 and 10-7 M. This would correspond to 80-800µg 
OVA per ml neat serum. The same calculation yields 800µg/ml OVA for OVA-
fed serum in the experiment of figure 3.6. 
3.3.1 ii SF may not be identical with native OVA 
Previous attempts to identify the tolerogenic serum factor also considered the 
possibility that native OVA which had escaped degradation in the gut conferred 
the tolerogenic properties. In these studies, the amounts of intact OVA in the 
serum of OVA-fed mice were measured by an radioimmunoassay (Hanson et al, 
1977) or ELISA using purified anti-OVA IgG (Bruce & Ferguson, 1986a; Peng, 
Turner, & Strobel, 1990). The amounts of OVA thus measured ranged between 
30-200ng/ml one hour after feeding 20-25mg of OVA to mice. The properties of 
this form of serum-retrieved OVA detectable by ELISA after FPLC gel filtration 
and anion exchange chromatography were indistinguishable from the native 
form of the molecule. However, this (presumably native) form of OVA 
detectable by ELISA could not explain the tolerogenicity of the serum (Peng, 
Turner, & Strobel, 1990). Thus, the previously reported concentrations of OVA 
measured in immunoassays (approximately 30-200 ng) were too small to account 
for the antigenic properties of SF in our experiments, assuming that SF 
represented whole OVA at 2-800µg/ml serum. 
OVA molecules subjected to gut passage and processing are likely to be 
denatured or otherwise modified thereby destroying epitopes characteristic of 
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the native protein to some extent while perhaps exposing others. Therefore, the 
amount of OVA, even intact OVA may be considerably higher than previous 
estimates for native OVA based on ELISA. 
OVA has served as a model molecule for numerous studies on 
physicochemical alterations as a function of various solvent conditions and 
temperature changes. Although OVA molecules could aggregate with varying 
degrees of polymerisation, the overall spherical conformation of the individual 
molecule appeared to be rather stable involving only a transition of a very 
limited portion of a helix to a coil. Nevertheless, certain regions buried within 
the molecule might be exposed at the surface after denaturation (Koseki et al, 
1989). This assumption was subsequently confirmed. The structural differences 
between native and denatured OVA appeared to be more substantial when 
subjected to immunological rather than physicochemical methods. The 
appearance of new antigenic determinants upon denaturation was demonstrated 
with monoclonal antibodies (MAbs) specific for soluble heat-denatured OVA. 
Five MAbs that exclusively recognized novel epitopes revealed by denaturation 
also bound to proteolytic fragments of OVA which - when analyzed by the 
hydropathy profile of OVA- were part of both the interior and the exterior of the 
molecule. (Ikura et al, 1992). Similar differences in antibody recognition of native 
and denatured OVA have also been reported for urea-denatured OVA (Varshney 
et al, 1991; Kilshaw et al, 1986). It is therefore possible that the discrepancies 
between previously reported amounts of native OVA in OVA-fed serum and the 
estimates for SF as whole OVA discussed in this chapter can be accounted for by 
some form of denaturation of OVA upon passage through the stomach and 
small intestine. These structural modifications might have destroyed some B cell 
epitopes, so that a proportion of whole OVA escaped detection by methods 
based on antibodies such as in radioimmunoassays and ELISA. In contrast, the 
biological assay used for this project relied on T cell responses. It is likely that T 
cell epitopes were processed and presented with comparable efficiency 
regardless as to whether APC's encountered OVA in its native or denatured 
form. 
3.3.1 iii Relationship between SF, TF and the phenomenon of oral tolerance to 
OVA 
Previous studies suggested that neither native OVA nor structural 
modification of the intact molecule as a consequence of passage through the gut 
could account for the tolerogenic properties of OVA-fed serum in transfer 
studies. In an attempt to mimic physicochemical alterations as a result of gut 
processing, 0.1-10 µg of either native, deaggregated or urea-denatured OVA 
68 
were injected i.p. Under these conditions native and denatured OVA had no 
effect on either antibody- or DTH responses whereas parenteral administration 
of deaggregated OVA suppressed both branches of OVA-specific immune 
responses (Bruce & Ferguson, 1986b). In another report, intravenous 
administration of deaggregated OVA over a wide range of doses was never as 
tolerogenic as pretreatment with OVA via the intragastric route, suggesting that 
oral tolerance to OVA was not sufficiently explained by the absorption of 
deaggregated molecules into the blood (Hanson et al, 1977). These findings 
contrast with tolerance by transfer of OVA-fed serum by which DTH responses 
were significantly suppressed while antibody titres appear to be unaffected 
(Strobel et al, 1983). 
Although the tolerogenic factor (TF) was generated from orally administered 
OVA, an intact intestinal epithelium was not a prerequisite for its generation. 
Severe irradiation damage of the gut epithelium was not responsible for the 
failure to generate TF, since the loss of tolerogenicity in the serum of irradiated 
mice could be overcome by reconstituting serum donors with normal spleen 
cells. Furthermore, TF was generated in cyclophoshamide-treated serum donors 
although the integrity of the intestinal epithelium was probably disrupted by 
this drug (Strobel et al, 1983). Thus, the splenocyte reconstitution experiment 
together with the finding that SCID mice failed to produce TF implied that 
cellular components of an intact systemic immune system but not the specialized 
architecture of GALT were required for the generation of TF. The ability to 
induce tolerance by i.p. injection of TF demonstrated that the mechanism by 
which TF suppressed DTH responses in recipients probably also operated 
independently of GALT. However, while pretreatment of OVA-fed serum 
donors with cyclophosphamide (CY) did not abrogate the tolerogenicity of the 
serum upon transfer, CY treatment of recipients prior to serum transfer did 
abolish the ability of OVA-fed serum to inhibit DTH responses to OVA (Strobel 
et al, 1983). This finding suggested that TF induced regulator cells in recipients 
which subsequently suppressed DTH reactions. 
Two experiments presented in this chapter addressed the inhibitory effect of 
OVA-fed serum on in vitro T cell proliferation (figure 3.11). Under exactly the 
same experimental conditions that were reported to inhibit DTH responses in 
recipients upon i.p. transfer of OVA-fed serum, there was no inhibitory effect on 
the proliferation of OVA-primed T cells in vitro (figure 3.1 la). If TF needed to be 
a component of the serum, either after OVA feeding or after absorption from the 
peritoneum into the circulation, then i.v. rather than i.p. injection would perhaps 
be a more effective route of administration. However, i.v. injection of OVA-fed 
serum also failed to inhibit T cell proliferation in vitro (figure 3.11b). When 
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considering a potentially tolerogenic role for SF rather than TF upon transfer, the 
data show that the amounts of whole OVA (native and/ or denatured) present in 
OVA-fed serum also failed to induce a form of T cell nonresponsiveness that was 
detectable by in vitro T cell proliferation. In the light of previous studies in other 
models of peripheral tolerance showing anergy induction by i.v. or i.p. injection 
of soluble antigens, a tolerogenic effect of SF seemed possible, although in the 
absence of a more thorough investigation testing various parameters such as 
dose and timing for serum transfer, we do not know whether it is principally 
impossible to induce tolerance with SF. However, lymphocytes from other 
groups of mice that had been fed with OVA directly in the same experiments 
proliferated less strongly compared to PBS-fed controls. We therefore have to 
conclude that OVA-fed serum on its own was not sufficient to account for the in 
vitro phenomenon of reduced T cell proliferation observed after oral 
administration of OVA. 
In summary, previous work and the data presented in this chapter showed 
that considerable amounts of OVA were present in the blood after intragastric 
administration of 20-25mg OVA in a form that was highly antigenic for both B 
cells (presumably native OVA) and T cells (presumably native and denatured 
OVA). Yet, these forms of OVA did not seem to interfere with the induction of 
oral tolerance nor could they account for the tolerogenic properties of OVA-fed 
serum . While in previous reports, the tolerogenic capacity of serum taken one 
hour after OVA feeding inhibited DTH responses in recipients, we could not 
demonstrate transfer of tolerance for secondary proliferative responses in vitro 
under the same conditions. 
3.3.2 The Role Of OVA 323-339 In Oral Tolerance To OVA- Anergy 
Versus Suppression 
All studies on lymphocyte proliferation presented in this chapter consistently 
demonstrated clear reduction of OVA-specific proliferative responses when mice 
were fed 20 mg OVA one week before priming. This was true for proliferation in 
response to both whole OVA and OVA 323-339 (figures 3.4 and 3.6). 
Proliferative responses to OVA 323-339 were also reduc.ed by prior feeding of 
OVA when T cells were subsequently primed with this peptide alone (figure 
3.7). This finding together with a lack of bystander suppression of the response 
to a second antigen HGG (figure 3.1) argues against a role for those suppressor 
mechanisms that were shown to mediate oral tolerance in some models of 
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autoimmune diseases. In the Lewis rat model of EAE, bystander regulation to 
epitopes of MBP other than the orally administered epitope was mediated by 
TGF-~ released by CDs+ T cells upon feeding and specific stimulation with MBP 
or the appropriate peptide. However, these CDs+ T cells only suppressed DTH 
responses when the peptide capable of triggering the release of TGF-~ was 
included as part of a subsequent antigenic challenge (Miller et al, 1993). 
Several lines of evidence suggest that the in vitro phenomenon of weaker 
specific T cell proliferation after OVA feeding reflects a direct suppressor-
independent mechanism of oral tolerance consistent with T cell anergy. In 
addition to the strictly antigen-specific effect of orally administered OVA and 
the ability to inhibit T cell proliferation after priming with a single I-Ad-
restricted peptide alone, we could not demonstrate this phenomenon by two 
procedures that have been shown to induce suppression. Neither the transfer of 
OVA-fed serum nor transfer of splenocytes either i.p or i.v. from OVA-fed 
donors affected in vitro proliferation of OVA-primed recipient lymphocytes 
(figures 3.11 and 3.10). Furthermore, preliminary experiments injecting rat IgG2b 
anti-CDS antibodies around the time of feeding under conditions shown to 
deplete CDS+ cells effectively in mice (reviewed in Cobbold et al, 1992) did not 
reverse the inhibitory effect of orally administered OVA on in vitro T cell 
proliferation (not shown). Other studies in which T cell responses were assessed 
in vitro were also consistent with T cell anergy rather than suppression. Here, 
the inhibitory effect of orally administered OVA was demonstrated by 
diminished T cell proliferation, IL-2 production and lack of IL-2 receptor 
expression (Melamed & Friedman, 1993a). When OVA-primed lymphocytes 
. from OVA-fed and PBS-fed mice were co-cultured, the degree of proliferation of 
co-cultured cells was in between the level of proliferation measured for each cell 
population on its own rather than less as would be expected if suppression 
mediated by lymphocytes from orally tolerized animals had occurred (Richman 
et al, 1978; Melamed & Friedman, 1993a). In one report, the significance for 
suppression-as a mechanism of oral tolerance to OVA was tested for both in vivo 
and in vitro immune responses. Here, transfer of tolerance with spleen cells from 
OVA-fed donors one week after feeding could b~ demonstrated in recipients for 
DTH reactions and antibody titres but not for T cell proliferation (Miller & 
Hanson, 1979). Interestingly, however, when mesenteric lymph node (MLN) 
cells from donors fed two or four days previously were transferred, there 
appeared to be some inhibition of vitro proliferation with recipient lymphocytes 
(Challacombe & Tomasi, 1980). As mentioned before, there is ample evidence for 
active suppression involved as a relevant mechanism for oral tolerance. Transfer 
of splenocytes, Peyer's patch (PP) cells or mesenteric lymph node (MLN) cells 
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from OVA-fed donors inhibited 0TH and antibody responses in recipients (Ishii 
et al, 1993; Richman et al, 1978; Ngan & Kind, 1978; Miller & Hanson, 1979). 
Suppression by cell transfer was abrogated by 2- deoxyguanosine (Mowat, 1986) 
or pretreating donor cells with anti-thy 1.2 (Richman et al, 1978) or anti-C08 but 
not with anti-C04 specific monoclonal antibodies (Ishii et al, 1993). Taken 
together, transfer of active regulatory mechanisms induced in donors by feeding 
OVA can readily be shown for 0TH and antibody responses while mostly failing 
to inhibit proliferation of the recipients' OVA-specific lymphocytes in vitro. 
If T cell anergy alone were responsible for reduced in vitro T cell 
proliferation, one might expect oral administration of OVA 323-339 on its own to 
be sufficient for this effect. Surprisingly, this was not the case. Neither a single 
intragastric dose of 1mg OVA 323-339 nor repeated feeding of 1mg peptide 7, 5, 
and 3 days before immunization induced a decrease of the proliferative response 
(figures 3.8 and 3.9). In the same experiments, a single dose of 20 mg OVA or 
approximately the same amount divided into three doses, i.e. 3x7mg given on 
the same days profoundly inhibited in vitro proliferation. Two possibilities 
could account for the failure to inhibit T cell proliferation by feeding peptide 
alone. Either OVA 323-339 can principally induce anergy when administered via 
the oral route, but the experimental conditions were not appropriate. 
Alternatively, other epitopes are required. The amount of 3x1mg peptide given 
in the second experiment (figure 3.9) not only exceeded equimolar amounts of 
OVA given to other mice at the same time, it was also well within the range of 
smaller doses of OVA between 1-Smg shown to inhibit 0TH responses in other 
studies (Lamont, Mowat, & Parrot, 1989). Although protease inhibitors were not 
included for peptide feeding, the sequence of OVA 323-339 does not contain any 
specific trypsin or chymotrypsin cleavage sites. It seems therefore unlikely that 
the oral doses of peptide were to small to be effective. However, current 
knowledge about the rules that govern anergy are not consistent with the 
possibility that the doses of fed peptide were too high to induce anergy. Rather, 
we would have expected higher doses to favour anergy induction. If we 
therefore propose that anergy by oral administration of OVA 323-339 was either 
not possible or not sufficient to account for the phenomenon of reduced T cell 
proliferation observed after feeding whole OVA, we are left with the 
requirement for the induction of some kind of regulator cell with specificity for 
an OVA epitopes distinct from OVA 323-339. Previous transfer studies using 
donor cell population one week after OVA feeding provided some evidence for 
a role of cos+ T suppressor cells. However, if results from our preliminary 
cos+ depletion experiments hold up in a more thorough analysis, then perhaps 
cos+ T cells are involved at a later time point after tolerance induction but not 
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immediately after feeding. For the depletion of CDS+ cells, anti-CDS antibodies 
were injected one day before and one day after priming which had no effect on 
the inhibition of T cell proliferation by OVA feeding (not shown). This obviously 
does not exclude the possibility of an early CD4+ regulatory T cell which is 
perhaps either generated in or migrating to MLN as implied by the observation 
in one report providing some evidence for reduced in vitro proliferation upon 
transfer with MLN cells (Challacombe & Tomasi, 1980). Perhaps, even though T 
cell proliferation was not affected by transfer with spleen cells seven days after 
donors were fed with OVA, this does not necessarily exclude that CDS+ 
regulator cells are involved at some stage after direct oral administration of 
OVA. Further studies are planned to include feeding experiments with the H-
2Kh-restricted OVA peptide 229-276 together with OVA 323-339 in C57BL/ 6 x 
Balb/c (H-2b x H-2d) mice. Possibly, the class I-restricted peptide which, 
intriguingly was defined by partial tryptic digestion (Carbone & Bevan, 1989) 
together with the class II-restricted epitope can substitute for oral administration 
of the whole OVA molecule. However, if this were true, then the mechanisms of 
regulation are presumably different from those previously described on the 
basis of bystander phenomenon and the requirement for reactivation at the time 
of priming, since the data in this chapter suggest a strictly antigen- specific effect 
in vitro and sufficient inhibition of proliferation after priming with OVA 323-339 
alone. In summary, it is possible that the in vitro phenomena indicative of T cell 
anergy as shown in this chapter and reported previously such as inhibition of T 
cell proliferation, IL-2 production and IL-2 receptor expression are the result of 
some early regulatory mechanism for which anergy is the result rather than the 
cause, and that several mechanisms, among them anergy, act coordinately in this 
model of oral tolerance to OVA. 
3.3.3 Effect Of Orally Administered OVA On Antibody Responses-
Regulation Of TH Subsets 
Earlier reports and data presented in this chapter showed that oral tolerance to 
OVA manifested itself as a reduction or abrogation of both T cell mediated 
responses and antibody production. Although lower immunoglobulin levels 
could also be a consequence of direct B cell tolerance, hapten-carrier experiments 
indicated that a lack of T cell help alone was sufficient to account for impaired 
immunoglobulin secretion. Mice fed with OVA responded poorly to DNP 
coupled to OVA but normally to DNP coupled to KLH. On the other hand, 
intragastric administration of KLH led to a marked reduction in the response to 
DNP-KLH (Hanson et al, 1977: Richman et al, 1978; Titus & Chiller, 1981). 
Furthermore, the inhibitory effect on serum immunoglobu_lin titres could be 
overcome by administration of bacterial lipopolysaccharide (LPS) at the same 
time of feeding or immunization .. LPS stimulates B cells directly, thereby 
probably circumventing the deficiency in T cell-mediated B cell help while 
leaving other inhibitory effects of antigen feeding on T cell functions unaltered 
(Titus & Chiller, 1881; Mowat et al, 1986). In addition, intragastric administration 
of T-independent antigens had no effect on subsequent specific antibody 
responses (Titus & Chiller, 1981). 
One possibility which would also provide a convenient candidate for an early 
CD4+ regulatory T cell is selective or preferential inhibition of THl cells, 
possibly accompanied by an expansion of TH2 cells which might further 
downregulate THl type responses such as in vivo DTH reactions and IL-2 
secretion/proliferation upon secondary stimulation in vitro. However, previous 
findings and those presented in this chapter are inconsistent with this concept: 
When levels of IgG2a and IgGl were analyzed, the overall reduction in total IgG 
levels as a result of feeding OVA could be attributed to inhibitory effects on both 
IgG2a and IgGl isotypes, i.e. indicators of both THl and TH2 types responses, 
respectively (table 3.2). In previous studies, intragastric pretreatment with OVA 
substantially inhibited IgE (TH2) and IgG ( THl and TH2) isotypes (Hanson et 
al, 1977; Ngan & Kind, 1978). Therefore, oral tolerance either affected TH cells at 
an early stage prior to differentiation into functional subsets or it impaired the B 
cell helper functions of both THl and TH2 cells to a comparable extent. 
The IgM levels three weeks after priming were generally very low and the 
differences between control and OVA-fed groups too small to be statistically 
significant (table 3.2). Three weeks after priming the IgM levels can be expected 
to be low unless the main mechanism by which oral tolerance affects the 
humoral imJ:!lune responses were inhibition of class switching from IgM to other 
isotypes. This was obviously not the case. However, when peak levels of IgM 
one or two weeks after immunization were examined the levels of this early 
isotype were also reduced as a result of OVA feeding (Mowat et al, 1982). In this 
study, IgM responses appeared to be more easily inhibited than IgG levels under 
more stringent experimental conditions such as feeding a small dose of OVA 
(2mg rather than 20mg) with a longer time interval between feeding and 
immunization (two weeks instead of one week). In the same study, T cell 
functions as assessed by DTH responses were only moderately affected under 
the same feeding and priming regime. Thus, with respect to T cell help, early B 
cell responses reflected by IgM production might be impaired to some extent but 
the insufficient inhibition of T cell functions after low dose feeding and long 
intervals between feeding and priming might allow the humoral responses to" 
catch up" and develop normal levels of IgG. 
In addition to the apparent discrepancy between in vivo and in vitro 
phenomena, there also seem to be different effects of OVA feeding on cellular 
versus humoral in vivo functions as shown for DTH and antibody responses. 
Transfer of OVA-fed serum inhibited DTH but not antibody responses (Strobel 
et al, 1983). Administration of 2-deoxyguanosine or cyclophosphamide both 
abrogated suppression of DTH and antibody responses (Mowat, 1986; Mowat et 
al, 1982). 2-deoxyguanosine also prevented tolerance transfer by spleen cells 
(Mowat, 1986). However, cell transfer could not substitute for all effects evoked 
by direct feeding of OVA: Feeding OVA 7-14 days after priming also 
suppressed DTH responses but not levels of OVA-specific IgG. Under these 
conditions 2-deoxy could not abrogate the inhibitory effect of feeding on DTH 
responses. Furthermore, attempts to transfer 2-deoxy-independent tolerance by 
spleen cells after priming were unsuccessful (Lamont et al, 1988). These findings 
suggest that suppressor cells might be involved at an early stage of oral 
tolerance, presumably by inhibiting the priming of naive OVA-specific T cells. In 
contrast, when lymphocytes have already encountered antigen in an 
immunogenic context, mechanisms independent of regulatory cells such as 
direct induction of anergy in responder cells might operate. 
3.4 SUMMARY AND CONCLUSION 
Most studies on oral tolerance to OVA address one or more of three T cell 
functions, namely T helper activity, T cell proliferation and the ability to mediate 
DTH responses. Many experimental approaches designed to unveil the 
mechanisms of oral tolerance such as transfer of various cell populations or 
serum from QVA-fed donors succeeded to reproduce some phenomena of oral 
tolerance. However, only direct feeding of OVA to mice appeared to consistently 
affect all three T cell functions. This implies that several mechanisms might 
operate, not all of which can be induced or revealed with all methods. 
In this chapter we showed that 20mg OVA administered orally one week 
before priming with either OVA or OVA 323-339 alone reduced in vitro 
proliferative T cell responses to OVA and OVA 323-339 by about 40-80% 
compared to controls. Some findings presented in this chapter and in previous 
reports were consistent with T cell anergy as a mechanism to account for 
impaired T cell proliferation in vitro. These include a strictly antigen-specific 
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effect of feeding rather than bystander regulation, no apparent requirement for 
regulatory epitopes at the time of an antigenic challenge, diminished levels of IL-
2, and IL-2 receptor expression in vitro, and the failure to demonstrate 
suppression, either in vivo upon transfer or in vitro in cell mixing experiments. 
However, other observations cannot readily be explained on the basis of anergy 
alone. Feeding high doses of OVA 323-339 (3xlmg) had no obvious inhibitory 
effect on OVA 323-339-specific T cells in vitro. Furthermore, if OVA and OVA 
fragments absorbed into the circulation induced anergy in the periphery, we 
would have expected i.p. or i.v. injected OVA-fed serum to inhibit T cell priming 
in recipients. Even if we exclude a role for TF, native and denatured OVA 
present in the serum might have induced anergy under these conditions. 
It is therefore conceivable that, although in vitro data appear to indicate T cell 
anergy, this may reflect a consequence rather than the initial mechanism of oral 
tolerance in this model. Possibly, CD4+ (but presumably not TH2) regulator cells 
are important at an early stage after feeding, while CDs+ T cells may be more 
significant later on. This question has to be further addressed in kinetic studies 
involving selective depletion and transfer of CD4+ and CDS+ T cells at different 
time points after OVA feeding and oral administration of both MHC class II and 
class I-restricted OVA peptides under various experimental conditions. Future 
experiments addressing the requirements for distinct OVA epitopes should 
compare DTH-, antibody-, and in vitro T cell responses to account for the 
discrepancies observed between cellular and humoral and in vivo versus in 
vitro phenomena. 
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Figure 3.1 Balb/c mice were fed 20 mg OVA in 200µ1 PBS (closed symbols) or 
200 µl PBS alone (open symbols). After 7 days groups of 3 mice were primed with 
either 100 µg OVA/CFA (circles), human gamma globulin/CPA (HGG, 
trian'gles), or a mixture of 100 µg of each OVA and HGG in CFA included in the 
same adjuvant (squares). Ten days later, lymphocytes from draining lymph nodes 
were restimulated in vitro with OVA (a) or HGG (b).Proliferation was measured 
by 3-H thymidine incorporation after 4 days in culture. Each symbol represents 
the arithmetic mean of triplicate samples, standard deviations were less than 20% 
of the mean. Medium and PPD controls are arithmetic means and standard 
deviations of triplicates in cpm. 
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Table 3.1 Testing Serum From 
OVA-Fed Balb/c Mice As A Source 
Of OVA-Derived Antigens 
Antigen OVA/CFA- PBS/CFA-primed 
primed lymphocytes 
lymphocytes 
Medium 1.8 + 0.2* 1.9 + 0.1 
PPD 85.3 ±3.4 121.1 + 2.9 
40 µg/ml OVA 80.3 ± 11.8 4.2 ± 0.4 
4µg/mlOVA 68.3± 7.6 2.5 + 0.3 
Serum from OVA-
fed Balb/c 
10% 41.0 ± 9.5 1.1 ± 0.5 
5% 59.4 ± 5.2 2.6 + 0.7 
2.5% 69.3 ±2.6 2.4± 0.8 
1.25% 62.6 ± 8.5 3.0±0.3 
Serum from PBS-
fed Balb/c 
10% 1.1±0.5 0.2± 0.0 
5% 2.6 + 0.7 0.9 ± 0.1 
2.5% 2.4± 0.8 1.1 ± 0.2 
1.25% 3.0 +0.3 1.6 + 0.1 
* mean 3-H thymidine incorporation [cpm/1000] ± SD 
Table 3.1 Balb/c mice were primed with 100 µg OVA/CFA or PBS/CFA alone. 
After 10 days lymphocytes from draining lymph nodes were used as responder 
cells to test the antigenicity of serum from OVA-fed mice. These sera were 
prepared from blood samples collected 1 hour after feeding Balb/c with either 
20 mg OVA in 200 µl PBS or 200 µl PBS only. Lymphocytes were restimulated 
with these sera in vitro. OVA, PPD and medium were included as controls. After 
4 days of culture, lymphocyte proliferation was measured by 3-H thymidine 
incorporation. 
Figure 3.2 Mice were primed with either 100 µg OVA/CFA (closed symbols) 
or 50 µg OVA 323-339/CFA (open symbols). Ten days later, lymphocytes 
from 5-7 mice per group were pooled and restimulated in vitro with OVA (a), 
OVA ~_23-339 (b) or dilutions of serum in IMDM. Serum samples were 
prepared from mice 1 hour after feeding 20 mg OVA (circles, plot c), or PBS 
(triangles, plot c). The highest concentration of serum was 10-2.3 parts in 
IMDM which equals 0.5% serum. Proliferation was measured by 3-H 
thymidine uptake after 4 days of culture. Symbols represent the arithmetic 
mean of triplicate samples, standard deviations were less than 20% of the 
mean. Control values expressed as cpm with medium /PPD were 5730 + 120 
/71,860 + 6160 for OVA-primed lymphocytes and 6400 ± 0 /72,240 + 6420 for 
OVA 323-3~9-primed cells. 
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Figure 3.2 In Vitro Proliferation Of OVA- Or 
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Figure 3.3 Sera were prepared from blood samples obtained 1 hour after 
feeding 20 mg OVA or PBS, and diluted 1/10 in PBS. In addition, diluted serum 
samples from PBS-fed mice were spiked with either 20 µg/ ml OVA or 300 
µg/ml OVA 323-339. All samples were spun through Millipore 10 kD size 
exclusion filters until about 3/ 4 of the total volume had passed through the 
filter. Both fractions i.e. > lOkD (a, open symbols) and < 10 kD (a, closed 
symbols) were used to restimulate OVA-primed lymphocytes in vitro as 
described before. For controls, OVA-primed lymphocytes were restimulated 
with OVA (b, circles) or OVA 323-339 (b, triangles). Symbols represent the 
arithmetic mean of triplicate samples, standard deviations were less than 20% of 
the mean. Medium/ PPD controls, mean and SD of triplicates in cpm were 3000 
± 510/33,890 ± 4630. 
Figure 3.3 Proliferative Responses 
Of OVA-Primed Lymphocytes To 
Fractionated Serum From OVA-Fed Balb/c 
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Figure 3.4 Effect Of Orally Administered OVA 
On Proliferative Responses of OVA-Primed 
lymphocytes To OVA And OVA 323-339 
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Figure 3.4 Four groups of 2-3 mice were fed either 200 µl PBS (open symbols) or 20 
mg OVA (closed symbols) 1 week prior to priming with 100 µg OVA/CFA. Ten 
days later, pooled lymphocytes were restimulated in vitro with either OVA (a) or 
OVA 323-339 (b). After 4 days proliferation was measured by 3-H thymidine 
uptake. Each symbol represents the arithmetic mean of triplicate samples, standard 
deviations were less than 20% of the mean. Means and standard deviations [cpm] of 
control cultures are included in the legend. 
Figure 3.5 Comparing The Antigenic Properties 
Of OVA-Fed Serum From Balb/c And SCIDs For 
Lymphocytes From PBS-Fed And OVA-Fed Balb/c 
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Figure 3.5 Balbi c mice were fed PBS (open symbols) or 20 mg OVA (closed 
symbols) 1 week prior to priming with 100 µg OVAICFA. Ten days later, 
lymphocytes were restimulated in vitro with OVA (a) or dilutions of serum 
samples derived from Balbi c or Balbi c SCID mice fed OVA or PBS one hour 
before blood samples were taken (b). Coded serum samples were kindly 
provided by Elizabeth Furrie and decoded after the data were available. 
Symbols of plot b: Serum taken from OVA-fed Balblc (circles), from PBS 
control-fed Balbi c (squares), and from OVA-fed Balbi c SCID mice (triangles). 
Proliferation of lymphocytes was measured by 3-H thymidine uptake. Each 
symbol represents the arithmetic mean of triplicate samples, standard deviations 
were less than 20% of the mean. Control values for medium IPPD in cpm were: 
2060 ± 130146,650 ± 130 for lymphocytes from PBS-fed mice and 1560 ± 
60140,220 ± 4070 for cells from OVA-fed mice. 
Figure 3.6 Balbi c mice were fed PBS (open symbols) or 20 mg OVA (closed 
symbols) and all primed with 100 µg OVAICFA 7 days later. After 10 days, 
lymphocytes were restimulated with OVA (a), OVA 323-339 (b), and 
dilutions of serum (c). For the data shown in plot c), aliquots of serum 
samples described in the legend of figure 3.5 were used, serum from OVA-
fed Balbi c (circles), or from OVA-fed Balbi c SCID mice (triangles). 
Proliferation was measured as described before. Symbols represent the 
mean of triplicate samples, standard deviations were less than 20% of the 
mean. MediumlPPD controls were 3060 ±. 250156,710 ±. 4750 for 
lymphocytes from PBS-fed mice and 2920 + 280160,020 + 6990 for cells from 
OVA-fed mice. 
Figure 3.6 Effect Of Orally Administered OVA On 
Proliferative Responses of OVA-Primed Lymphocytes 
To OVA, OVA 323-339, And OVA-Fed Serum 
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Figure 3.7 This figure contains the results of two separate experiments u
sing 
exactly the same protocol. Plots a) and b) present data of experiment 1, plots c) 
and d) of experiment 2. Balbi c mice were fed PBS (open circles) or 20 mg OVA 
(closed circles). Seven days later all were primed with 50 µg OVA 323-339/CFA. 
After 10 days lymphocyte proliferation was measured in response to OVA
 323-
339 (a and c) and OVA (band d) by 3-H thymidine incorporation as described 
before. Symbols represent the mean of triplicate samples, standard deviat
ions 
were less than 20% of the mean. Medium/PPD controls [cpm] in experiment 
lwere 2980 + 130/44,050 + 1460 for the PBS-fed group and 3180 + 150/47,41
0 + 
1510 for lymphocytes from OVA-fed mice. The corresponding control dat
a in 
experiment 2 were 2890 + 260/59,470 + 5300 for the PBS-fed group and 183
0 + 
180/£7,950 +7570 for cell samples from OVA-fed mice. For more conven
ient 
comparison of the relative effect of OVA feeding on the response to OVA
 and 
OVA 323-339, the relative reduction as a result of OVA feeding on prolifera
tion 
is stated in a table below. % reduction= 100- 100 x cpm OVA-fed 
data from plot 
exp.1 a (versus OVA 323-339) 
b ( versus OVA) 
exp.2 c (versus OVA 323-339) 
d (versus OVA) 
cpmPBS-fed 
% reduction after OVA 
feeding 
10-6M 10-7M 
43 45 
65 44 
73 81 
82 77 
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Figure 3.7 Effect Of Orally Administered 
OVA On The Proliferative Responses Of 
Lymphocytes Primed With OVA 323-339 
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Figure 3.8 Comparing The Effect Of Orally 
Administered OVA Or OVA 323-339 On Proliferative 
Responses Of OVA-Primed Lymphocytes, I 
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Figure 3.8 Within 1 hour, mice were given 2 intragastric doses of 10mg OVA 
(closed circles) or 0.5mg OVA 323-339 (closed triangles), both in 250 µl 0.15M 
NaHC03 buffer, or 2 x 250µ1 buffer alone (open circles). After l week, all mice were 
immunized with lOOµg OVA/CFA, and 10 days later, lymphocytes pooled from 3 
mice per group stimulated in vitro with either OVA (a) or OVA 323-339 (b). 
Proliferation was measured as described before. Each symbol represents the 
arithmetic mean of triplicate samples, standard deviations were less than 20% of the 
mean. Means and standard deviations of medium and PPD controls [cpm] are 
indicated as part of the legend. 
Figure 3.9 Comparing The Effect Of Orally 
Administered OVA Or OVA 323-339 On Proliferative 
Responses Of OVA-Primed Lymphocytes, II 
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Figure 3.9 Mice were fed either 1 mg OVA 323-339 (triangles), 7 mg OVA 
(closed circles) both administered in 200 µl 0.15 M NaHC03 buffer, or 200 µl 
buffer alone (open circles) on days -7, -5, and -3. On day 0, all mice were 
immunized with 100 µg OVA/CPA, and lymphocyte proliferation assayed in 
response to OVA (a) or OVA 323-339 (b) 10 days later as described before. 
Each symbol represents the arithmetic mean of triplicate samples, standard 
· deviations were less than 20% of the mean. The equivalent data for medium 
and PPD controls [cpm] are included in the legend. 
Figure 3.10 Effect Of Spleen Cell Transfer From 
OVA-Fed Donors On Secondary In Vitro Proliferation 
Of Lymphocytes From OVA-Primed Recipients 
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Figure 3.10 This figure contains results of two separate experiments. For both 
experiments, single spleen cell suspensions were prepared from mice that had 
been fed a single dose of 200µ1 PBS (open circles) or 20mg OVA (closed circles) 1 
week before. In experiment 1 (plot a), spleen cell suspensions pooled from 4 
donors were injected immediately i.p. (in 0.5 ml PBS per recipient) into equal 
numbers of naive Balbi c mice. All recipients were immunized with lOOµg 
OVA/CFA 1 day after cell transfer. For experiment 2 (plot b) spleen cell 
suspensions pooled from 5 donors were washed twice and counted. Each of 4 
naive recipient per group was injected with 108 cells in 0.5 ml IMDM i.v. Two 
hours later, all were primed with lOOµg OVA/CFA. After 10 days, lymphocyte 
proliferation was assayed as in all other previous experiments. Each symbol 
represents the arithmetic mean of triplicate samples, standard deviations were less 
than 20% of the mean. Control medium/PPD values for experiment 1 expressed in 
cpm were 6860 ± 810/ 52,320 ± 5380, and 7080 ± 1470/ · 53,360 + 4260 for 
lymphocytes from recipients of splenocytes from PBS-fed donors and OVA-fed 
donors, respectively. The corresponding controls in experiment 2 were 1770 ± 
210/ 26,480 ± 2050, and 2440 ± 530/ 38,030 ± 2220. 
Figure 3.11 Plots a) and b) show data from two separate experiments. For 
both assays, Balb/c mice were fed either 20mg OVA or 200µ1 PBS. 3-4 animals 
per group were not further treated prior to immunization and represented 
PBS-fed (open circles) and OVA-fed (closed circles) groups. From the 
remaining mice, serum samples were prepared 1 hour after feeding. In 
experiment 1 (plot a), 1ml of serum from either PBS-fed (open triangles) or 
OV ~-fed donors (closed triangles) was injected i.p. into each of 3-4 recipients 
per group. In experiment 2 (plot b), 05 ml serum per recipient was injected 
i.v. One week later, all groups were immunized with lOOµg OVA/CFA and 
lymphocytes assayed for proliferation as described. Symbols represent the 
mean of triplicate samples, standard deviations were less than 20% of the 
mean. Controls in cpm are included in the legend. 
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Figure 3.11 Comparing The Impact Of Orally 
Administered OVA And Transfer Of OVA-Fed Serum 
On The Proliferation Of OVA-Primed Lymphocytes 
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Experiment 1 , plot a Medium PPD 
---0- PBS-fed 3080± 90 "35,740±1080 
• OVA-fed 1800± 580 32,370±530 
1:11. PBS-fed, serum transfer 2350±260 19,880±800 
.. OVA-fed, serum transfer 2560±240 43,200±4580 
Experiment 2, plot b Medium PPD 
---0- PBS-fed 1820± 120 19,480± 1380 
• OVA-fed 1390± 290 14,520± 1750 
6 PBS-fed, serum transfer 1110± 50 11 ,930± 1760 
.. OVA-fed, serum transfer 1680± 120 14,090±4550 
exp.1 
exp.2 
Table 3.2 Comparing The Effect Of Orally 
Administered OVA On Serum Levels Of 
Different Immunoglobulin Isotypes 
Group Immunoglobulin concentrations of serum 
[arbitrary units] 
IgM IgG total a IgG2a b IgGl c 
1. PBS-fed, 97+34 1250 + 510 800 + 510 960 +330 
n=11 
2. OVA-fed, 79±14 690 + 320 360 ± 140 490 ±350 
n=11 
3. PBS-fed, 166 ± 118 1090 + 520 370 + 320 179 ± 133 
n=11 
4. OVA-fed, 105 ± 174 490 + 390 180 + 110 78±71 
n=10 
Groups 1 and 2 ap < 0.01 (Student's t-test) 
bp < 0.02 (Behrens-Fisher test) 
Cp < 0.01 (Student's t-test) 
Groups 3 and 4 ap <0.01 (Student's t-test) 
Cp <0.05 (Student's t-test) 
Table 3.2 Groups of 10-11 Balb/c mice were fed 20mg OVA or 200µ1 PBS. One 
week later, all were immunized with lOOµg OVA/CFA. After 3 weeks, serum 
samples were prepared from individual mice and assayed for IgM, total IgG, 
IgG2a, and IgGl by ELISA. Dilutions of sera and a standard anti-OVA IgG (for 
IgG, IgG2a, and IgGl) or a standard serum (for IgM) were added to OVA-coated 
microtitre plates, and serum immunoglobulins detected with isotype-specific 
secondary antibodies as described in materials & methods. The concentrations of 
serum antibodies were read at an appropriate serum dilution from the titration 
plots of standards included on each plate. Serum dilutions for data analysis were 
1/100 for IgM, 1/1000 for total IgG and IgG'2a, and 1/2000 for IgGl. For 
statistical analysis, the data distribution between the relevant PBS-fed and OVA-
fed groups were tested for variance differences (F-test). Data were analysed 
using either the Behrens-Fisher test (if variances differed significantly) or 
Student's t-test. 
CHAPTER4 
Oral Administration Of An 
Encephalitogenic Peptide 
And Myelin Protein 
In A H-2u Mouse Model Of EAE 
4.1 INTRODUCTION 
Oral tolerance has been studied in various models of autoimmune diseases 
and viewed as a potential therapeutic approach (reviewed in Thompson & 
Staines, 1990;Weiner et al, 1994). In numerous reports, a protective effect was 
critically dependent on the dose of orally administered antigens. In rat models of 
collagen-induced or adjuvant-induced arthritis, greater suppression of disease 
was achieved with lower doses of fed collagen (2.5µg or 3µg) than with ten times 
higher doses (Thompson & Staines, 1985; Zhang et al, 1990). In a mouse model of 
arthritis feeding 3 mg of collagen had no protective effect while feeding 0.5 mg 
reduced the clinical severity of arthritis (Nagler-Anderson et al, 1986). In 
contrast, a recent study on pristane-induced arthritis in mice revealed improved 
protection with increasing doses of intragastrically administered type II collagen 
(Thompson et al, 1993). A positive correlation between ~he amounts of fed target 
antigen and the degree of protection from disease was also shown for Lewis rat 
models of EAU and EAE (Nussenblatt et al, 1,990; Higgins & Weiner, 1988). 
Furthermore, different doses and epitopes appeared to selectively trigger 
distinct mechanisms. In the Lewis rat model of EAE, oral tolerance was achieved 
with a nonencephalitogenic fragment and - to a lesser . extent- also with an 
encephalitogenic fragment of MBP (Higgins & Weiner, 1988). Subsequently, the 
suppressive effect of antigen feeding could be attributed to transforming growth 
factor ~ (TGF-~) which was released by CDs+ T cells upon antigen-specific 
stimulation (Miller et al., 1992a). Only non-encephalitogenic epitopes of MBP 
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triggered the release of TGF-~ by CDs+ T cells. Nevertheless, the 
encephalitogenic epitopes were also capable of inducing oral tolerance by a yet 
undefined mechanism (Miller et al., 1993). Other investigators failed to 
demonstrate evidence for suppression in the same model. In one report, reduced 
in vitro proliferation and IL-2 production of MBP-specific T cells and failure to 
transfer tolerance were interpreted as evidence for clonal anergy (Whitacre et al., 
1991). The discrepancies between these two studies were suspected to arise from 
different experimental protocols, in particular that the higher amount of fed 
MBP (4 x 5 mg versus 5 x 1 mg) in the latter study favoured anergy induction 
over suppression. Recent studies on oral tolerance in EAU demonstrated that the 
mechanism of oral tolerance was strictly dependent on the dose of fed retinal S 
antigen (SAg) -derived peptides. High intragastric doses of the pathogenic 
peptide (5mg/feeding) induced oral tolerance which lacked characteristics of 
active suppression in as much as it was strictly epitope-specific (no bystander 
effects) and not transferrable. In contrast, low dose feeding (250µg/ feeding) of 
the same peptide fulfilled these criteria for suppression (Gregerson, Obritsch, & 
Donoso, 1993). Therefore, while the high dose tolerance could be interpreted on 
the basis of direct Ts-independent effects on uveitogenic T cells such as anergy 
or deletion, this explanation did not account for the phenomena of suppression 
as a result of low dose feeding. 
An answer to the central question addressing the nature of the tolerogenic 
epitopes therefore provides necessary but not always sufficient information 
about the mechanisms of oral tolerance. If oral tolerance is accomplished with an 
epitope distinct from the disease-inducing MHC class II-restricted epitope, then 
the tolerogenic effect on CD4 + T cells cannot solely be accounted for by anergy 
as a direct effect of peptide-MHC-TCR interactions. In this case, regulatory 
(suppressor) functions mediated by at least one other type of T cell have to be 
proposed, with TCR specificity for a tolerogenic, non-antigenic peptide. On the 
other hand, if the same peptide can be either tolerogenic or antigenic depending 
on the route· of administration, then the concept of anergy may constitute a 
sufficient mechanistic model of tolerance. However, the significance of CD4 + 
regulatory T cells also has to be considered. 
The H-2u mouse model of EAE is well suited to address the epitope question. 
Feeding the major encephalitogenic peptide Acl-9 (or Acl-11) should reveal 
whether oral tolerance can be induced with this N-terminal peptide alone. 
Furthermore, the higher affinity analogues of this peptide with alanine or 
tyrosine at position four provide useful tools to study the significance of higher 
avidity MHC-peptide-TCR interactions in oral tolerance. The putative role of 
distinct regulatory epitopes is tested by oral administration of whole myelin 
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basic protein purified from pig spinal cord. Porcine MBP and mouse MBP are 
90% homologous with the N-termini being identical (Fritz & Mcfarlin, 1989). 
Additionally, whole mouse spinal cord homogenate is fed as a rich source of 
homologous MBP. 
4.2 RESULTS 
4.2.1 Feeding Acl-11 And Its Higher Affinity Analogues 
In a first series of experiments we investigated whether oral tolerance to EAE 
was inducible with the encephalitogenic peptide in PL/J mice. A single 
intragastric dose of 800µg Acl-11[4K] (which was considered a high dose 
compared to the amounts of peptides fed in rat models) had no inhibitory effect 
on disease induced with the same peptide (figure 4.1). However, this negative 
result was perhaps due to peptide degradation in the stomach and/ or small 
intestine. Furthermore, one study suggested that repeated feeding was more 
effective than a single dose (Higgins & Weiner, 1988). These aspects were 
considered in the next experiment in which Acl-11 [4K] was fed three times on 
days -7, -5, and -2 over a wide range of doses (figure 4.2), with total amounts of 
7.5, 75, and 750µg fed peptide. The peptide was mixed with bicarbonate buffer 
and trypsin inhibitor to avoid proteolysis in the stomach and the intestinal tract. 
(Acl-11[4K] has no preferred cleavage sites for chymotrypsin). However, the 
data of figure 4.2 do not reveal any significant impact of feeding on incidence, 
onset or severity of disease for any of the groups. The plot shows almost 
identical disease patterns for the first phase of EAE. However, the possibility 
that peptide feeding protected against relapses could not be excluded. We 
subsequently tested either the original peptide Acl-11[4K] or a higher affinity 
analogue with alanine at position 4 (figure 4.3). The results demonstrate that 
neither of the -peptides at a total dose of 800µg conferred protection against EAE. 
Incidence, onset, and severity were virtually identical between groups. In this 
experiment, there was no tendency of orally ad,:ninistered peptide to protect 
against relapses. If anything, the group fed with Acl-11[4K] displayed an 
aggravated relapse compared with controls. 
A possible explanation for the failure to inhibit EAE was that neither the 
amounts nor the affinities of orally administered peptides sufficed to reach a 
critical avidity threshold for tolerance induction. In an attempt to force the 
immune system towards T cell nonresponsiveness, high amounts (3 x 1 mg) of 
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the highest affinity analogue Acl-9[4Y] were administered intragastrically in 
basic buffer and trypsin/ chymotrypsin inhibitor. This lead to complete 
abrogation of in vitro T cell proliferation in response to the encephalitogenic 
peptide Acl-9[4K] and conferred full protection from peptide-induced EAE 
(figure 4.4). In a preliminary experiment to analyze the dose and affinity 
dependence in more detail, the ability to abrogate in vitro T cell proliferation by 
feeding 3 x 1 mg of Acl-9[4Y] was confirmed while the same dose of the 4A 
analogue and 4K did not appear to have any effect (not shown). 
4.2.2 Feeding Whole Myelin Proteins 
The peptide feeding experiments revealed that tolerance induced by the 
intragastric route was difficult to achieve in this mouse model of EAE, and only 
observed with very high doses of the highest affinity peptide. However, figure 
4.2 shows that low doses (previously suggested to induce suppressor 
mechanisms) also failed to protect animals from disease. It was therefore 
conceivable that regulatory cells other than CD4+ T cells specific for Acl-9 were 
required for suppression in this model. This would entail recognition of distinct 
epitopes generated from intragastrically administered whole MBP. To test this 
possibility, mice were fed three times with either 0.1, 0.5, or 1mg (porcine) MBP 
(figure 4.5). There were no statistically significant differences between any of the 
groups, although some tendencies were worth noting: the lower doses of MBP 
appeared to exacerbate disease to some extent in this experiment. The highest 
dose of 3xlmg MBP possibly influenced the course of EAE. There was a 
tendency of milder disease during the first phase around day 13 after EAE 
induction followed by more a pronounced second phase. While the incidence 
and mean maximal severity were at least as high as in all other groups, the onset 
of disease seemed to be slightly delayed. 
In all experiments shown so far, EAE was induced with the encephalitogenic 
peptide. How ever, if regulatory epitopes distinct from Acl-11 are required to 
induce oral tolerance, then T cells specific for this epitope probably have to be 
able to encounter this putative epitope again at the time of priming. Although 
endogenous MBP may get processed and presented during the course of EAE, 
oral tolerance may be more readily inducible if mice are primed with whole 
MBP. The experiment shown in figure 6 addresses this possibility. Mice were fed 
3 x 1 mg MBP, and EAE was subsequently induced with either Acl-11 [4K] 
(figure 4.6a) or MBP (figure 4.6b). When mice were primed with peptide, prior 
feeding of MBP had no protective effect. Again, as observed before (figure 4.5) 
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there was a tendency of an aggravated second phase around day 35 in the MBP-
fed group. However, in this experiment, there was a moderate increase rather 
than a decline during the first phase of EAE in the MBP-fed group compared to 
controls. In contrast, there was an encouraging tendency for fed MBP to protect 
mice from MBP-induced EAE. The plot indicates a delayed onset, and the data in 
the table show a tendency for an overall lower incidence, although this was not 
statistically significant.(p = 0.075). However, when the experiment shown in 
figure 4.6b was repeated in exactly the same way, these impressions were not 
confirmed (figure 4.7). Rather, intragastric administration of MBP generally 
appeared to reinforce the establishment of EAE. 
While the amino termini containing the major encephalitogenic epitope are 
identical in mouse and pig MBP, there are some minor sequence differences in 
other parts of the molecule. It was therefore conceivable that putative regulatory 
epitopes could either not be efficiently processed and presented by mouse APC 
or not effectively recognized by T cells. To circumvent this problem, mice were 
fed with whole mouse spinal cord homogenate (SCH) prior to SCH-induced 
EAE. However, rather than protecting, intragastric administration of 3 x 2 mg of 
SCH (containing approximately 3xlmg mouse myelin) lead to a significant 
aggravation of disease in a first experiment (figure 4.8) while having no effect in 
a second experiment (figure 4.9). 
4.3 DISCUSSION 
. 4.3.1 Intragastric Administration Of The N-Terminal Peptide Of 
MBP 
The data presented in this chapter demonstrate that the natural 
encephalitogenic peptide (4K) failed to induce oral tolerance when fed in total 
doses ranging from 7.5 µg-800µg (figures 4.1 and 4.2). Two intragastric doses of 
400µg of the 4A analogue were also ineffective (figure 4.3). In contrast, an 
attempt to enforce tolerance using high doses (3 ~ 1 mg) of the peptide analogue 
with the highest affinity (4Y) revealed complete abrogation of Acl-9 specific T 
cell responses as assessed by specific in vitro lymphocyte proliferation and in 
vivo with respect to EAE (figure 4.4). Although the overall incidence and 
severity of disease were low in the control group, the complete lack of disease in 
the 4Y-fed group was nevertheless striking. However, in preliminary 
experiments to analyze the conditions for oral tolerance with peptide in more 
detail, feeding the same high amounts (3 x 1mg) of 4K or 4A did not abrogate 
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specific in vitro T cell proliferation (not shown). We therefore have to conclude 
that the natural encephalitogenic peptide, and probably also the 4A analogue fail 
to induce oral tolerance while the high affinity 4Y analogue, the only peptide 
among the three (4K, 4A, and 4Y) capable of forming stable complexes with the 
I-Au restriction element (Fairchild et al, 1993) is a powerful tolerogen, at least at 
very high doses. It will now be necessary to establish the minimal dose of 4Y 
that can induce tolerance upon feeding. 
The mechanism by which the 4Y peptide interfered with T cell priming 
remains to be established. It is possible that with such high doses of a single 
epitope, a considerable proportion of 4Y was absorbed into the periphery. 
Therefore, the mode of tolerance induced in the experiment shown in figure 4.4 
may have been determined by the rules for peripheral T cell downregulation in 
general rather than by GALT. The fact that a high dose of a high affinity peptide 
was required to demonstrate any tolerogenic effect is consistent with the idea of 
direct, suppressor-independent T cell anergy. As discussed earlier for the HEL 
model, an avidity threshold for tolerance induction may not be confined to 
central thymic tolerance but may also restrict T cell downregulation in the 
periphery. In the HEL model, a hierarchy of epitope dominance coincided with a 
hierarchy of tolerogenicity (Cibotti et al, 1992). However, in the H-2u mouse 
model of EAE, the dominant encephalitogenic epitope of MBP is of such low 
affinity that a putative avidity threshold might not have been reached by 
peptide feeding. Perhaps the highly unstable I-AU-Acl-9 complex formation 
does not only permit the escape from central tolerance but also prevent the 
induction of peripheral tolerance. However, the 4Y feeding experiment (figure 
4.4) shows that it is not principally impossible to downregulate encephalitogenic 
Acl-9-specific T cells by the oral route. Other reports also demonstrate a direct 
epitope-specific inhibitory effect induced by oral administration of a major 
CD4+ T cell -specific target epitope. A recent study analyzed the role of 
encephalitogenic and non-encephalitogenic epitopes in oral tolerance (Miller et 
al, 1993). Three non-encephalitogenic epitopes, 21-40, 51-70, and 101-120 of 
guinea pig MBP could induce oral tolerance and trigger the release of TGF-p. 
The encephalitogenic peptide 71-90 did not mediate TGF-P release, yet it was 
possible to induce oral tolerance with this peptide, as well. Although the 
mechanism by which the orally administered encephalitogenic peptide exerted 
its tolerogenic effect in the Lewis rat model or EAE was not established, it was 
consistent with clonal anergy. While in this EAE model, different epitopes 
induced different mechanisms, different doses of the same peptide appeared to 
trigger distinct mechanisms in the Lewis rat model of EAU. Repeated feedings of 
low doses (250µg) of an S-antigen peptide was protective against EAU induced 
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with either the same peptide (343-362), whole S-ag or with a distinct pathogenic 
epitope comprising residues 270-289. Under these conditions, protection could 
also be adoptively transferred, thereby meeting two general criteria for 
suppression. In contrast, when high doses of 343-362 of S-ag were fed 
(5mg/feeding), protection was only achieved against EAU induced with the 
same peptide and was not transferable, observations consistent with clonal 
anergy. The cells that mediated suppression under the low dose feeding regime 
were not identified, but the finding that the same peptide could induce both 
active suppressor mechanisms and induce CD4+- dependent EAU suggested 
that the peptide either induced CD4+ Ts cells upon feeding or that it could also 
bind to class I MHC thereby inducing cos+ regulator cells (Gregerson et al., 
1993). However, in our study, there was no evidence for protection from EAE 
with any of the doses of intragastrically administered Acl-11 as shown in figures 
4.1-4.3We therefore have to conclude that low doses of the encephalitogenic 
peptide failed to induce suppressor mechanisms in this mouse model of EAE. 
The terms "high" and "low" are, of course, both vague and relative. At the 
time when the project on oral tolerance in the PL/J mouse model was started, to 
our knowledge no reports were available on mouse models of oral tolerance in 
EAE or any other experimental autoimmune disease. Since the body weight of 
mice is approximately only 10% of the rat body weight (about 20mg versus 
200mg), the effective doses in mice can be expected to differ from those applied 
in the rat models of oral tolerance. However, the encephalitogenic peptide Acl-
11 was fed three times on days -7, -5, and -2, a time frame known to be effective 
in the rat model, and over a wide range of doses, namely three feedings of either 
2.Sµg, 25µg, or 250µg (figure 4.2). This dose range included the amounts that 
· induced suppression in the rat model of EAU (3 x 250 µg) as well as a ten-fold 
lower dose to account for the differences in body weight between rats and mice. 
It is, of course, possible that an effective oral dose of Acl-11 lies within such a 
narrow range that we missed it in our experiments. Furthermore, effective doses 
and time fraP1es of feeding are presumably characteristic for each antigen and 
each model and cannot readily be extrapolated from one system to another. 
An alternative explanation for the failure to induce oral tolerance with Acl-11 
or Acl-9 focuses on the potential role of APC. All reports discussed above use 
relatively long peptides consisting of about twenty residues . Although 
Gregerson et al. also report oral tolerance induction by a 9-mer and 13-mer in the 
EAU model, the clearest suppressive effect appeared to be achieved with the 
longer peptide 343-362 (Gregerson, Obritsch, & Donoso, 1993). It is not known 
whether in these experiments, the long peptides bound directly to free class II or 
class I MHC displayed on the surface of APC or whether they required uptake, 
- "" 
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further processing and intracellular association with MHC molecules. In the 
PL/J model, these requirements apply to Acl-20 since fixed APC fail to 
stimulate a Acl-11- specific T cell hybridoma (Fairchild et al, 1993). Possibly, the 
actual process of intracellular antigen handling by APC induces physiological 
responses in the APC beyond mere antigen proteolysis which in turn influence 
the outcome of the immune response, for instance by lymphokine release of 
differential expression of cell surface molecules either on the APC itself and/ or 
on proximate lymphocytes 
4.3.2 lntragastric Administration Of Whole Myelin Protein 
The failure to induce oral tolerance with the major encephalitogenic peptide 
implied that CD4+ T cell mediated regulation could not be induced by the 
intragastric route in the PL/J mouse model. We therefore tested the significance 
of distinct regulatory epitopes by feeding whole MBP. As expected, MBP was 
strongly encephalitogenic in PL/J mice (figures 4.6b and 4.7). Since the major 
encephalitogenic peptide was obviously processed from MBP in vivo we could 
test the idea discussed above that this peptide might induce oral tolerance if it 
were processed from whole MBP. 
In the first feeding experiment, EAE was induced with Acl-11 after oral 
administration of three doses of 1mg MBP. In another study in which 20mg of 
MBP were fed to Lewis rats, the authors interpret their data revealing inhibition 
of in vitro T cell proliferation, IL-2 production and lack of tolerance transfer in 
favour of clonal anergy rather than suppression although suppressor 
mechanisms were not rigorously excluded (Whitacre et al, 1991). In any case, if 
higher amounts of fed protein were needed to induce anergy than suppression, 
the total amount of 3mg MBP fed to mice should have been sufficiently high 
compared to 20mg MBP fed to rats. The data presented in figures 4.5 and 4.6a 
demonstrate; however, that oral administration of MBP did not protect against 
EAE. Furthermore, mice fed MBP displayed some relapse between days 30-40 
after disease induction which was not observed in the control groups in .either 
of the two experiments. Figure 4.5 also shows a lack of protection with smaller 
doses of fed MBP. If anything, 3x100µg and 3x500µg oral doses of MBP caused 
more severe disease compared to PBS-fed controls. 
In the absence of clonal anergy or CD4+ T cell mediated suppression, EAE 
induction with Acl-11 alone after feeding whole MBP might have hindered the 
development of alternative suppressor mechanism. Several studies have shown 
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that "suppressor epitopes" usually need to be included within the antigenic 
challenge to enable cognate Ts cell mediated downregulation of the responses to 
other epitopes. For instance, oral administration of the epitope 21-40 of MBP 
capable of triggering TGF-~ release from CDs+ regulator cells only suppressed 
DTH responses to whole MBP but not to 71-90. Feeding of peptide 21-40, 
however, inhibited EAE induced by 71-90, postulated to be mediated by 21-40-
specific T cells that migrate to the CNS and are subsequently stimulated by 
peptide 21-40 processed from endogenous MBP(Miller et al, 1993). Nevertheless, 
we tested the possibility that if the need to process and present regulatory 
epitopes from endogenous MBP in the CNS were circumvented by challenging 
with whole MBP rather than only with the encephalitogenic peptide, the 
induction of suppression might be facilitated. Therefore, in the following 
experiments shown in figures 4.6b and 4.7, mice were primed with MBP after 
feeding MBP. The data presented in figure 4.6 suggest that feeding MBP had 
some protective effect if EAE was subsequently induced with MBP instead of 
Acl-11. Although the differences between MBP-fed animals and the control 
group (groups 4 and 3 in the table, figure 4.6b) fell short of being statistically 
significant, the apparent delay of disease and the overall lower incidence of EAE 
in the MBP-fed group were encouraging to further study this phenomenon. 
However, when this experiment was repeated under exactly the same 
conditions, there was no indication of oral tolerance. On the contrary, animals 
fed with MBP appeared to recover less readily after the first phase of EAE and 
displayed a more chronic disease in contrast to the sharply biphasic course in the 
control group (figure 4.7). 
Although there is 90% homology between pig and mouse MBP, the 
possibility remained that a relevant regulatory epitope required for the 
induction of oral tolerance in the mouse was missing or could not be efficiently 
processed and presented. One report suggested that homologous MBP was a 
more efficient oral tolerogen than heterologous MBP (Miller et al, 1992b). We 
therefore dedded to feed mouse spinal cord homogenate (SCH) as a rich source 
of homologous MBP. However, feeding SCH significantly exacerbated disease in 
one experiment (figure 4.8) and had no obvious effect on the course of EAE in a 
second experiment (figure 4.9). 
4.4 SUMMARY AND CONCLUSION 
The data presented in this chapter failed to provide evidence for oral 
tolerance by the major encephalitogenic peptide Acl-11 or the higher affinity 
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analogue 4A in the PL/J mouse model of EAE. Only high doses of the 4Y 
analogue, capable of forming stable complexes with I-AU abrogated EAE and in 
vitro T cell proliferative responses. The dose dependence for 4Y needs to be 
established in more detail. To account for the possible need for antigen 
processing in GALT and the role of distinct regulatory epitopes involved in oral 
tolerance, subsequent studies inclu.ded intragastric administration of purified 
porcine MBP and mouse spinal cord homogenate. However, these feeding 
regimes did not show any reproducible protective effect, either. While there was 
one single experiment where feeding MBP tended to delay disease and reduce 
the incidence of EAE (figure 4.6b), many other experiments did not reveal any 
effect of feeding (e.g. figures 4.1 and 4.9) or showed a tendency to exacerbate 
disease at some stage of the experiment (figures 4.2, 4.5 ,4.6a, 4.7, and 4.8). 
It remains to be established whether feeding even higher doses of Ac1-9[4K] 
and [4A] or whole myelin proteins can inhibit EAE. It is also possible that 
antigen was not fed frequently enough or within an appropriate time frame. 
Furthermore, SCH might contain substances (such as lipids) that interfere with 
the induction of oral tolerance. Therefore, further studies should employ murine 
MBP, for which a recombinant form may soon enable the expression of 
sufficiently high amounts. 
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Figure 4.1 Oral Administration Of Ac1-11[4K] 
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Figure 4.1. PL/J mice were fed a single dos.e of 800µg Acl-11[4K] 
in 200µ1 PBS (closed circles) or PBS alone (open circles). Seven days 
later, EAE was induced with SOµg Ac1-11[4K]/ CFA. 
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Figure 4.2 Oral Administration Of 
Different Doses Of Ac1-11[4K] 
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Day after EAE induction 
GROUP INCIDENCE MEDIAN DAY MEAN MAXIMAL 
OF DISEASE OF ONSET GRADE EAE 
3X buffer 6/8 14 2.6 ± 2.1 
3X 2.5 µg 5/7 14 2.0 ± 1.8 
3X 25 µg 5/9 15 2.2 ± 2.2 
3X 250 µg 6/8 13 2.5± 1.8 
3x buffer 
3x 2.5µg 
3x 25µg 
3x 250µg 
Figure 4.2 PL/J mice were fed the indicated amounts of Ac1-11[4K] in 
75 mM NaHC03 buffer plus 20 mg/ml trypsin inhibitor or 200 µl buffer 
plus trypsin inhibitor alone three times on days -7, -5, and -2. On day 0 
EAE was induced with 50µg Ac1-11[4K]/ CFA. 
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Figure 4.3 Comparing The Effect Of 
Feeding Ac1-11[4K] And Ac1-11[4A] 
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Day after EAE induction 
GROUP INCIDENCE MEDIAN DAY MEAN MAXIMAL 
OF DISEASE OF ONSET GRADE EAE 
PBS 8/8 12 1.7±0.7 
Ac1-11 [4K] 6/6 11.5 2.0 ±0,9 
Ac1-11 [4A] 6/6 10 2.0 ± 1.1 
Figure 4.3. On days -7 and -5, PL/J mice were fed 400µg of either Acl-
11[4K] (triangles) or Acl-11[4A] (squares) in 75mM NaHC03 buffer 
including 20mg/ml trypsin inhibitor. Controls (circles) received buffer 
plus trypsin inhibitor only. EAE was induced with SOµg Acl-11[4K]/ CFA 
on day 0. 
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Figure 4.4 Effect of high oral doses of Ac1-9[4Y] 
on in vitro lymphocyte proliferation and EAE 
Figure 4.4 Pl/J mice were fed 1mg Acl-9[4Y] on days -7, -5, and -3. Peptide was 
administered in 500µ1 150mM NaHC03 buffer including 2.5 mg/ml trypsin-
chymotrypsin inhibitor (closed circles). Controls received 500µ1 buffer plus 
protease inhibitors only (open circles). On day 0, the experiment was split to test 
the effect of peptide feeding on in vitro lymphocyte proliferation (a) and on EAE 
(b). Figure 4.4a: On day 0, mice were primed with 50µg Ac1-9[4K]/CFA 
subcutaneously at the base of the tail, as described in material and methods. Ten 
days later, lymphocytes were restimulated in vitro with Acl-9[4K], and 
proliferation measured by 3-H thymidine uptake. Symbols represent the 
arithmetic mean of triplicates, standard deviations were less than 20% of the 
mea9. Controls for medium/PPD in cpm were 490+40/39,480+660 for 
lymphocytes from control-fed mice, and 370±70/34,020±1700 with lymphocytes 
from the peptide-fed group. Figure 4.4b: On day 0, EAE was induced with 50µg 
Acl-9[4K]/CFA including 2 injections of PTX as described in material and 
methods. 
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Figure 4.5 Feeding Different Doses Of 
MBP Before Peptide-Induced EAE 
0 3x PBS 
3x 100µg 
2.0 
• 3x 500µg 
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Day after EAE induction 
GROUP INCIDENCE MEDIAN DAY MEAN MAXIMAL 
OF DISEASE OF ONSET GRADE EAE 
3X PBS 5/8 12.5 1.5 ± 1.6 
3X 100 µg 7/8 12.0 2.6 ± 1.6 
3X 500 µg 717 12.5 2.3 ± 1.5 
3X 1 mg 5/5 19.0 2.4± 0.9 
Figure 4.5. PL/J mice were fed the indicated amounts of porcine MBP or 
200µ1 PBS on days -7, -5, and -2. EAE was induced on day O with SOµg 
Acl-9[4K]/ CFA. 
Figure 4.6 Feeding MBP Before Peptide-
Induced Or MBP-Induced EAE 
Figure 4.6 PL/J mice received 3 x 1mg of MBP in PBS (closed circles) or 
200µ1 PBS alone (open circles) on days -7, -5, and -2. On day O EAE was 
induced with either SOµg Acl-11[4K]/ CPA (figure a) or 1mg 
porcineMBP / CPA (figure b). 
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Figure 4.6 
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Figure 4.7 Feeding MBP Before MBP-Induced EAE 
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Figure 4.7 PL/J mice received 3 x 1mg of MBP in PBS (closed circles) or 200µ1 
PBS only (open circles) on days -7, -5, and -2. EAE was induced with 1mg 
MBP/CFA ondayO. 
Figure 4.8 Oral Administration Of Mouse Spinal 
Cord Homogenate (SCH) Before SCH-Induced EAE, I 
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Figure 4.8 PL/J mice were fed 2mg SCH in PBS (closed circles) or 
200µ1 PBS only (open circles) 7, 5, and 2 days prior to EAE induction 
with 1mg SCH/ CFA. 
Figure 4.9 Oral Administration Of Mouse Spinal 
Cord Homogenate (SCH) Before SCH-Induced EAE, II 
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Figure 4.9 PL/J mice were fed 2mg SCH in PBS (closed circles) or 
200µ1 PBS only (open circles) 7, 5, and 2 days prior to EAE induction 
with 1mg SCH/ CFA. 
CHAPTERS 
The Effect Of Peptide Inhalation 
On The Response Of Encephalitogenic 
T Cells 
5.1 INTRODUCTION 
In addition to oral tolerance, antigen inhalation has also been revealed as a 
potentially tolerogenic route. Inhalation of antigen has been demonstrated to 
specifically downregulate immune responses to soluble proteins such as OVA 
(reviewed in Holt & McMenamin, 1989), and one report also mentioned that 
administration of MBP as an aerosol suppressed EAE (Weiner et al., 1991). For 
our studies, parallel to experiments on oral tolerance, other groups of mice 
received an intranasal dose of the encephalitogenic peptide Acl-9 (or Acl-11) or 
its higher affinity analogues 4A and 4Y to examine whether inhalation of a single 
epitope was sufficient to inhibit EAE. If this were the case, an I-Au restricted 
direct (suppressor independent) inhibitory effect on CD4 + encephalitogenic T 
cells might operate and be improved with the higher affinity analogues 4A and 
4Y. For the first experiments EAE was induced with Acl-11. To test the 
inhibitory potential of inhaled peptide further, we subsequently extended this 
project to disease induced with whole mouse spinal cord homogenate (SCH) 
which often induces more vigorous disease than peptide alone and also allows 
for the processing and presentation of additional epitopes. To address the 
epitope specificity of the immune response mediated by inhaled peptide, we 
examined the effect of peptide inhalation on secondary in vitro lymphocyte 
proliferation in response to two well characterized encephalitogenic epitopes, 
Acl-9 and 35-47 of MBP. 
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5.2 RESULTS 
5.2.1 Effect Of Peptide Inhalation On EAE Induced With Acl-11 
In a first series of experiments (figures 5.1-5.3) we tested whether the N-
terminal peptide of MBP given by inhalation could protect from EAE induced 
with the same epitope Acl-11. Mice· received a single intranasal dose of 100µg 
peptide one week prior to EAE induction. Figure 5.1 shows that, even though 
the incidence of disease was hardly affected, inhalation of the low affinity wild 
type peptide Acl-11 significantly reduced disease severity (p<0.01). The effect of 
the 4A peptide analogue given by inhalation was even more pronounced than 
protection achieved with the wild type 4K peptide (figure 5.2). Here, inhalation 
of Acl-11 [4A] almost completely suppressed the pathological signs of EAE. The 
impact of the 4K peptide on disease was weaker in this experiment and not 
statistically significant for the data presented in the table. However, there was a 
tendency for less severe disease in the 4K-pretreated group, as well. This was 
perhaps most clearly demonstrated in the plot showing a peak in disease 
severity around day 17 in the control group at which time the mean grade EAE 
was more than one grade lower in the 4K-pretreated group. 
The finding that the 4A analogue was a more powerful tolerogen when 
administered by inhalation implied a positive correlation between peptide-MHC 
affinity and tolerogenicity. However, the 4A peptide is not encephalitogenic in 
the PL/J and (PL/J x B10.PL) Fl strains and only poorly encephalitogenic in 
BlO.PL mice. In contrast, the 4Y analogue and the wild type peptide 4K peptides 
are equally encephalitogenic in PL/J and (PL/J x B10.PL) Fl mice, and the 4Y 
peptide appears to be more encephalitogenic in the B10.PL strain (unpublished 
observations, not shown). Thus, if the tolerogenic effect of inhaled peptide were 
truly affinity dependent, then we would expect the 4Y analogue to confer the 
highest degree of inhibition. Figure 5.3 compares the relative protective effects of 
all three peptides, 4K, 4A, and 4Y. Although the overall severity of EAE in the 
control group was low when compared to previous experiments, the incidence 
(9/10) was high. Significant protection as most clearly revealed by decreasing 
incidence of EAE was achieved with all three peptides and there was a clear 
positive correlation between peptide-MHC affinity and tolerogenicity. 
5.2.2 Effect Of Peptide Inhalation On EAE Induced With Spinal 
Cord Homogenate 
The results described above implied an epitope-specific mechanism of 
tolerance that was improved by high avidity APC- CD4+ T cell interactions. 
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However, these findings did not exclude that Acl-11-specific T cells rendered 
unresponsive to subsequent antigenic challenge with the same epitope were also 
capable of impairing the encephalitogenic functions of T cells specific for other 
epitopes such as 35-47 of MBP. Therefore, we next examined whether peptide 
inhalation could also inhibit EAE induced with a complex mixture of several 
potential autoantigens as present in whole spinal cord homogenate (SCH). As 
shown in figure 5.4, the 4A peptide conferred highly significant protection from 
EAE induced with SCH. This was most clearly revealed by the lower disease 
incidence (2/10 versus 9/9). Furthermore, the plot indicates that the onset of 
EAE was delayed by 1-2 weeks in the two animals that got disease in the 4A-
pretreated group compared to controls. The tolerogenic effect on SCH-induced 
EAE was not confined to the higher affinity 4A analogue but was also 
demonstrated for the original 4K peptide (figure 5.5). Although the incidence of 
disease was hardly affected, the data presented in the plot and table demonstrate 
substantially diminished disease severity as a result of 4K inhalation. 
Furthermore, as already shown for peptide-induced EAE, protection from 
disease appeared to be improved with the higher affinity 4A analogue with a 
significant number of mice being completely protected from any clinical signs of 
EAE(p=0.042). 
To investigate this phenomenon further, the tolerogenic properties of all 
three peptides 4K, 4A, and 4Y on SCH-induced EAE were tested in all three H-
2u strains available for our studies, i.e. PL/J, BlO.PL, and (PL/J x BlO.PL) Fl. In 
the experiment shown in figure 5.6 the inhibitory effect on EAE was confirmed 
for all three peptides in (PL/J x BlO.PL) Fl mice. Perhaps the most significant 
observation was that inhalation of either of the three peptides completely 
abrogated relapses in SCH-induced EAE. The plot illustrates that both higher 
affinity analogues (but not the 4K peptide) also reduced disease severity during 
the first phase of EAE around days 12-14. Overall, both the 4A and the 4Y 
peptide significantly reduced the incidence of disease. However, the difference 
in affinity between 4A a nd 4Y was not reflected in their tolerogenicity in this 
experiment. 
When this experiment was repeated in the BlO.PL strain, unlike in all 
previous experiments, inhalation of 4K did not appear to affect EAE. The plot of 
figure 5.7 reveals almost identical disease patterns for control and 4K-pretreated 
groups. The data in the table show identical incidences of disease and only a 
marginally lower value for mean maximal grade EAE in the 4K-treated group 
compared to PBS controls. In contrast, pretreatment with 4A and 4Y by 
inhalation profoundly ameliorated disease. The data presented in the plot show 
that the mean grade EAE was at least one grade lower during the peak of disease 
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on day 13 and at all times thereafter in the groups that had inhaled either of the 
higher affinity analogues. Although the differences between the 4A and the 4Y 
treated groups were not substantial, the 4Y peptide appeared to confer slightly 
better protection than the 4A analogue. Significantly, all mice that did get EAE in 
the 4Y treated group fully recovered and no relapses occurred. Interestingly, the 
data reveal a slight relapse in the 4A group between days 32 and 37 which is 
parallel to the relapse in the control (but not the 4K) group. 
In PL/J mice, the patterns of tolerogenicity among the wild type 4K peptide 
and both higher affinity analogues 4A and 4Y were very similar in peptide-
induced (figure 5.3) and SCH-induced EAE (figure 5.8). All three peptides given 
by inhalation conferred significant protection from EAE with a clear positive 
correlation between peptide-MHC affinity and tolerogenicity. One critical issue 
of the experiment shown in figure 5.3 for protection from peptide-induced EAE 
could have concerned the overall low grade of disease which might have greatly 
facilitated tolerance induction. This was not a problem in the experiment shown 
in figure 5.8. Here, not only the incidence of disease but also the overall severity 
was high, the disease severity in fact being highest among all experiments with 
SCH-induced EAE. Yet, mice pretreated with 4Y by inhalation were almost 
completely protected from disease, and substantial inhibition of EAE as well as 
delay of disease onset was also achieved by inhalation of 4K and 4A. 
The unusual pattern of disease in figure 5.8 demands a few additional 
comments. Typically, EAE in these mouse strains is characterized by a 
pronounced first phase with a peak around days 12-17. Thereafter, mice may 
either remain chronically ill at their maximal (rare) or at a lower grade of EAE 
(common) or recover completely. This phase may be followed by a more or less 
pronounced relapse which sometimes reaches the peak height of the first phase 
but is rarely substantially more severe. The experiment of figure 5.8 is a not 
previously encountered exception from this rule in the sense that a relatively 
mild first phase of EAE is followed by a rapid exacerbation reaching its peak on 
day 39, an ul).usually late time point. Here, disease is far more severe in the 
second than during the . first phase with two grades higher on average. 
Interestingly, in the 4K treated group, both peaks also occur, albeit with 
markedly lower average grades and also with delays for both phases, day 19 
compared to day 18 and - more clearly- day 45 compared to day 39. None of the 
4A or 4Y pretreated animals display clinical signs of EAE until days 39 and 36, 
respectively. In the 4Y treated group the two mice that got low grade EAE 
recovered completely while the 4A group displayed a disease pattern parallel to 
the 4K group but with a lower average grade of EAE. However, in this 
experiment, data analysis was hampered to a certain extent by the unusually 
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high number of deaths without prior clinical signs of EAE. The fact that these 
deaths occurred at the time of most severe EAE between days 31-39 might have 
indicated that deterioration happened too suddenly to be detected within the 24 
hours intervals of monitoring. On the other hand, the lack of previous signs of 
EAE excludes the classification of theses cases as grade 5. Because of this 
ambiguity, these cases were stated separately and excluded from statistical 
analysis. They do not, however, affect the observations stated above concerning 
the relative tolerogenic effects of the three peptide when administered by 
inhalation prior to the induction of EAE with SCH. 
In summary, a single dose of 100µg Ac1-11(or Acl-9) and its 4A and 4Y 
analogues given by inhalation one week prior to disease induction, protected 
mice from EAE induced with either Acl-11 or SCH. Furthermore, there was a 
direct positive correlation between affinity and tolerogenicity in PL/J mice. In 
the two EAE experiments done in (PL/J x BlO.PL) Fland BlO.PL in which the 
inhibitory effects of all three peptides were compared, both higher affinity 
analogues inhibited disease more strongly than the 4K peptide, but there was no 
clear and reproducible difference between 4A and 4Y. 
5.2.3 Effect Of Peptide Inhalation On In Vitro Proliferative 
Responses To Encephalitogenic Peptides 
The positive correlation between peptide- I-Au affinity and tolerogenicity 
suggested that this form of inhalation tolerance was based on direct interactions 
between encephalitogenic T cells and APC without the· requirements for 
additional suppressor mechanisms. However, the finding that inhalation of Acl-
9 and its higher affinity analogues 4A and 4Y not only interfered with disease 
induced by the same epitope but also by whole SCH implied that peptide 
inhalation might trigger regulatory mechanisms which could also affect the 
functions of other encephalitogenic T cells in a bystander fashion. However, 
despite the existence of other encephalitogenic epitopes within SCH (such as 35-
47) only Acl-11 of MBP is primarily recognized upon priming with the intact 
MBP protein (Zamvil et al, 1986; Urban et al, 1988). Therefore, preventing the 
response to this dominant epitope would be ~ufficient to inhibit EAE. In an 
attempt to distinguish between these possibilities we examined the effect of 
inhaling a single peptide on the response of lymphocytes primed with either 
Acl-9 (or Acl-11) or 35-47 or a mixture of both peptides. Although lymphocytes 
respond weakly to 35-47 after immunization with whole SCH (David Wraith, 
unpublished data), priming with 35-47 might enforce a strong immune response 
to this otherwise subdominant epitope. Thus, under these conditions, any 
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inhibition of the response to 35-47 cannot be explained on the basis of epitope 
dominance/ subdominance. 
Previous experiments suggested that the best protection against SCH-
induced EAE was achieved by prior inhalation of the 4Y analogue in PL/J mice 
(figure 5.8). Therefore, if peptide inhalation initiated bystander regulation, it was 
most likely to be detected in this model. In order to 'dissect' the responses to 
Acl-9 and 35-47 after inhalation of individual peptides and immunizing with 
either peptide alone of both peptides together, the P.roliferative responses of 
primed lymphocytes to these two epitopes were testifn vitro. When mice were 
immunized with either peptide alone, inhalation of 4Y completely abrogated the 
proliferative response to Acl-11 (figure 5.9 a) while restimulation of 
lymphocytes with 35-47 was not impaired (figure 5.9 b). This experiment also 
revealed that strong immune responses to MBP 35-47 could be provoked by 
priming with this peptide (rather than with whole myelin protein). When 
administered by inhalation, MBP 35-47 inhibited the response to itself but not to 
Acl-11 (figure 5.10). Here, lymphocytes primed with Acl-11 displayed even 
higher specific proliferative responses after inhalation of 35-47 compared to PBS 
controls (figure 5.10 a). However, this was probably due to higher background 
proliferation in medium alone in this group. 
The results presented in figures 5.9 and 5.10 demonstrated strictly epitope-
specific inhibition by inhaled peptide in a situation where mice were immunized 
with individual peptides. Before addressing the question of bystander 
suppression by inhalation in a co-immunization protocol with a mixture of Acl-
11 and 35-47 of MBP, we needed to examine the impact of one co-injected 
peptide on the specific immune response to the second peptide. It was 
conceivable that lymphocytes specific for one epitope might benefit from growth 
factors and lymphokines released upon cognate TCR ligation by T cells specific 
for the second epitope, i.e. they would receive bystander help. Alternatively, 
there might be competition between both peptides for presentation by APC. 
However, sine~ Acl-11 binds to I-AU and 35-47 is I-EU- restricted, this possibility 
seemed less likely. Figure 5.11 shows the proliferative responses of lymphocytes 
from mice primed with a mixture of Acl-11 and 35-47 compared to lymphocytes 
primed with either peptide alone. The data suggest that the presence of both 
peptides within the same adjuvant did not affect the priming to individual 
peptides since the specific responses to Acl-11 (figure 5.11a) and MBP 35-47 
(figure 5.llb) were almost identical between groups of lymphocytes. The 
marginally lower levels of proliferation with Acl-11 of co-primed lymphocytes 
compared to Acl-11-primed cells, and slightly higher values when assayed 
against 35-47 can readily be accounted for by moderately lower and higher 
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medium and PPD controls in the co-immunized group compared with each 
peptide alone in plots 5.lla and 5.llb, respectively. 
Since co-immunization with two peptides per se did not appear to modulate 
specific T cell responses to individual peptides, we subsequently tested peptide 
inhalation for bystander inhibition. Mice received an intranasal dose of either 
Ac1-9[4Y] or 35-47 one week before priming with a mixture of Acl-9 and 35-47 
(figure 5.12). As shown before in figures 5.9 and 5.10, the data reveal complete 
specific inhibition of the response to Acl-9 and also lower levels of proliferation 
with 35-47 after inhalation of this peptide. There also might have been a 
moderate degree of bystander inhibition of the response to Acl-9 after inhaling 
35-47 and vice versa. However, a conclusive analysis of these data with respect 
to the significance of the subtle bystander effects was hampered by the fact that 
the background (proliferation with medium alone) was twice as high in the PBS 
controls than in both groups that had inhaled peptide. To clarify the issue of 
bystander effects, the following experiment (figure 5.13) included groups co-
immunized with Acl-9 and 35-47 or primed with either peptide alone. For this 
experiment, only Ac1-9[4Y] was used for inhalation. Although the control values 
for medium and PPD varied among groups thus thwarting direct comparisons, 
the results contain some useful information. As shown before, inhalation of 4Y 
abrogated the response to Acl-9 whether Acl-9 had been injected on its own or 
in combination with 35-47. Although in the latter case the inhibition was not 
complete, the background proliferation with medium only was substantially 
higher in the 4Y-inhaled and co-immunized group compared to lymphocytes 
from mice that were immunized with Acl-9 only. Inhalation of 4Y probably did 
not inhibit 35-47 -specific cells nonspecifically when animals had been primed 
with this peptide alone. Although the level of proliferation against 35-47 was 
lower in the 4Y-pretreated group, the positive control (PPD) reached only about 
50% of the PPD response of the PBS-pretreated group. As to the question of 
bystander effects, co-immunization with Acl-9 and 35-47 did not appear to affect 
the response_ to either peptide compared to lymphocytes primed with either 
peptide alone. The response to Ac 1-9 was almost identical between 
individually-and co-immunized groups (figure 5.13 a) with similar medium and 
PPD controls among these two groups. When restimulated with 35-47, the level 
of proliferation with lymphocytes from co-immunized mice was slightly lower 
when compared to lymphocytes from animals primed with 35-47 alone. This 
difference could be accounted for by lower medium and PPD controls. Taken 
together, there was clearly no indication of bystander help in this model. 
Furthermore, inhalation of 4Y did not reduce the in vitro proliferative response 
to 35-47 when this was co-injected with Acl-9. In this assay, the response to 35-
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47 after 4Y inhalation was even higher compared to PBS-pretreated and co-
immunized controls. However, as mentioned before, the higher specific 
responses in this group were presumably due to higher medium and PPD 
controls. Therefore, there was probably no net effect of inhaling 4Y on the 
response of 35-47-specific T cells regardless of whether 35-47 was injected on its 
own or in combination with Acl-9. 
5.3 DISCUSSION 
5.3.1 The Significance Of High Avidity TCR-MHC Class II-Peptide 
Interactions For Nonresponsiveness Induced By Peptide 
Inhalation 
The data presented in this chapter show that inhalation of the N-terminal 
encephalitogenic peptide of MBP and its higher affinity analogues markedly 
inhibited EAE in mice of the H-2u haplotype. The fact that the encephalitogenic 
peptide on its own was sufficient to inhibit EAE upon inhalation clearly 
indicated that suppressor epitopes distinct from the encephalitogenic epitope 
were not required for this route of immune intervention. In all EAE experiments 
in PL/J mice there was a clear direct positive correlation between peptide-MHC 
affinity and the degree of protection from disease. In BlO.PL and (PL/J x BlO.PL) 
Fl both higher affinity analogues 4A and 4Y conferred better protection from 
EAE than the wild type peptide, but the differences between 4A and 4Y were 
less clear. Since PL/J and BlO.PL strains are of identical class II haplotype, genes 
of the BlO.PL background other than those constituting class II MHC may also 
influence the degree of nonresponsiveness. Furthermore, it is possible that 
residue four of Acl-9 has an impact on TCR recognition in addition to its well 
defined role for MHC-binding. This is supported by the observation that EAE 
can be induced with the 4A peptide in BlO.PL in some (but not all) experiments 
while this analogue has never been encephalitogenic in PL/J or (PL/J x BlO.PL) 
Fl mice (unpublished data, not shown). Additionally, 4Y induces consistently 
more severe EAE than 4K in BlO.PL whereas in the two other strains 4K and 4Y 
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are equally encephalitogenic even though 4Y but not 4K forms stable complexes 11 J j 
with I-Au (unpublished data, and Fairchild et al, 1993). However, the findings 
that an encephalitogenic epitope given by inhalation was sufficient to inhibit 
subsequent immune responses to itself, and that analogues of Acl-9 with higher 
affinity for I-Au were more potent tolerogens than the original low affinity j" 
47 after 4Y inhalation was even higher compared to PBS-pretreated and co-
immunized controls. However, as mentioned before, the higher specific 
responses in this group were presumably due to higher medium and PPD 
controls. Therefore, there was probably no net effect of inhaling 4Y on the 
response of 35-47-specific T cells regardless of whether 35-47 was injected on its 
own or in combination with Acl-9. 
5.3 DISCUSSION 
5.3.1 The Significance Of High Avidity TCR-MHC Class II-Peptide 
Interactions For Nonresponsiveness Induced By Peptide 
Inhalation 
The data presented in this chapter show that inhalation of the N-terminal 
encephalitogenic peptide of MBP and its higher affinity analogues markedly 
inhibited EAE in mice of the H-2u haplotype. The fact that the encephalitogenic 
peptide on its own was sufficient to inhibit EAE upon inhalation clearly 
indicated that suppressor epitopes distinct from the encephalitogenic epitope 
were not required for this route of immune intervention. In all EAE experiments 
in PL/J mice there was a clear direct positive correlation between peptide-MHC 
affinity and the degree of protection from disease. In B10.PL and (PL/J x B10.PL) 
Fl both higher affinity analogues 4A and 4Y conferred better· protection from 
EAE than the wild type peptide, but the differences between 4A and 4Y were 
less clear. Since PL/J and B10.PL strains are of identical class II haplotype, genes 
of the B10.PL background other than those constituting class II MHC may also 
influence the degree of nonresponsiveness. Furthermore, it is possible that 
residue four of Acl-9 has an impact on TCR recognition in addition to its well 
defined role for MHC-binding. This is supported by the observation that EAE 
can be induced with the 4A peptide in B10.PL in some (but not all) experiments 
while this analogue has never been encephalitogenic in PL/J or (PL/J x B10.PL) 
F1 mice (unpublished data, not shown). Additionally, 4Y induces consistently 
more severe EAE than 4K in B10.PL whereas in the two other strains 4K and 4Y 
are equally encephalitogenic even though 4Y but not 4K forms stable complexes 
with I-Au (unpublished data, and Fairchild et al, 1993). However, the findings 
that an encephalitogenic epitope given by inhalation was sufficient to inhibit 
subsequent immune responses to itself, and that analogues of Acl-9 with higher 
affinity for I-Au were more potent tolerogens than the original low affinity 
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peptide imply that high avidity ligation of the trimolecular complex formed by 
TCR-MHC-peptide is of pivotal importance for T cell inactivation in this model. 
Protection from EAE by peptide inhalation was not confined to peptide-
induced disease but also to EAE induced with whole spinal cord homogenate 
(SCH). Two explanations could account for this observation: either there was 
bystander regulation of the response to epitopes other than the inhaled one or, 
alternatively, the N-terminal peptide of MBP is such a dominant epitope that 
immune responses to all other peptides processed and presented from SCH are 
virtually negligible. Recent evidence argues in favour of the second possibility. 
In contrast to Ac1-9, MBP 35-47 only induced low incidence and low grade EAE 
(not shown). Furthermore, when mice were primed with SCH, lymphocytes 
proliferated strongly when restimulated in vitro with Ac1-9, while the responses 
to 35-47 were substantially weaker and required much higher peptide 
concentrations. Another interesting observation in this system was that 
inhalation of the 4A peptide reduced in vitro proliferation and IFNy production 
of SCH-primed lymphocytes to both Ac1-9 and 35-47 while inhalation of 35-47 
had no effect on the in vitro response to either peptide (David Wraith, 
unpublished data). However, data presented in this chapter reveal that 
inhalation of MBP 35-47 could reduce the proliferative response to this peptide 
after priming with 35-47 alone (figure 5.10) or co-priming with MBP 35-47 and 
Ac1-9 (figure 5.12). It is therefore conceivable that the mechanism of 
nonresponsiveness by peptide inhalation in this model is dependent on strong 
(dominant) T cell-antigen interactions, not only at the time of inhalation, but also 
upon the antigenic challenge. This hypothesis could account for the failure to 
inhibit the subdominant response to 35-47 by inhaling this peptide prior to 
priming with SCH. In contrast to a challenge with whole antigen, lymphocytes 
from mice primed with peptides, MBP 35-47 alone or in combination with Ac1-9, 
proliferated almost equally strongly in response to both peptides (figure 5.11). 
Thus, when the subdominance of MBP 35-47 was overridden by peptide 
priming, inhalation of 35-47 reduced the response to itself (figure 5.10) even 
when the otherwise dominant epitope Ac1-9 was included for immunization 
(figure 5.12). 
Taken together, the positive correlation between peptide-I-Au affinity on the 
one hand, and the apparent need for a dominant T cell response on the other 
hand suggest that, similar to the HEL model of peripheral tolerance discussed in 
chapter 1, high avidity interactions of the trimolecular complex TCR-MHC-
peptide are required for the induction of nonresponsiveness by peptide 
inhalation in this model. If this were true, then a gradual increase in avidity by 
higher amounts of 35-47 should improve the conditions for 35-47-specific T cell 
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responses to be impaired by the same peptide given by inhalation. For instance, 
spiking SCH with increasing amounts of 35-47 should then reveal an increasing 
inhibitory effect of 35-47 upon inhalation. 
5.3.2 Mechanism 
5.3.2 i Bystander regulation? 
A series of experiments presented in this chapter (figures 5.4-5.8) show that 
peptide inhalation inhibited not only EAE induced with the encephalitogenic 
peptide but also disease induced with a mixture of several potential antigens 
such as SCH. This suggests a possibility for bystander effects. Alternatively, if 
one epitope dominates an immune response to such a large degree as Acl-9 in 
this model of EAE, inhibiting the response to this dominant epitope may be 
sufficient to downregulate autoimmune responses to the whole antigen. 
However, one finding mentioned in the previous section, namely that Ac1-9[4A] 
given by inhalation was able to reduce 35-47-specific in vitro responses of SCH-
primed lymphocytes (David Wraith, unpublished data) implies a bystander 
effect. Generally, two explanations could account for this finding : either 
inhalation of the dominant epitope abrogates bystander help for the 
development of the subdominant immune response or, alternatively, it actively 
induces bystander suppression. 
The strong immune response to the dominant epitope is probably associated 
with high concentrations of IFN-y and IL-2 at some stages of T cell activation. 
Therefore, whenever T cell responses to subdominant epitopes are initiated 
within the same micro-environment, they might benefit from the high local 
concentrations of stimulatory lymphokines triggered by the dominant immune 
response. In this situation, the response to Acl-9 would provide bystander help 
for T cells specific for 35-47. Consequently, inhalation of Acl-9 might only 
directly inhibit T cells specific for this same epitope and yet also indirectly 
impair the response to 35-47 by depriving 35-47-specific T lymphocytes of 
bystander help. Alternatively, inhalation of the N-terminal peptide of MBP or its 
higher affinity analogues might create a tolerogenic microenvironment that 
would mainly affect T cells specific for Acl-9 but which might also have an 
impact on adjacent T cells of other epitope specificities. For instance, it is 
possible that the intranasal route of antigen administration favours TH2 over TH1 
type responses. T cells that encounter peptide administered by inhalation might 
be induced to produce lymphokines such as IL-4 and IL-6 that inhibit 
96 
inflammatory THI-mediated responses central to the manifestation of EAE in 
vivo or IFN-y production in vitro. These TH2 type lymphokines might also bias 
the functions of nearby T cells of other specificities that were attracted to the 
same site of antigen presentation. Other candidates for inhibitory lymphokines 
such as TGF-P might also be involved. Although the immunosuppressive role of 
TGF-P has mainly been discussed in .the context of cos+ Ts cells, TGF-P -
secretion by CD4+ T cells has not been ruled out. In any case, if peptide 
inhalation provoked a lymphokine profile that would counteract the 
manifestation of T dependent inflammatory responses, then inhibition of SCH-
induced EAE after inhalation of a single epitope could be explained on the basis 
of bystander suppression. 
In an attempt to analyse how immune responses to Acl-9 and 35-47 influence 
each other in the absence of a hierarchy of dominance, mice were primed with a 
mixture of both peptides or either peptide alone. The data in figures 5.11 and 
5.13 suggest that co-priming with both peptides did not enhance proliferation in 
response to individual peptides compared with lymphocyte proliferation after 
priming with either peptide alone. Therefore, there was no evidence for 
bystander help under these conditions. Furthermore, inhalation of a single 
peptide did not appear to induce bystander suppression of the second co-
injected peptide. Figures 5.12 and 5.13 demonstrate clear specific inhibition of 
the proliferative response to the same peptide that had previously been inhaled 
while there was no significant (suppressive) effect on the response to the second 
epitope. Taken together, these experiments failed to reveal bystq.nder effects in a 
situation where a mixture of two peptides was injected. These observations were 
confirmed in preliminary experiments in another model, for which (BIOZZI x 
PL/J) Fl mice were primed with a mixture of 56-71 of proteolipid protein (PLP) 
and Acl-9. Here again, inhalation of each peptide profoundly diminished the in 
vitro proliferative response to itself but not to the second epitope (not shown). 
Thus, in a situation in which immune responses to two epitopes are both strong 
and apparently co-dominant, the phenomenon of inhalation -induced 
nonresponsiveness appears to be strictly epitope-specific, at least in vitro. 
In the case of Acl-9 inhalation prior to priming with SCH, the question as to 
whether lack of bystander help or the presence of bystander suppression 
diminished in vitro responses of 35-47-specific lymphocytes remains to be 
answered. One approach could · utilize recombinant MBP for which the 
nucleotide sequence coding for the N-terminus has been altered by mutagenesis 
so that Acl-9 can no longer bind to the I-AU molecule and/or can no longer be 
recognized by the T cell receptor. If bystander help were important for the 
activation of 35-47-specific T cells, then the response to 35-47 after priming with 
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modified MBP should be even weaker compared to priming with wild type MBP 
bearing the intact dominant N-terminal epitope. 
In order to define the mechanism of inhalation-induced immune 
downregulation, a number of questions will have to be addressed in detail: 
1. Where does the peptide locate after inhalation? 
2. Which APC are involved in tolerance induction? 
3. Can peptide inhalation induce regulator (suppressor) cells? 
4. What are the biochemical events in T cells that render them unresponsive to 
subsequent antigenic challenge? 
5. Can inhalation of whole antigen rather than peptide also inhibit T cell 
activation? 
6. Can inhalation modulate an immune response of already primed 
lymphocytes? 
5.3.2 ii. Localization of peptide after inhalation and the role of APC 
As discussed in chapter one, studies following the route of inhaled proteins 
showed that they can line the whole of the respiratory tract (provided the 
droplet size is appropriate) as well as being detected in the intestinal tract, other 
organs and the serum. Proteins and dyes that were directly applied to the nasal 
mucosa rather than in aerosolized form were detected in the lymphatics and the 
circulation (reviewed in Yoffey & Courtice, 1970; Willoughby & Willoughby, 
1977). The procedure adopted for our studies, to directly administer peptide to 
the nasal mucosa in a volume of 25µ1 probably did not produce droplets of a 
well defined size upon inhalation. However, this method has been successfully 
applied for the uptake of influenza virus particles into the lung (Taylor & 
Askonas, 1986). It seems therefore likely, that intranasally administered peptide 
is widely distributed within the body, both locally within the respiratory tract 
and draining lymph nodes, but also in the circulation, thereby gaining access to 
the spleen. Some of the inhaled peptide probably ends up in the intestinal tract. 
However, the failure to induce oral tolerance with much higher amounts of Acl-
11[4K and [4A] excludes the possibility of inhaled peptide to induce 
nonresponsiveness by the intragastric route. The question therefore arises as to 
which of the several possible routes is important for peptide to exert its 
tolerogenic effect. Or does sequestration of peptide and encephalitogenic T cells 
within the lymph nodes draining the respiratory tract provide a trivial 
explanation for the lack of response after subsequent priming at a different site 
such as the base of the tail? Further studies using radiolabelled peptide to 
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evaluate the tissue distribution of inhaled peptide and encephalitogenic T cells 
in transgenic mice are planned to address this question. 
Atpresent, the immunomodulatory properties of Acl-9 and its higher affinity 
analogues upon inhalation may be, but need not be explained on the basis of a 
particular immunosuppressive environment within the respiratory tract. 
Peptide-induced nonresponsiveness in EAE has been achieved under a variety 
of conditions. When encephalitogenic MBP peptides were administered in 
incomplete Freund's adjuvant (IFA) they conferred protection against EAE 
induced with the same peptide (Smilek et al., 1991; Gaur et al, 1992). In 
accordance with our observations with inhaled peptide, the higher affinity 4A 
analogue of Acl-11 given in IPA inhibited EAE more effectively than the original 
peptide (Smilek et al, 1991). Likewise, intravenous administration of 
encephalitogenic peptides coupled to splenocytes induced a form of highly 
epitope-specific non-responsiveness (Tan, Kennedy, & Miller, 1992). 
Furthermore, the specific inhibition of EAE and in vitro lymphocyte 
proliferation achieved by intraperitoneal injection of Acl-9 and the 4A and 4Y 
analogues closely resembles the results obtained from peptide inhalation 
experiments (George Liu, submitted for publication). Taken together, these 
findings can all be accounted for if the induced nonresponsiveness were a direct 
consequence of interactions between T cells and peptide-MHC complexes under 
conditions that fail to provide certain additional secondary signals required to 
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elicit an immune response (Schwartz, 1992). I , 
Recent evidence suggests that immune responses to soluble proteins are also 
downregulated locally in the lung and upper airways. Dendritic cells (DC) from 1 , 
airway epithelium and lung parenchyma were found to be functionally 
impaired in their ability to activate T cells. Alveolar macrophages appeared to 
mediate the inhibitory effect on adjacent DC both in vitro and in vivo (Holt et al, 
1993). It is therefore conceivable that, in our model, inhaled peptide was 
presented by functionally impaired DC and/ or alveolar macrophages, a mode of 
antigen presentation which might render potentially encephalitogenic T cells 
refractory to subsequent antigenic stimuli. 
5.3.2 iii Inhalation of whole antigen and the implication for suppression 
The results from our studies in the H-2u mouse model suggest that high 
avidity TCR-MHC-peptide interactions are favourable to induce 
nonresponsiveness by peptide inhalation. Since inhalation of a single MHC class 
II-restricted peptide is sufficient, it is unlikely that cos+ T suppressor cells are 
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involved in this model. This contrasts with a rat model of tolerance induction 
with aerosolized whole OVA. Here, tolerance could be adoptively transferred 
with class I-restricted CDS+ T cells. The induction of these suppressor cells, 
however, was preceded by a first phase of a class II-dependent and CD4+ T cell 
mediated TR2 type response (McMenamin & Holt, 1993). Although the models 
of inhalation tolerance in this report and our own studies are quite different, it is 
possible that inhalation of whole myelin antigens might enable additional, MHC 
class I-restricted and CDS+ T cell- mediated regulation beyond the inhibitory 
effects achieved with the dominant epitope of MBP alone. 
Recently, inhalation tolerance has also been studied in the Lewis rat model of 
EAU (Dick et al, 1993). The observations reported by Dick et al. are interesting to 
compare with our experiments in as much as they also adopted direct intranasal 
inoculation of antigen into the nostrils under light ether anaesthesia rather than 
continuous exposure to an aerosol. Under these conditions, inhalation of whole 
retinal antigen (RE) protected against EAU induced with either RE or S-antigen 
(S-ag). However, their data did not reveal bystander effects since inhalation of S-
ag only protected against EAU induced with S-ag but not with RE. This does not 
necessarily suggest distinct mechanisms of inhalation tolerance in the Lewis rat 
model of EAU and the H-zu mouse model of EAE. Rather, dominance and 
subdominance of antigenic epitopes might be less pronounced in EAU than in 
our model of EAE. Consequently, as suggested by our in vitro proliferation data 
after priming with peptides (figures 5.11 and 5.13) bystander effects may not 
significantly influence an immune response where epitopes are .co-dominant. 
It is therefore desirable to exte114l our studies on inhalation tolerance to whole 
myelin antigens. These might initiate further - possibly class I-restricted-
regulatory pathways to induce more potent tolerance than achievable by 
peptide alone under some circumstances, especially with co-dominant responses 
to several autoantigenic epitopes. Furthermore, inhalation of whole antigen will 
be the only option to modulate immune responses for which the (dominant) 
class II-restricted epitopes have not been identified. 
5.3.2. iv Effect on T cells 
The previous sections emphasized the central role of the trimolecular 
complex of MHC-peptide-TCR in the induction of inhalation tolerance in our 
model. Further studies will now have to address the molecular basis underlying 
this phenomenon of nonresponsiveness. Although this remains largely 
speculative at present, other models of peripheral tolerance have provided some 
1-
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insight into peripheral T cell regulation which might also contribute to our 
understanding of immune manipulation by peptide inhalation. 
The inhibition of EAE in vivo and proliferation and IFNy production in vitro 
after peptide inhalation reflect the downregulation of THl type immune 
responses. As discussed in detail in chapter one, several previously reported 
findings could account for this phenomenon. Antigen presentation in the 
absence of co-stimulatory signals may selectively affect THl- mediated 
responses while TH2 cell functions may be independent of such co-stimulation. 
In the absence of further regulatory mechanisms, antigen presentation that 
favours T cell anergy over activation can be expected to result in a strictly 
epitope-specific mode of peripheral tolerance. The data presented in figures 5.12 
and 5.13 support this mechanism of nonresponsiveness. Here, inhalation of one 
peptide only reduced the proliferative response to the same peptide even when 
another peptide was included in the same adjuvant for priming. 
The interlinked biochemical pathways that convert the message of TCR 
ligation into intracellular signalling cascades have been outlined in chapter one. 
Considering the delicate balance of these finely tuned inter-related signalling 
pathways, it is conceivable that perturbation of this intracellular communication 
network alone may be sufficient to account for differential outcomes of TCR 
ligation. For instance, moderate degrees of TCR ligation may allow for activation 
signals to prevail and enable the expression of IL2 concentrations which are 
appropriate for T cell activation and proliferation. In this situation, negative 
regulatory mechanisms will ensure that IL2 does not reach toxic levels which 
would inhibit further T cell function. In contrast, persistent antigenic stimulation 
may overcome these control functions. Furthermore, the modulatory potential of 
second messenger pathways involving the metabolism of IP3 and cAMP and the 
replenishment of Ca2+ stores may be exhausted under persistent and strong 
TCR-mediated stimulation (Gajewsky et al, 1994). These events may form the 
molecular basis of some phenomena of specific T cell nonresponsiveness, 
following super-optimal avidity of the MHC-peptide-TCR complex achieved by 
high doses of antigen and/or with high affinity ligands (as suggested by data 
presented in this chapter). The time factor may also constitute another 
significant parameter: Different time intervals' between a first antigenic 
encounter and subsequent TCR re-engagement may lead to either further 
activation or nonresponsiveness depending on the physiological "history" of the 
T cell. 
Obviously, for Acl-9 and its higher affinity analogues administered by 
inhalation, the amount of lOOµg given one week prior to an antigenic challenge 
was appropriate to induce nonresponsiveness. Furthermore, if the hypothesis 
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discussed earlier were true, namely that dominant or at least sufficiently strong 
T cell responses at the time of priming are required for the manifestation of 
inhalation tolerance, this would also emphasize the significance of efficient TCR 
re-engagement. However, since these ideas focus on the MHC-peptide-TCR 
complex linked to intracellular signalling events as one major factor of 
inhalation-induced nonresponsiveness, we may expect other ligands that form 
MHC-peptide-TCR complexes of different avidities to require different doses 
and/ or timing for the induction of nonresponsiveness by inhalation. Preliminary 
experiments in other models suggest that the nature of this trimolecular complex 
might indeed be more important than putative universal immunosuppressive 
conditions for antigens applied via the mucosa of the respiratory tract. For 
instance, the same conditions of peptide inhalation that induce 
nonresponsiveness in the H-2u mouse model of EAE did not modify the in vitro 
proliferative responses to OVA 323-339 or OVA after inhalation of OVA 323-339 
(not shown). Preliminary studies in an H-2s mouse model of EAE suggest that 
tolerogenic doses of inhaled peptides have to be defined for each model and 
each peptide (David Wraith, unpublished observations). 
Thus, peptide inhalation does not appear to lead to tolerance induction by 
default, and further insight into the rules that govern the fate of specific T 
lymphocytes when peptide antigens are administered via the mucosa of the 
respiratory tract will be crucial. Further studies are now planned to investigate 
the underlying biochemical events such as Ca2+ fluxes, and IP3 and cAMP 
levels. 
The bystander effect on the response to 35-47 after priming with SCH and 
inhalation of Acl-9 can be sufficiently explained by the abrogation of bystander 
help otherwise provided by the response to the dominant epitope. However, 
bystander suppression cannot be excluded. Any binding of Acl-9 that is 
detectable by FACS analysis is inhibitable by anti I-Au antibodies (David 
Wraith, unpublished observation). It is therefore unlikely that this peptide can 
induce MHCclass I-restricted cos+ T suppressor cells. However, CD4+ T cells 
may also actively downregulate the function of other T cells. In particular, TH2 
type cells can be regarded as suppressor cells for THI-mediated responses. Their 
action based on antagonistic lymphokines might also allow for bystander effects 
in a fashion similar to TGF-B secreted by cos+ T cells in oral tolerance. As 
discussed in chapter one, there is evidence to suggest that antigen presentation 
by B cells may not only induce tolerance in naive T cells but also preferentially 
induce TH2 cells. In the Lewis rat model, EAE was suppressed when an 
encephalitogenic peptide was linked to anti IgD antibodies and thereby targeted 
to B cells for antigen presentation (Day et al, 1992). A relevant question to ask is 
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therefore whether Acl-9 constitutes a sufficient epitope to be specifically taken 
up by B cells via membrane bound immunoglobulin. If this were the case then 
we should be able to raise antibodies against Acl-9 after priming with this 
peptide alone. However, after priming with Acl-9, only very few mice 
developed antibody responses to MBP or the longer peptide Acl-20. In contrast, 
priming with Acl-20 considerably increased the number of animals capable of 
mounting antibody responses to MBP or Acl-20 (George Liu, unpublished data). 
A recently published report on a mouse model of allergic immune responses to 
the group I allergen Der pl of the house dust mite showed that intranasal 
administration of the dominant CD4+ T cell epitope pl 111-139 prior to priming 
with the whole antigen Der pl lead to profoundly diminished in vitro IL-2 
production in response to both the dominant as well as other epitopes of Der pl. 
Although the question of bystander help was not addressed the authors argue in 
favour of classical suppression, since lymphocytes from mice treated by peptide 
inhalation were able to suppress in vitro antibody production by spleen cells 
from Der pl- primed mice (Hoyne et al, 1993). It is therefore tempting to 
speculate that this peptide pl 111-139 consisting of 18 residues was sufficiently 
long to serve as a B cell epitope thereby possibly enabling the induction of TH2 
-mediated suppression. Interestingly, however, this report also suggests a 
significant role for high avidity interactions of TCR-MHC-peptide interactions. 
While a single intranasal dose of the dominant epitopes was sufficient to inhibit 
in vitro T cell responses, at least three doses of a peptide containing a minor 
epitope were required to induce immune inhibition by inhalation. 
Taken together, these finding suggest that high avidity ligation of the 
trimolecular complex under tolerogenic conditions (as provided by peptide 
inhalation) is central to the phenomenon of specific nonresponsiveness induced 
by intranasal administration of peptide. Although this implies an epitope-
specific mode of inhibition, it is possible that additional suppressor mechanisms 
may be inducable with appropriate peptides, for instance if the peptide can 
serve as a B ·cell epitope. A direct comparison of Acl-9 and Acl-20 given by 
inhalation might provide further insight into possible B cell-mediated regulation 
in this model. However, even if Acl-9 cannot efficiently bind to membrane 
bound immunoglobulin, this is not sufficient to disprove bystander regulation of 
the response to 35-47. More studies are needed to rigorously distinguish 
between the lack of bystander help and the presence of bystander suppression. 
As mentioned earlier, disrupting expression or recognition of Acl-9 within MBP 
might shed more light on this issue. 
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5.3.2. v Can peptide inhalation affect the function of primed lymphocytes? 
Without detailed knowledge of the mechanisms that are initiated after 
peptide inhalation, we will not be able to anticipate the biological consequences 
of intranasal inoculation of antigen under varying experimental conditions. We 
do know, however, that the inhibition of immune responses after peptide 
inhalation is not necessarily an all-or-none event and does not depend on the 
complete abrogation of T cell priming. In several experiments (e.g. figure 5.1 and 
figure 5.5 groups 1 and 2) the severity of EAE was markedly reduced while the 
incidence of disease was hardly affected. On a cellular level, these results may 
reflect successful or only moderately impaired priming and subsequent 
inhibition of effector functions rather than priming itself. Taking this issue 
further, we might then ask whether peptide inhalation could also inhibit effector 
functions after the induction of EAE. Apart from additional information about T 
cell regulation, this question is also of paramount importance for peptide 
inhalation as a potential therapeutic approach to various autoimmune and 
allergic conditions. Preliminary studies that address this point are presented in 
the following chapter. 
5.4 SUMMARY AND CONCLUSION 
The data presented in this chapter show that a single lOOµg dose of Acl-9 or 
Acl-11 of MBP and its higher affinity analogues 4A and 4Y profoundly inhibit 
EAE when administered by inhalation one week prior to disease induction. The 
positive correlation between the degree of protection from EAE and the affinity 
of peptides for the H-2u molecule suggest that direct (CDs+ T-independent) 
interactions between APC and encephalitogenic T cells play a significant role for 
the intranasal route of tolerance induction. High avidity ligation of TCR-MHC-
peptide complexes are possibly also important upon an antigenic challenge after 
peptide inhalation. This may explain the preliminary evidence that inhaled MBP 
35-47 peptide failed to inhibit the weak in vitro response to this subdominant 
epitope after priming with SCH, while priming with 35-47 of MBP elicited 
strong specific in vitro responses which were inhibitable by prior inhalation of 
35-47. 
The finding that inhalation of a single peptide Acl-9 or its higher affinity 
analogues protected against EAE induced with SCH may be · explained by the 
large degree of dominance of Acl-9 over other epitopes. Therefore, without the 
need for suppressor mechanisms, direct specific downregulation of the 
dominant response may be sufficient to inhibit autoimmune responses to the 
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whole antigen. However, inhibition of in vitro lymphocyte responses to 35-47 
after 4A inhalation and priming with SCH suggested bystander effects (not 
shown). Since peptide inhalation prior to co-priming with a mixture of peptides 
revealed a strictly epitope-specific mode of inhibition, the bystander effect on the 
subdominant epitope after priming with SCH can be accounted for by a lack of 
bystander help that might otherwise .be provided by the dominant immune 
response . However, bystander regulation within a tolerogenic 
microenvironment cannot be excluded. 
Further studies are planned to investigate the route of peptide upon 
inhalation and the relevant location and APC for tolerance induction. A 
transgenic H-2u mouse model of EAE will enable us to investigate the fate of 
encephalitogenic T cells after the inhalation of peptide or whole MBP and to 
facilitate transfer studies with potential regulator cells. On a cellular level, 
studies on T cell signalling may reveal physiological changes as a consequence 
of antigen encounter after inhalation. 
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Figure 5.1 Inhalation Of Acl-11 
Before Peptide-Induced EAE 
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GROUP INCIDENCE MEDIAN DAY MEAN MAXIMAL 
OF DISEASE OF ONSET GRADE EAEa 
PBS 9/9 14 4.1 ± 1.4 
Ac1-11 [4K] 6/8 16 1.7±1.7 
a P< 0.01 
Figure 5.1 Pl/J mice inhaled 100µg Acl-11 in a single 25µ1 droplet 
(closed circles) or 25µ1 PBS (open circles) under light ether anaesthesia. 
Seven days later, EAE was induced with SOµg Acl-11/CFA. 
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Figure 5.2 Inhalation Of Acl-11 And Ac1-11[4A] 
Before Peptide-Induced EAE 
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Figure 5.2 PL/J mice were treated with a single dose of lOOµg Acl-
11[4K] (closed circles), Acl-11[4A] (triangles) in 25 µl PBS or PBS 
alone (open circles) by inhalation. After one week, EAE was induced 
with 50 µg Acl-11[4K]/CFA. 
Figure 5.3 Effect of peptide - I-Au affinity on 
protection from EAE by peptide inhalation 
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GROUP INCIDENCE MEDIAN DAY MEAN MAXIMAL 
OF DISEASEa OF ONSET GRADE EAE 
1) PBS 9/10 13 1.2 ± 0.8 
2)Ac1-11[4K] 4/10 >time of experiment 0.5 ± 0.7* 
3) Ac1-11 [4A] 2/10 >time of experiment 0.2 ± 0.4* 
4) Ac1-11 [4Y] 0/10 
a groups 1 and 2, P =0.029 
groups 1 and 3, p = 0.0027 
groups 1 and 4, p = 0.00006 
Figure 5.3 PL/J mice received a single intranasal dose of either lOOµg 
Ac1-11[4K] (closed circles), Ac1-11[4A] (triangles), Ac1-11[4Y] (squares) 
or 25µ1 PBS alone (open circles) one week before EAE was induced with 
50µg Ac1-11[4K]/CFA. 
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Figure 5.3 Effect of peptide - I-Au affinity on 
protection from EAE by peptide inhalation 
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GROUP INCIDENCE MEDIAN DAY MEAN MAXIMAL 
OF DISEASEa OF ONSET GRADE EAE 
1) PBS 9/10 13 1.2 ± 0.8 
2) Ac1-11 [4K] 4/10 >time of experiment 0.5 ± 0.7* 
3) Ac1-11 [4A] 2/10 >time of experiment 0.2 ± 0.4* 
4) Ac1-11 [4Y] 0/10 
a groups 1 and 2, P =0.029 
groups 1 and 3, p = 0.0027 
groups 1 and 4, p = 0.00006 
Figure 5.3 PL/J mice received a single intranasal dose of either lOOµg 
Acl-11[4K] (closed circles), Acl-11[4A] (triangles), Acl-11[4Y] (squares) 
or 25µ1 PBS alone (open circles) one week before EAE was induced with 
SOµg Acl-11[4K]/CFA. 
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Figure 5.4 Peptide Inhalation Before EAE Induced 
With Whole SCH In (PL/JxB10.PL) Fl Mice 
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Figure 5.4 Mice were treated with lOOµg Ac1-11[4A] (closed circles) or 25µ1 
PBS (open circles) by inhalation; Seven days later disease was induced with 
1mg SCH/CFA. 
Figure 5.5 Effect Of Peptide Inhalation On 
EAE Induced With SCH In (PL/JxB10.PL)F1 
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GROUP INCIDENCE MEDIAN DAY MEAN MAXIMAL 
OF DISEASEa OF ONSET GRADE EAEb 
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Figure 5.5 Mice were given one intranasal dose of lOOµg Acl-9[4K] 
(closed circles), Acl-11[4A] (triangles) or 25µ1 PBS only (open circles). 
One week later, EAE was induced with 1mg SCH/CFA. 
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Figure 5.6 Inhalation Of Acl-11 And 
Its Higher Affinity Analogues Prior To 
SCH-Induced EAE In (PL/JxB10.PL)F1 
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Figure 5.6 Mice were given one intranasal dose of lOOµg Ac1-11[4K] 
(closed circles), Acl-11[4A] (triangles), Ac1-11[4Y] (squares), or 25µ1 
PBS only (open circles). One week later, EAE was induced with 1mg 
SCH/CFA. 
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Figure 5.7 Inhalation Of Acl-11 And Its 
Higher Affinity Analogues Prior To 
SCH-Induced EAE In BlO.PL Mice 
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Figure 5.7 Mice inhaled lOOµg of either peptide Ac1-11[4K], Ac1-11[4A], 
Ac1-11[4Y] or 25µ1 PBS one week before EAE was induced with 1mg 
SCH/CFA. 
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Figure 5.8 Inhalation Of Acl-11 And Its 
Higher Affinity Analogues Prior To 
SCH-Induced EAE In PL/J mice 
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a groups 1 and 2, p < 0.01 
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Figure 5.8 Mice inhaled lOOµg of either peptide Ac1-11[4K], Ac1-
11[4A], Ac1-11[4Y] or 25µ1 PBS one week before EAE was induced with 
lmgSCH/CFA. 
Figure 5.9 Effect Of Ac1-11[4Y] Inhalation On In 
Vitro Proliferation In Response To Acl-11 And 35-47 
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Figure 5.9 PL/J mice inhaled 100 µg of Acl-11[4Y] (closed symbols) or 25 µl PBS 
(open symbols). One week later they were immunized with either 50 µg of Acl-
11/CFA (circles) or 35-47 /CFA (triangles). After 10 days, lymphocytes were 
restimulated in vitro with Acl-11 (a) or 35-47 of MBP (b). Each symbol represents 
the arithmetic mean of triplicate samples, standard deviations were less than 20% 
of the mean. Medium and PPD controls are arithmetic means and standard 
deviations of triplicate cultures in cpm. 
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Figure 5.10 Effect Of 35-47 Inhalation On In 
Vitro Proliferative Responses To Acl-11 And 35-47 
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Figure 5.10 PL/J mice inhaled 100 µg of 35-47( closed symbols) or 25 µl PBS 
(open symbols). One week later they were immunized with either 50 µg of Acl-
11/CFA (circles) or 35-47 /CFA (triangles). After 10 days, lymphocytes were 
restimulated in vitro with Acl-11 (a) or 35-47 of MBP(b). Each symbol 
represents the arithmetic mean of triplicate samples, standard deviations were 
less than 20% of the mean. Controls are cpm arithmetic means + SD of 
triplicates. 
Figure 5.11 PL/J mice were immunized with 50 µg Acl-11/CFA (circles), 50 
µg 35-47 /CFA (triangles) or 50 µg Acl-11 plus 50 µg 35-47 of MBP in CFA 
j• included in the same adjuvant. (squares). Ten days later, lymphocytes from 
draining lymph nodes were restimulated in vitro with Acl-11 (a) or 35-47 (b). 
Each symbol represents the arithmetic mean of triplicate samples, standard 
deviations were less than 20% of the mean. Medium and PPD controls are 
arithmetic means and standard deviations of triplicate cultures in cpm. 
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Figure 5.11 Comparing The In Vitro Proliferative 
Response Of Lymphocytes After Priming With 
Acl-11, 35-47, Or Co-Immunization With Both Peptides 
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Figure 5.12 Effect Of Inhaling Either Ac1-9[4Y] Or 
MBP 35-47 On The Proliferative Response To Acl-9 
Or 35-47 After Co-Immunization With Both Peptides 
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Figure 5.12 PL/J mice inhaled 100 µg of Acl-9[4Y] (closed circles) or 35-47 (closed 
triangles) or 25 µl PBS alone (open circles). One week later all were primed with 
both 50 µg Acl-9 and 50 µg 35-47 in CFA included in the same adjuvant. 
Lymphocyte proliferation was assayed 10 days later in vitro against Acl-9 (a) and 
35-47 (b). Each symbol represents the arithmetic mean of triplicate samples, 
standard deviations were less than 20% of the mean. Medium and PPD controls 
are arithmetic means and standard deviations of triplicate cultures in cpm. 
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Figure 5.13 PL/J mice inhaled 100 µg of Acl-9[4Y] (closed symbols) or 25µ1 PBS 
(open symbols). Seven days later, mice were primed with either 50µg Acl-
9[4K]/CFA (circles), 50µg MBP 35-47 /CFA (triangles), or with a mixture 
containing 50µg of each peptide in CFA (squares). Lymphocyte proliferation was 
assayed 10 days later in vitro against Acl-9 (a) and MBP 35-47 (b). Symbols 
represent the arithmetic mean of triplicate samples, standard deviations were 
less than 20% of the mean. Control values (means + SD of triplicates) for 
medium and PPD are included in the legend. 
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Figure 5.13 Effect Of Ac1-9[4Y] Inhalation On 
The Proliferative Response To Acl-9 Or 35-47 After 
Immunizing With Both Peptides Or Either Peptide Alone 
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CHAPTER6 
The Effect Of Peptide Inhalation On 
The Response Of Primed 
Encephalitogenic T Cells 
6.1 INTRODUCTION 
In the previous chapter we argued that the tolerogenic effect of the dominant 
MBP peptide Acl-9 and its higher affinity analogues given by inhalation was 
largely governed by direct ligation of the T cell receptor under conditions that 
favoured nonresponsiveness over activation. This presumably involved 
modulation of T cell signalling in a yet undefined manner which might interfere 
with subsequent priming, thereby inhibiting the encephalitogenic potential of T 
cells. In this chapter we examine the consequences of peptide inhalation when T 
lymphocytes have already encountered myelin antigen after subcutaneous 
priming in complete Freund's adjuvant. If T cells encounter further antigenic 
peptide (administered by inhalation) during an already ongoing immune 
response, three scenarios are conceivable: 
1. A strong antigenic challenge with CFA irreversibly biases the immune 
response towards activation. If T cells are already stimulated to their maximum 
capacity, further antigen encountered at a later time point will not influence T 
cell functions any longer. At submaximal levels of T cell activation, inhaled 
peptide can only further stimulate but never inhibit an already ongoing immune 
response. In this situation we would expect mice treated with peptide by 
inhalation after priming either not to differ from control groups or to develop 
exacerbated disease. 
2. Peptide inhalation under conditions shown to be tolerogenic before 
priming will also downregulate T cell activation after priming. This concept 
proposes that subcutaneous challenge of antigen in adjuvant and antigen 
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administration by inhalation initiate qualitatively distinct biochemical events 
within lymphocytes and perhaps also in APC. These mechanisms triggered by 
two modes of antigenic encounter will compete with each other and, depending 
on their relative strength, their effects may either cancel one another or one or 
the other may prevail. If this were true, then peptide inhalation after priming 
would be expected to have either no effect or to induce varying degrees of 
inhibition. We would not, however, expect exacerbation of EAE since an 
appropriate dose of peptide given by inhalation would always be tolerogenic by 
nature. 
3. On a cellular level, the biochemical events following TCR-peptide-MHC 
ligation with inhaled peptide or peptide included in adjuvant do not 
substantially differ in quality. Rather, different quantities (thresholds) of the 
same or similar and interrelated intracellular events may determine qualitatively 
different T cell responses. This concept predicts that, depending on the timing 
between priming and inhalation and the resulting physiological state of 
immunocompetent cell, peptide inhalation after priming may initiate the whole 
spectrum of conceivable immunological effects: It may either exacerbate EAE, it 
may have no obvious consequences, or it may confer protection from disease. 
All experiments presented in this chapter examine the effect of peptide 
inhalation after the induction of EAE with SCH. We aimed to administer a single 
intranasal dose of lOOµg Acl-9 or the 4A and 4Y analogues at a time point when 
T cells were already primed, yet before or around the onset of paralysis. After 
the onset of paralysis, further pathological signs of EAE may to some extent 
reflect T cell-independent inflammatory processes which might be difficult to 
manipulate any further in an antigen-specific manner. The onset of disease can 
vary among experiments. However, moderate body weight loss often precedes 
paralysis, presumably due to inflammatory mediators such as TNFa released by 
activated encephalitogenic T cells. The body weight was therefore monitored to 
anticipate the likely onset of EAE. 
6.2 RESULTS 
The results obtained from the first experiment (figure 6.1) indicate that 
inhalation of the 4A peptide 8 days after disease induction profoundly inhibited 
EAE. The plots of mean grade EAE and mean body weight are almost mirror 
images suggesting that weight loss and paralysis reflected disease severity in a 
similar fashion. The arrows marking the time points of peptide inhalation in the 
plots show that mice of both groups had lost some but very little weight 
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between days 3 and 8 after EAE induction. Nevertheless, one animal in the 
group that was to be treated with peptide already had a flaccid tail, so that 
peptide treatment was no longer postponed. Immediately after day 8 i.e. the day 
of peptide inhalation, the plots reveal rapid exacerbation of disease reflected 
both by rapid weight loss and grade of EAE in the control group. In contrast, 
animals that had received the 4A peptide by inhalation were substantially 
protected from further weight loss and paralysis. In place of the sharp peak of 
the first phase of disease in the control group, there were two smaller peaks in 
the 4A-treated group indicating both milder symptoms of EAE and an overall 
delay of disease onset (p< 0.05). Although the incidence of disease shows that 
most animals were not completely protected from EAE, the mean maximal grade 
was significantly lower in the peptide-treated group (p< 0.01). Both plots of 
figure 6.1 reveal that the protective effect of peptide inhalation was most 
pronounced during the first phase of EAE between days ten and twenty. 
Our working hypothesis for subsequent experiments proposed that the 
earlier the time point chosen for peptide inhalation after EAE induction, the 
more readily will animals be protected from disease. To test this idea, four 
groups of mice received an intranasal dose of the 4A peptide or PBS either on 
day 8 or day 10 after EAE induction (figure 6.2). Appropriate timing for the 
earlier of the two time points was hampered by the finding that some mice were 
obviously still growing and gaining rather than lo sing weight (figure 6.2b). 
Nevertheless, day 8 proved to be the turning point followed by a steep rise in 
mean grade EAE (plots a and c) and rapid weight loss (plots band d).In this 
experiment, inhalation of 4A on day 8 did not have such a pronounced effect as 
in the previous experiment (figure 6.1). However, even though the mean body 
weight was only marginally higher, mice treated with 4A displayed significantly 
milder grades of EAE than control animals (p=0.05). This was most obvious for 
the first phase of disease between days 10-20 (plot a) where 4A-treated mice had 
EAE of one grade lower on average compared with the control group. In 
contrast, inhalation of the 4A peptide two days later on day 10 no longer 
appeared to inhibit disease. Plot c of figure 6.2 shows an almost identical rise 
and climax of EAE around days 13-15 for both groups, although later on, 4A-
treated mice seemed to have recovered more readily than control animals. 
We then examined whether a protective "therapeutic" effect could also be 
achieved with the 4K and the 4Y peptides and -if yes- whether protection would 
be improved with the higher affinity analogue. Therefore, both peptides were 
included in the following experiment in which mice received an intranasal dose 
of either peptide 4K or 4Y or PBS eight days after disease induction (figure 6.3). 
The data clearly reveal that neither peptide inhibited EAE. Two explanations 
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could account for this result. Firstly, the protective properties of peptide inhaled 
after priming might be peculiar to the nonencephalitogenic 4A analogue. 
Secondly, the plots of figure 6.3 show that compared with the two previous 
experiments (figures 6.1 and 6.2), the average body weight had dropped more 
sharply by day 8, and while none of the mice displayed signs of paralysis on day 
7, several animals in all groups had at least grade one EAE on day 8. It is 
therefore conceivable that day 8 in this experiment resembled the situation 
shown for day 10 in figure 6.2 where EAE was apparently already too advanced 
for inhaled peptide to confer protection. 
Although the data presented in the table of figure 6.3 show virtually identical 
values for all groups, the differences in disease patterns among groups deserve 
further consideration. The course of EAE in the 4K-treated group seemed to 
closely follow the course of disease in the control group with a relatively mild 
first phase around days 10-14 and a second phase between days 25-30 with 
higher mean grades of EAE. In this case, the difference between the two phases 
was not reflected by the mean body weight for which the minimum coincided 
with the first phase of EAE and -after partial recovery- fell less sharply during 
the second phase. In contrast, mice that had inhaled the 4Y peptide got more 
severe EAE during the first phase compared with 4K-treated and control 
animals, but this was foLLowed by faster recovery as shown both for the mean 
grade EAE and mean body weight. Although there were also some relapses 
between days 25-30 this was far below the degree of EAE observed for the other 
two groups during the same period and was not accompanied by weight loss. 
These findings implied that the 4Y peptide could at least manipulate the 
course of disease. The question then arose as to whether inhalation of 4Y after 
EAE induction would not only ameliorate relapses (possibly at the expense of 
more severe EAE at an earlier stage) but could also interfere with the first phase 
of EAE provided it was administered early enough. The design of the 
experiment to address this question (figure 6.4) followed the same principle as 
shown for figure 6.2. We wanted to ensure that the earlier of the two time points 
lacked any signs of EAE either weight loss or paralysis. For figure 6.2 this was 
true for day 8. However, in the subsequent experiment (figure 6.3) disease was 
already more advanced by day 8. We therefore chose day 6 after EAE induction 
as the earlier of two time points for 4Y inhalation. Although not shown in the 
plots (figure 6.4 band d), the body weight was also monHored daily between 
days 3 and 6. During that period there was no indication of weight loss. The 
plots of figure 6.4 show that the two time points, days 6 and 8 appeared to be 
appropriate for the purpose of our question: day 6 as an early post priming-pre 
EAE stage and day 8 already indicating a steep fall in body weight and 
I 
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I' 
110 
subsequent rapid onset of disease. The plots of figure 6.4 reveal that the effect of 
4Y inhalation as a function of time after the induction of EAE was somewhat 
contrary to our working hypothesis. 4Y administered on day 8 was more 
protective than on day 6, the opposite of what we would have expected. For the 
first phase of EAE between days 10 and 15, 4Y inhaled on day 6 appeared to 
evoke more vigorous disease compared to the control group (figure 6.4 a and b). 
The almost complete recovery in both groups was succeeded by a second peak 
of virtually the same shape as the first peak in the control group while this 
second phase of EAE between days 20 and 30 was substantially dampened in the 
4Y-treated group (figure 6.4a). In this experiment there was also a third wave of 
disease between days 38 and 50 among controls. In contrast, none of the 4Y-
treated mice displayed further signs of paralysis at this late stage. In summary, 
the overall effect of 4Y inhalation on day 6 was a somewhat aggravated first 
phase of disease compared to controls after which 4Y-treated mice were largely 
protected from the pronounced relapses characteristic of the control group in 
this experiment (figure 6.4a and b). 
The development of disease after the inhalation of 4Y on day 8 disclosed a 
very different picture (figure 6.4c and d). Between days 6 and 8, the body weight 
plots for both the controls and the group that was to be treated with 4Y were 
virtually identical. On average, mice lost almost two grams, i.e. about ten 
percent of their body weight between days 6 and 8. While the average weight 
dropped continuously in the control group reaching its minimum on day 16, the 
4Y-treated group showed only marginal further weight loss between days 8 and 
9 followed by a short period of rapid recovery until on day 11, the original level 
of weight was reached again. Thereafter, a shallow trough appeared to parallel 
· the weight loss in the control group, albeit on a much smaller scale. The 
protective effect of 4Y inhalation on day 8 was also clearly revealed by 
substantially diminished disease severity. The values in the table indicate that 
although most mice were not completely protected from EAE, the overall 
maximal grcide of EAE was significantly lower for 4Y-treated animals (p<0.02). 
Furthermore, figure 6.4c illustrates that in contrast to controls, there were hardly 
any relapses between days 35 and 50. In addition, 4Y-treated mice tended to 
develop EAE more slowly than controls. Although the values in the table do not 
state a statistically significant delay, the slope of mean grade EAE in figure 6.4c 
is steeper for controls than for the 4Y group, reaching its maximum on day 16 for 
controls and on day 23 for the 4Y-treated group. Thus, in contrast to 4Y 
inhalation on day 6, treatment with this peptide by inhalation two days later on 
day 8 inhibited EAE during the whole course of this experiment. 
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We wished to confirm the observation that the 4Y peptide administered by 
inhalation at an early time point after disease induction tended to exacerbate the 
first phase of EAE while protecting against relapses. Unlike with 4Y, figure 6.2 
suggests that the idea of better protection at an earlier time point seems to hold 
true for the 4A peptide. Perhaps if 4A were inhaled even before day 8 we would 
observe still more pronounced inhibition of EAE. Therefore, in the following 
experiment (figure 6.5), the effect of all three peptides 4K, 4A, and 4Y given by 
inhalation on day 6 after EAE induction was compared. Both plots of figure 6.5 
show that the disease profile of the 4Y group differs most clearly from the 
controls and the two other peptide-treated groups. The first phase of EAE in the 
4Y-treated group is characterized by a steep, narrow peak revealing more rapid 
and -at its maximum- more severe EAE than any of the other groups. Again, as 
observed in previous experiments, mice that had inhaled 4Y appeared to be 
protected from relapses. These observations are also illustrated by the plot of 
mean body weight showing the sharpest fall in weight ensued by the highest 
weight gain until the end of the experiment. 
The effects of the other two peptides 4A and 4K were less clear. Inhalation of 
4A on day 6 certainly did not confer the degree of protection we might have 
predicted from previous data. In fact, the plots for the 4A and control groups are 
so similar that any emphasis on marginal differences would presumably be 
misleading. The 4K peptide, however, might have supported the development of 
EAE in this experiment. There was a tendency (although not significant) of 
higher mean maximal grades of EAE after 4K inhalation. The plot of mean grade 
EAE shows a slightly earlier onset in the 4K group then in all other groups. 
Furthermore, fewer 4K-treated mice recovered after the first phase of disease 
and more animals relapsed compared to all other groups. 
6.3 DISCUSSION 
Among the three proposed outcomes of peptide inhalation after the 
induction of EAE, no effect/further activation, no net effect/inhibition, or either 
no effect/inhibition/further activation, the data· presented in this chapter are 
only consistent with the third hypothesis. Sometimes, the course of EAE after 
peptide inhalation closely resembled disease in the control group, while in other 
experiments or with other peptides, inhalation clearly reduced disease severity 
or modified the course of EAE to a more pronounced first phase followed by an 
apparent resistance to relapses. Thus, even 6-10 days after a strong antigenic and 
inflammatory challenge such as with SCH in CFA, primed encephalitogenic T 
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cells were not irreversibly locked into a certain activation pathway but remained 
susceptible to modification by intranasally administered peptide. 
Having rejected the concept of a characteristic biochemical signalling 
pathway that induces T cell nonresponsiveness as a tolerogenic default 
mechanism after peptide inhalation, it is likely that the effect of inhaled peptide 
is largely determined by the physiological state of specific T cells. Furthermore, 
while lOOµg of peptide was suitable to downregulate a presumably small 
number of specific T cells before priming (chapter 5), after EAE induction, the 
same amount of intranasally administered peptide might not necessarily be 
sufficient to downregulate an expanding population of encephalitogenic T cells. 
Prior to an antigenic challenge in CFA, peptide inhalation consistently induced 
downregulation of in vivo and in vitro responses of Acl-9 specific T cells, as 
shown in chapter 5. After priming, the effects of inhaled peptide appeared to 
cover the whole spectrum of conceivable events, inhibition, no net effect, or 
exacerbation of EAE. In order to predict the effect of peptide inhalation after 
priming, it will therefore be essential to characterize the physiological state of T 
cells at various time points after priming. Without detailed knowledge of 
intracellular events and the surface expression of certain activation markers (e.g. 
characteristic isoforms of CD45), this remains largely speculative. Initially, we 
proposed that peptide inhalation at earlier time points would inhibit EAE more 
readily than at a later stage. This idea implies a linear increase in T cell activation 
(both with respect to absolute numbers, i.e. proliferation of precursors, and the 
activation state of individual T lymphocytes) after priming and, in parallel, a 
linear decrease in the susceptibility to tolerance induction. 
However, the data reveal a more complex picture than we would have 
expected according to this simple rule. In figure 6.1, inhalation of 4A 8 days after 
EAE induction profoundly inhibited the development of disease. The degree of 
protection was similar to what we had previously observed for 4A inhalation 
before the induction of EAE (figures 5.5 and 5.6). Yet, in another experiment in 
which mice received an intranasal dose of 4A two days earlier on day 6 (figure 
6.5) both the plot and the data in the table show virtually identical patterns of 
disease between 4A-treated and control groups. Although it is difficult to draw 
conclusions about timing between two separate · experiments, there was no 
indication of an unusually rapid onset of disease or weight loss in the 
experiment of figure 6.5. It is therefore unlikely that the lack of protection by 4A 
inhalation on day 6 in this experiments as opposed to day 8 in figure 6.1 can be 
explained by a higher degree of T cell activation at which 4A inhalation could no 
longer be protective. In a direct comparison of 4A inhalation on days 8 and 10, 
there was some indication for protection after 4A inhalation on day 8 (figure 
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6.2a) although the effect on weight loss was marginal (figure 6.2b). Two days 
later on day 10, the peak of disease between controls and 4A-treated animals 
were virtually identical. The significance of the more complete recovery of 4A-
treated mice was less clear since the overall weight gain was similar in both 
groups (figure 6.2d), although more mice remained with chronicle low grade 
EAE in the control group (figure 6.2c), Two interpretations of these findings are 
possible: the prediction of better protection at an earlier time point after EAE 
induction might have been true for this experiment. Alternatively, if the more 
rapid recovery of 4A-treated mice on day 10 were significant, then 4A inhalation 
on day 10 was too late to affect the peak of disease, but at later stages, it 
supported recovery from disease. On a cellular level, 4A might have accelerated 
the downregulation of activated T cells after the first phase of EAE. 
A direct comparison of the effect mediated by the highest and lowest affinity 
peptides 4K and 4Y administered 8 days after EAE induction provides further 
insight into possible modulation of T cell activity by inhaled peptide (figure 6.3). 
4Y inhalation caused a strikingly different pattern of disease, with a steep higher 
first peak of EAE followed by a very low grade relapse compared to both control 
and 4K-treated groups. This modification of the course of EAE by 4Y was 
confirmed in a direct comparison with 4K and 4A inhalation on day 6 (figure 6.5) 
and also when tested on its own against controls in another experiment shown 
in figure 6.4 a and b. This pattern of an exacerbated first phase after which 
animals were more protected from further relapses was characteristic after 
inhalation of 4Y and not observed with either 4K or 4A in. any experiment. 
Presumably, this phenomenon reflects an additive effect of 4Y to T cell priming 
after which encephalitogenic T cells were either no longer present or refractory 
to further stimulation. It is tempting to compare this finding with the 
phenomenon of anergy or deletion through activation discussed in chapter 1. 
Here, high doses of soluble antigens in the periphery induce cell death or T cell 
anergy, often preceded by a phase of activation. A recent study investigated the 
phenomenon _of high dose tolerance in a transgenic H-2u mouse model of EAE, 
with transgenic TCR specific for Acl-11 of MBP. High intravenous doses of MBP 
(8x400µg) or Acl-11 (8xl.4mg) caused deletion of encephalitogenic T cells and 
protected mice from disease. On a cellular level, this finding was explained by 
TCR reengagement after initial T cell activation and cell cycle progression at 
high levels of IL-2, conditions required to induce cell death in vitro ( Critchfield 
et al, 1994). Although the experimental conditions for our studies were different, 
inhalation of 4Y after EAE induction possibly met the conditions for this form of 
high zone tolerance. Priming with SCH in CFA represents a strong antigenic 
challenge that probably induces high levels of IL-2. Presumably, inhalation of 4Y 
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initially accelerated and supported T cell activation and IL-2 production even 
further as suggested by steeper and higher peaks of EAE compared to controls. 
This might have lead to cytotoxic lymphokine levels that subsequently either 
induced cell death or-T cell anergy. Although the amounts of peptide used to 
induce high zone tolerance in the report by Critchfield et al were about 100 times 
higher than the intranasal dose of peptide administered in our experiments, it is 
possible that the ability of 4Y to form stable complexes with I-Au was sufficient 
to reach the threshold of TCR-MHC-peptide engagement required for high zone 
tolerance. If this were true, then perhaps high zone tolerance reflects high 
avidity rather than just high dose tolerance. The finding that the same amount 
(lOOµg) of neither 4K or 4A given by inhalation induced the same effect is 
consistent with this idea (figures 6.3 and 6.5). In this case, higher intranasal doses 
of 4K and 4A might be able to compensate for the lack of affinity. 
However, plots c and d of figure 6.4 show that the effect of 4Y did not always 
follow the same pattern of early disease exacerbation and subsequent inhibition. 
Here, 4Y inhalation 8 days after EAE induction reduced the severity of disease 
over the whole course of the experiment. Possibly at this later stage (compared 
to day 6 in the same experiment) T cell activation had passed its maximum 
already so that TCR ligation with further antigen only caused anergy or deletion, 
but no longer further activation. This may also account for the high degree of 
protection achieved by 4A inhalation shown in figure 6.1. The ability of 4A to 
protect might either be due to a very early stage of T cell activation at which T 
cells were still susceptible to tolerance induction, or, alternatively, T cells might 
have passed a physiological stage of maximal cell cycling and IL-2 production 
after which they were again susceptible to downregulation. However, in this 
case we have to conclude that the loss of body weight did not faithfully reflect T 
cell activation simultaneously, but occurred with some delay after maximal 
activation. However, while this idea is consistent with the data of figures 6.1, 6.4 
and 6.5, it does not account for the results in figure 6.3 showing the 
characteristic pattern or enhanced disease/inhibition after inhalation at a time 
when the average body weight had already fallen dramatically. Clearly, without 
further kinetic studies, including a direct comparison of all three peptides as 
well as a biochemical analysis of T cell at different times after disease induction, 
all explanations will be largely speculative. However, the data permit one 
conclusion: there appeared to be at least two distinct stages at which peptides 
given by inhalation exerted different effects. At one stage (perhaps a stage of 
maximal activation) inhalation of 4Y lead to an enhanced first peak of disease 
followed by profound protection from further relapses (figures 6.3-6.5). Under 
these conditions, neither the 4A or the 4K-treated groups displayed a disease 
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pattern that differed substantially from controls (figures 6.3 and 6.5). At another 
stage, inhalation of 4A inhibited disease to some extent figures 6.1 and 6.2a), and 
inhalation of 4Y at this same or yet another stage of T cell priming conferred 
protection throughout the whole course of EAE (figure 6.4c). 
6.4 SUMMARY AND CONCLUSION 
Modulation of encephalitogenic T cells by peptide inhalation 6-10 days after 
EAE induction with SCH was possible but the effect appeared largely 
unpredictable. The positive correlation between peptide-I-Au affinity and the 
degree of protection from EAE as shown in chapter 5 for inhalation as a pre-
treatment did not apply to peptide inhalation after disease induction. Instead, 
different peptides seemed to modulate EAE in different ways: 4K had either no 
effect or exacerbated disease slightly. 4A had either no effect or inhibited EAE to 
varying degrees between different experiments. Treatment with 4Y induced a 
characteristic pattern of an exacerbated first phase of disease after which animals 
were refractory to further relapses. This phenomenon resembles the concept of 
anergy / deletion through activation described for several models of peripheral 
tolerance. In one . experiment, however, the effect of 4Y was different and 
reduced disease severity during the whole course of the experiment. These 
findings imply differential effects of intranasally administered peptide on 
different stages of T cell activation. It will now be necessary to analyze the effect 
of peptide inhalation on T cell physiology at different stages of activation. 
Additionally, different experimental conditions such as repeated rather than 
single doses of inhaled peptide might be required to override T cell activation in 
favour of tolerance induction. 
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Figure 6.1 (BlO.PL x PL/J) Fl mice were primed with 1 mg 
SCH/CFA for the induction of EAE. Eight days later, all were 
tresited with 100 µg Acl-11[4A] in PBS (closed circles) or 25 µl PBS 
alone (open circles) by inhalation. 
Figure 6.1 Inhalation of Ac1-11[4A] 
eight days after the induction of EAE 
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Figure 6.2 Inhalation of Ac1-11[4A] on days 
eight or ten after the induction of EAE 
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Figure 6. 3 (BlO.PL x PL/J) Fl mice were primed with 1 mg 
SCH /CFA for the induction of EAE. Eight days later, all 
,. received an intranasal 100 µg dose of either Acl-9[4K] (closed 
circles), Acl-9[4Y] (closed triangles), or 25 µl PBS alone (open 
circles). 
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Figure 6.3 Inhalation of Ac1-9[4K] or [4Y] 
eight days after the induction of EAE 
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Figure 6.4 (B10.PL x PL/J) Fl mice were primed with 1 mg SCH/CFA for 
the induction of EAE. Mice received an intranasal dose of 100 µg Ac1-9[4Y] 
(close
1
d circles) or 25 µl PBS (open circles) on day six (a, b) or day eight (c, d) 
after the induction of EAE. 
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Figure 6.4 Inhalation of Ac1-9[4Y] on day six 
or day eight after the induction of EAE 
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Figure 6.5 (BlO.PL x PL/J) Fl mice were primed with 1 mg SCH/CFA 
for the induction of EAE. Six days later, all were treated with 100 µg of 
either Acl-9[4K], Acl-9[4A], Acl-9[4Y] or 25 µl PBS by inhalation. 
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Figure 6.5 Comparing the effect of Ac1-9[4K], 
[4A], and [4Y] given by inhalation six days 
after the induction of EAE 
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CHAPTER 7 
Discussion 
7.1 ACTIVATION VERSUS TOLERANCE BY ANTIGEN 
ADMINISTRATION VIA MUCOSAL SURFACES 
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The intragastric and intranasal routes of antigen administration have been 
widely explored to achieve two opposite effects of antigen on the immune 
system: specific activation and tolerance. Both routes have been studied for the 
induction of anti-viral immune responses to develop suitable strategies for 
vaccination (Van Cott et al, 1993; Onorato et al, 1991), and a wide range of 
effector mechanisms, many of them IgA- and IgE-mediated humoral responses 
combat bacterial and parasite infections in the intestinal- and respiratory tract 
(Mazanec et al, 1993; Hagan, 1993). In contrast, as described in numerous 
previous reports and shown in this thesis, intragastric and intranasal 
administration of soluble antigens often induces a state of specific 
immunological nonresponsiveness. 
In order to develop appropriate immune responses to either potentially 
detrimental pathogens or innocuous agents, safe and unambiguous criteria are 
required to guide the immune system towards activation or tolerance. Similar to 
their effect on priming by subcutaneous administration, bacterial particles 
appear to favour the development of effector functions as opposed to tolerance 
after oral or intranasal antigen administration. Oral tolerance was more readily 
demonstrated with soluble proteins than with particulate bacterial antigens, 
probably due to an adjuvant effect of bacterial lipids (Challacombe & Tomasi, 
1980). However, feeding particulate antigens may also induce oral tolerance as 
shown for sheep red blood cells (Mattingly & Waksman, 1978), suggesting that 
the absence of bacterial components is perhaps more important than the 
solubility of an antigen. Curiously, however, bacterial LPS, commonly used as a 
nonspecific B cell activator, appeared to support the induction of oral tolerance 
11 
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in the Lewis rat model of EAE (Khoury et al, 1990). In this case, a later report 
suggested that the local adjuvant effects of LPS in GALT resulted in the 
activation of PGE2- producing regulator cells which synergized with TGF-~ 
secreting cos+ T cells to protect rats from EAE (Khoury, Hancock, & Weiner. 
1992). 
As mentioned earlier, alveolar macrophages (AM) create an 
immunosuppressive environment in the respiratory tract by means of their 
apparently inherent ability to inhibit T cell responses directly, and to 
functionally impair the ability of airway dendritic cells to activate T cells. 
However, under experimental conditions that mimic a challenge with inhaled 
microbial ( and thus potentially pathogenic) antigens, AMs loose their 
immunosuppressive capacity. In one study, AMs incubated with medium 
generated with LPS-stimulated whole lung, no longer inhibited in vitro 
lymphocyte proliferation. Therefore, in this situation, LPS inhibited rather than 
supported immunosuppression. This effect could be abrogated with antibodies 
to granulocyte/macrophage colony-stimulating factor (GM-CSF), mimicked 
with recombinant GM-CSF, and enhanced by TNFa (Bilyk and Holt, 1993). 
An adjuvant effect was also achieved when antigens were incorporated into 
synthetic lipid particles (lipophilic immune-stimulating complexes, ISCOMS). In 
these studies, oral administrations of antigens such as OVA which usually 
induce oral tolerance when given in a soluble form, provoked a wide range of 
local and systemic immune responses upon feeding in ISCOMS. Such lipid 
particles also functioned as adjuvants for intranasally applied antigens(reviewed 
in Mowat & Donachie, 1991). Bacterial toxins such as pertussis and cholera 
toxins also served as adjuvants for orally administered antigens and abrogated 
tolerance induction by antigen feeding or inhalation (reviewed in Holt & 
McMenamin, 1989; Pierre, Denis, & Bazin, 1992). Together, these reports suggest 
that generally, antigens administered by feeding or inhalation only induce 
tolerance if they are encountered in the absence of substances with adjuvant 
properties. LPS might represent an exception to this rules for models of oral 
tolerance in which LPS activates regulator cells that support the inhibitory effect 
of fed antigen. 
However, even in the absence of adjuvants, soluble antigens given by feeding 
or inhalation do not induce nonresponsiveness by default. As discussed before, 
the dose and timing constitute significant parameters for tolerance induction. In 
the OVA model of oral tolerance, doses between 1-25 mg suppressed 
subsequently induced systemic immune responses, while some smaller doses 
had either no effect or supported priming (Lamont, Mowat, & Parrot, 1989). In 
studies on oral tolerance in models of autoimmune diseases, there was either a 
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positive correlation between the amounts of fed antigen and tolerance 
(Thompson et al, 1993; Nussenblatt et al, 1990; Higgins & Weiner, 1988) or, by 
contrast, smaller doses were more effective than high oral doses (Thompson & 
Staines, 1985; Zhang et al, 1990). Generally, repeated feeding tended to induce 
tolerance more readily than a single dose (Ngan & Kind, 1978; Higgins & 
Weiner, 1988). 
Although a thorough analysis of these factors, dose and timing, was not 
central to this thesis, some of the data presented and other preliminary 
observations allow for some comments. In chapter 3, feeding 3 x 7 mg OVA 7, 5, 
and 3 days before priming (figure 3.9) reduced T cell proliferation to at least the 
same degree as a single 20 mg dose given 7 days before an antigenic challenge. 
Compared to some experiments (e.g. figures 3.4 and 3.6), 3 x 7 mg appeared to 
be more effective than 1 x 20 mg. However, in other experiments in which mice 
received a single 20 mg dose, the titration plots of lymphocytes from OVA-fed 
mice were similar to the data of figure 3.9 (figures 3.1 and 3.5) so that the benefit 
of repeated lower doses of OVA was presumably not significant. Other 
preliminary studies in the Balb/c model that addressed the dose requirement for 
orally administered OVA to affect T cell proliferation suggested that 3 x 1 mg 
OVA given 7, 5, and 3 days before priming also resulted in lower proliferative 
responses (not shown). In contrast, the data presented in chapter 4 reveal that, 
with the same doses and similar timing (3 x 1 mg on days -7, -5, -2), MBP did not 
induce oral tolerance in the H-2u mouse model as assessed by the failure to 
protect against EAE. In some experiments, oral administration of Acl-11 or MBP 
even tended to exacerbate disease at some stages (discussed in chapter 4). 
Fewer reports are available on dose-responses for intranasal administration 
of antigen. In the mouse model of immunity to the house dust mite antigen Der 
Pl, in vitro T cell nonresponsiveness was equally induced by either of 3x lµg, 
lOµg, or 100 µg of Der Pl or the peptide representing a dominant epitope 
(Hoyne et al, 1993). In the Lewis rat model of EAU, intranasal doses of retinal 
extract ranging form 4.2mg-4.2µg per day for 10 days appeared to inhibit disease 
to a similar extent. Below that dose, rats were less well protected (Dick et al, 
1993). In the H-2u mouse model of EAE, a single intranasal dose of lOOµg Acl-11 
or the 4A and 4Y analogues administered 7 days· before immunization was 
appropriate to inhibit EAE and -as shown for 4Y- to abrogate in vitro T cell 
proliferation (chapter 5). However, preliminary experiments applying the same 
protocol to other models provided no evidence for tolerance. A single dose of 
lOOµg OVA 323-339 or 2 mg OVA administered intranasally did not reduce T 
cell proliferation in response to OVA (not shown). Preliminary attempts to 
induce tolerance by intranasal administration of encephalitogenic peptides in 
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another mouse model of EAE were.unsuccessful (David Wraith, unpublished 
observations). Therefore, even in the absence of adjuvants, an effective dose (and 
appropriate timing) capable of inducing tolerance by the oral or intranasal route 
appears to be characteristic for each antigen and experimental model. 
7.2 MUCOSAL VERSUS PERIPHERAL MECHANISMS OF 
TOLERANCE 
7.2.1 Oral Administration Of Antigen 
Orally and intranasally administered antigens are encountered by lymphoid 
elements in the intestinal and respiratory tract, but they are also absorbed into 
the peripheral circulation, thus adding some complexity to attempts to evaluate 
the relative significance of local mucosal versus general peripheral contributions 
to tolerance induction. 
In oral tolerance to OVA, studies on the tolerogenic serum factor (TF) 
suggested that both the generation and action of TF might be independent of 
GALT (discussed in chapter 3). If TF induced regulator cells as concluded from 
the ability to abrogate tolerance in serum recipients by CY-treatment, then these 
putative suppressor cells were also GALT-independent. On the other hand, 
transfer of spleen cells but not OVA-fed serum inhibited subsequent antibody 
responses in recipients. Together, these observations suggest that oral 
administration of OVA generates more than one type of regulator mechanism, 
one of which is GALT-independent and induced by TF, but confined to cellular 
immune responses such as DTH, whereas direct feeding may induce regulator 
cells that are present in the spleen seven days after feeding, and which are also 
capable of downregulating humoral immune responses. In contrast, neither 
spleen cell transfer from donors fed with OVA one week before nor transfer of 
OVA-fed serum (containing both TF and SF) by the i.v. or i.p. route could 
substitute for direct oral administration of OVA to inhibit secondary in vitro T 
cell proliferation. In chapter 3, we argue that the failure to reduce T cell 
proliferation by feeding OVA peptide 323-339 aione is not easily reconcilable 
with a concept of direct T cell anergy as the only mechanism for this in vitro 
phenomenon of oral tolerance. If the preliminary data obtained from the in vivo 
CD8 depletion experiment hold up, then CDs+ regulator cells might not be 
involved at early stages after OVA feeding. However, the ability to show some 
inhibitory effect on T cell proliferation by the transfer of MLN cells 2-4 days after 
OVA feeding implies a role for an early GALT-derived regulatory cell 
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(Challacombe & Tomasi, 1980). These findings together with results presented in 
chapter 3 and other reports that failed to provide evidence for suppression in 
vitro or upon spleen cell transfer suggest that the in vitro phenomenon of 
reduced T cell proliferation after OVA-feeding might reflect the outcome of a 
GALT-dependent regulatory mechanism that takes place at an early time point 
after feeding. 
Although TCRyo+ T cells represent a predominant population of 
intraepithelial lymphocytes in the gut, their strikingly different mode of 
maturation, antigen recognition, and MHC restriction compared to TCRa.!3+ T 
cells (discussed in chapter 1) makes them unlikely candidates for suppressor 
cells in oral tolerance. To our knowledge, there is only evidence for a role of 
CD4+ or CDS+ TCRa.!3+ regulator cells in oral tolerance. These may arise from 
GALT, but presumably from PP and/or MLN rather than the gut epithelium. 
Transfer of PP - or spleen cells from OVA-fed donors inhibited OVA-specific IgE 
and IgG titres in recipients. (Ngan & Kind, 1978). Oral tolerance to SRBC 
inhibited both the number of plaque forming cells (PFC) and DTH responses in 
fed ra s. In this model, the significance of suppressor cells was demonstrated by 
the ability of PP-, MLN-, spleen- or thymic cells from SRBC-fed donors to reduce 
the number of PFC in vitro. Kinetic studies suggested a migration pattern of 
suppressor cells form GALT to peripheral lymphoid tissues and to the thymus. 
Two days after feeding, suppression of PFC was observed with cells form PP 
and MLN, but not with thymic or spleen cells. In contrast, 4 days after feeding, 
suppressor cells were present in the spleen and thymus, but no longer in PP and 
MLN (Mattingly & Waksman, 1978). As discussed in chapter 4, oral tolerance in 
the Lewis rat model of EAE was attributed to CDs+ T cells in mesenteric lymph 
nodes and spleens from MBP-fed animals which conferred protection from EAE 
in recipients, and inhibited proliferative responses in vitro (Lider et al, 1989). 
Subsequent studies revealed TGF-13 as a major inhibitory lymphokine to account 
for specific suppression as well as for the ability to mediate suppression to a 
second antigen in.a bystander fashion (Miller, Lider & Weiner, 1991; Miller et al, 
1992a). Similarly, oral tolerance to the hapten trinitrochlorobenzene (TNCB) in 
mice was also mediated by suppressor cells in GALT and spleen that produced a 
nonspecific soluble suppressor factor upon TNCB-specific activation. However, 
this form of immune regulation was not confined to antigen feeding but was also 
observed after i.v. injection of TNBC (Gautam & Battisto, 1985). Furthermore, the 
dose dependence of orally administered antigen to induce either suppressor-
mediated regulation at low doses or suppressor-independent tolerance at high 
doses (Gregerson, Obritsch, & Donoso, 1993, discussed in chapter 4) was 
observed as early as 1979 in elegant studies by Sherr et al for i.v. injected antigen 
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coupled to splenocytes. In these experiments, i.v. injection of lng of a palmitoyl 
derivative of fowl "tglobulin (p-F)C) coupled to 103 spleen cells induced a form 
of tolerance that was transferable after a minimum of 7 days and could be 
abrogated by CY-treatment. Analogous to what was later referred to as 
bystander suppression, recipients of spleen cells from F)C-nonresponsive mice 
(as assessed by DTH to F)C and PFC r~sponses to TNP-F)C) also showed 
suppressed TNP-specific responses when immunized with TNP-KLH provided 
that F)C was added to the inoculum, thereby demonstrating that the activity of 
F)C-induced suppressor cells was non-specific but not manifest unless the 
suppressor cells were exposed to the antigen used for their induction. 
Alternatively, at least 106 antigen-coupled splenocytes were required to induce 
nonresponsiveness at an early stage 3 days after i.v. injection. Under these 
conditions, tolerance could not be transferred and was not inhibited by CY-
trea tment, suggesting a direct, Ts-independent mechanism (Sherr et al, 1979). 
Together, these studies suggest that the induction of a suppressor mechanism 
characterized by low dose stimulation and a nonspecific effector component 
may ensue from but is not restricted to the intragastric route of antigen 
administration. 
However, while in some models, high dose feeding prevented the induction 
of suppressor cells, this did not seem to apply to the mouse model of oral 
tolerance to OVA. An oral dose of 20 mg OVA can probably be regarded as high. 
Yet, as discussed in chapter 3, feeding this dose was appropriate for the 
induction of regulator cells as well as for phenomena of T cell 
nonresponsiveness consistent with anergy. It is therefore possible that in this 
model, doses of orally administered antigen suitable to induce either 
suppression or anergy overlap, so that both mechanisms can be induced under 
the same experimental conditions. 
Although orally administered antigen may lead to T cell anergy under some 
conditions, it is not clear whether anergy is induced within GALT or in 
peripheral lymphoid organs upon antigen absorption into the general 
circulation. The only successful attempt to induce oral tolerance to EAE in PL/J 
mice was made with high doses (3xlmg) of the highest affinity analogue Ac1-
9[4Y] (chapter 4). This did not prove but was consistent with the induction of T 
cell anergy favoured by high avidity TCR-MHC-peptide interactions. In chapter 
4 we argue that with these high oral doses of a single peptide, it is likely that a 
considerable amount of peptide gained access to the periphery, although this 
does not exclude that encephalitogenic T cells were also rendered nonresponsive 
within GALT. However, if high avidity interaction of the trimolecular complex 
were a sufficient criterion for anergy induction, then it would be difficult to 
I 
11 I 
122 
understand why the same amounts of orally administered OVA 323-339 peptide 
failed to downregulate T cell proliferation (chapter 3). This peptide was shown 
to form stable complexes with I-Ad (Buus et al, 1987), and should therefore fulfil 
the requirement to mediate high avidity interactions. The strong proliferative 
responses to OVA 323-339 exclude the possibility of inefficient TCR interactions 
with OVA 323-339-I-Ad complexes. However, this peptide also failed to induce 
nonresponsiveness by inhalation (not shown), in sharp contrast to Acl-9 and its 
analogues (chapter 5). One might speculate that T cells specific for Acl-9 and 
OVA 323-339 somehow differ in their biochemical make-up even before an 
encounter with their respective antigens in the periphery. As discussed in 
chapter 1, Acl-9 might represent a naturally processed epitope which, as part of 
the trimolecular TCR-MHC-peptide complex, does not reach the avidity 
threshold for negative selection. In this case, although T cells specific for Acl-9 
escape deletion in the thymus, they might nevertheless be biochemically 
"stamped" by a cognate antigenic encounter within the thymus. As a 
consequence, they might be more readily downregulated as mature T cells than 
those T cells with specificity for non-self molecules such as OVA 323-339 that 
were not presented for negative selection. 
To conclude, oral tolerance does not appear to operate by mechanisms that 
are confined to GALT, and that could not principally also be induced by 
peripheral antigen administration in some models under appropriate 
experimental conditions. This does not exclude, however, that in certain models 
such as oral tolerance to OVA, the oral route of antigen administration may 
induce tolerance more efficiently and/ or a wider range of mechanisms than 
could be achieved by a peripheral encounter of antigen alone. 
7.2.2 Intranasal Administration Of Peptide 
The data presented in chapter 5 show a positive correlation between the 
affinity of intranasally applied peptide (Acl-9 or 1-11 and the 4A and 4Y 
analogues) and the degree of protection from EAE. Bystander effects to the 
subdominant epitope MBP 35-47 after priming with SCH are possible. However, 
the above finding suggests that initially, a direct (suppressor-independent) 
tolerogenic effect on encephalitogenic T cells favoured by high avidity TCR-
MHC-peptide interactions plays a predominant role in this model. The 
underlying mechanism might therefore largely operate by T cell anergy, and 
possibly also by deletion. As discussed in chapter 1, anergy and deletion were 
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frequently observed after peripheral antigen administration (i.v. or i.p.) in a 
tolerogenic form ( soluble, or in IFA, or coupled to fixed APCs so as to abrogate 
costimulation). On the other hand, it is possible that peptide presentation by 
airway DC and pulmonary macrophages within the respiratory tract (discussed 
in chapters 1 and 5) may also induce direct T cell nonresponsiveness. 
The question as to the significance of tolerogenic mechanisms within the 
respiratory tract remains open and needs to be addressed in future studies. 
However, there are now recent preliminary data to suggest that a significant 
amount of intranasally administered peptide is indeed absorbed into the 
periphery, and gains access to the thymus. In TCR V~8.2 PL/J transgenic mice, 
inhalation of Ac1-9[4Y] appeared to reduce the population of double positive 
cells in the thymus (Heather Pope & David Wraith, unpublished data). Although 
the functional significance of this observation remains to be established, it 
suggests that the intranasal route of peptide administration allows peptide to 
gain access to the periphery and the thymus. 
In order to assess the relative contributions of the respiratory and peripheral 
lymphoid organs, a direct comparison of intranasally versus i.v. administered 
peptide will be necessary. However, recent experiments investigating the effect 
of i. p. injected peptides in the same model revealed very similar results. A single 
i.p. dose of lOOµg Acl-9 and the 4A and 4Y analogues 1 week prior to priming 
downregulated the encephalitogenic capacity of T cells with a direct positive 
correlation between peptide-MHC affinity and the degree of protection from 
EAE as well as the reduction of in vitro T cell proliferation (George Liu & David 
Wraith, submitted for publication). Furthermore, the i.p. route of peptide 
administration in transgenic mice also reduced the percentage of double positive 
cells among thymocytes (Paul Fairchild, George Liu, and Richard Smith, 
unpublished data). 
If most or all of the N-terminal peptide of MBP exerted its tolerogenic effect 
in the periphery upon intranasal administration, a very recent publication might 
shed more light on the possible mechanism. In these studies, Kearney et al 
monitored the impact of peptide on the fate of a limited number of transferred 
transgenic T cells specific for OVA 323-339 in normal syngeneic recipients. After 
s.c. administration of peptide in CFA, these T cells ac·cumulated and proliferated 
within the paracortex of draining lymph nodes, and were subsequently also 
detected within follicles. In contrast, after i.v. or i.p. injection of soluble peptide, 
specific T cells transiently accumulated and proliferated in all lymphoid tissues, 
but with faster kinetics and without entering follicles . Furthermore, at a later 
stage, when the majority of T cells had disappeared from the lymph nodes, the 
few remaining T lymphocytes were more sensitive to restimulation with peptide 
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after s.c. injection of peptide in CFA (compared to naive transgenic T cells), 
whereas i.p. or i.v. administration of OVA 323-339 left a small population of 
hyporesponsive cells that was refractory to further antigenic stimulation both in 
vivo and in vitro (Kearney et al, 1994). 
It is conceivable that peptide inhalation triggered a similar sequence of 
events. Acl-9 given by inhalation might have induced early and transient 
proliferation of encephalitogenic T cells, leaving a small population of these T 
cells which would then be refractory to further stimulation by subcutaneously 
injected antigen (Acl-9 or SCH) in CFA. In this case, rather than anergy alone, 
the concept of anergy / deletion through activation speculated to be a possible 
mechanism by which the 4Y peptide operated when given after EAE induction 
(chapter 6) would also apply to peptide inhalation prior to immunization. 
In summary, there is some indirect evidence to suggest that peptide 
administered intranasally under the conditions applied to all experiments 
presented in this thesis (chapters 5 and 6) is absorbed into the periphery, where 
it may induce immunological nonresponsiveness of encephalitogenic T cells. The 
observation that intranasally or i.p. administered peptide may have an impact 
on thymocytes raises the question as to what extent these peptides also 
contribute to central tolerance in immature T ly,mphocytes. However, there is 
no evidence against a role for inhibitory mechanisms within the respiratory tract 
itself. 
7.3 ORAL VERSUS INTRANASAL ANTIGEN 
ADMINISTRATION 
GALT and BALT display striking morphological similarities, yet their 
ultrastructure and cellular composition appear to differ (discussed in chapter 1). 
With respect to antigen presentation, several studies suggest that intragastric 
administration ~f soluble protein does not compromise the function of APC 
directly. Intestinal DC could bind antigenic fragments derived from fed protein 
and activate naive T cells in vivo upon transfer (Liu & MacPherson, 1993). 
Furthermore, macrophages derived from PP presented orally administered 
antigen to primed T cells in vitro (Richman et al, 1981). To our knowledge, there 
is no evidence that the immunosuppressive properties shown by Holt and co-
workers for airway and lung DC and macrophages (discussed in chapters 1, 5, 
and 7.1) also apply to intestinal APC. A common feature of both gut and lung 
DC is a higher turnover rate compared to epidermal Langerhans cells, which 
subsequently give rise to the DC population within lymphoid organs (Holt et al, 
125 
1994; reviewed in Fossum, 1989). The significance of this higher turnover rate of 
mucosa! DC for the induction of mucosa! tolerance is not clear. A recent report 
demonstrating rapid DC recruitment at mucosa! sites as a reaction to an 
inflammatory response (McWilliam et al, 1994), suggests, however, that it might 
be an adaptation to strong antigenic challenges, and hence important for 
immune surveillance rather than immunological tolerance. 
Both the oral and intranasal routes of antigen administration can lead to the 
inhibition of DTH-and inflammatory autoimmune reactions characteristic of 
TH1 types immune responses in rat and mouse models. One might argue that 
direct intranasal as opposed to small droplet-sized aerosol antigen 
administration downregulates TH1 responses by peripheral rather than 
mucosal-associated mechanisms. As pointed out in the previous section, there is 
now indirect evidence to suggest that the tolerogenic effect of intranasally 
administered Acl-9 (and analogues) may to some extent be accounted for by 
peptide absorption into the periphery. In other reports such as on intranasal 
administration of Der P1(Hoyne et al, 1993) and retinal antigens (Dick et al, 
1993) the question of peripheral versus mucosa! mechanisms was not directly 
addressed. In an early study, however, direct intratracheal instillation of soluble 
metal salts inhibited specific DTH responses to these salts. Intubation of Evans 
blue by the same route revealed that the dye penetrated throughout the lung 
(Parker & Turk, 1978). This finding does not necessarily argue in favour of 
pulmonary mechanisms to inhibit DTH responses, since antigens may readily be 
absorbed through the whole of the respiratory tract (discussed in chapter 1). It 
does suggest, however, that tolerance to TH1 type responses is not confined to 
intranasal antigen administration by which a high proportion of antigen may 
bypass pulmonary tissue and be directly absorbed into the periphery. 
Both feeding and inhalation of antigen was shown to induce CDs+ and/ or 
CD4+ regulator cells, depending on the experimental model. In one study, 
aerosolized OVA induced IFNy-producing CDS+ T cells to abrogate a CD4+-
mediated OVA-specific IgE response. This was interpreted as immune deviation 
from a TH2 response (McMenamin & Holt, 1993). In the Lewis rat model of 
EAU, the data supported a concept of CD4+ suppressor T cells (Gregerson, 
Obritsch, & Donoso, 1993) while oral tolerance to EAE. in the Lewis rat induced 
TGF-~ producing CDs+ T cells. In the latter model there was also some evidence 
for immune deviation towards a TH2 response. Immunohistology of brain 
samples revealed reduc:;ed expression of inflammatory lymphokines such as 
IFNy and TNFa in MBP-fed rats compared to controls. Furthermore, as 
mentioned in section 7.1, oral administration of LPS together with MBP had a 
synergistic protective effect. In this case, brain sections also showed 
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upregulation of PGE2 and IL-4, implying activation of TH2-specific immune 
reactions. It is therefore possible that in some models, antigen inhalation might 
favour immune deviation towards a THl response, whereas intragastric 
administration might selectively downregulate THl and also activate TH2 
responses under appropriate conditions, such as in the presence of LPS. These 
findings, however, do not reflect general rules of immune regulation as a 
consequence of feeding or inhaling antigen. In oral tolerance to OVA, 
suppression of IgE and IgG titres as well as DTH responses suggested 
downregulation of all T cell-mediated functions (discussed in chapter 3). The 
data presented in chapter 3 (table 2) provide no evidence for immune deviation 
in this model of oral tolerance. Furthermore, as discussed before, the ability to 
downregulate inflammatory autoimmune reactions by intranasal antigen 
administration shows that mechanisms other than deviation towards THl 
responses are possible by the respiratory route. 
If fed or inhaled antigens exert their inhibitory effect largely in the periphery 
rather than GALT and BALT, then the respiratory tract is probably a far more 
effective route of delivering antigens to the periphery than the oral route. This 
might explain the finding that in contrast to oral administration of Acl-9 and its 
higher affinity analogues (chapter 4), the intranasally applied peptides induced 
profound immunological nonresponsiveness (chapter 5). This is not surprising, 
since secretions and proteases within the gastrointestinal tract presumably 
hamper effective absorption. 
To conclude, it is possible that differences between GALT and. BALT favour 
different modes of immune regulation under some conditions. Presumably, 
however, these differences are not always the cause of distinct mechanisms for 
tolerance. Rather, the wide range of phenomena observed in numerous studies 
on oral and inhalation-induced tolerance might largely depend on the 
experimental models themselves, and the protocols for antigen administration. 
7.4 CONCLUSIONS AND FURTHER STUDIES 
The following conclusions can be drawn from the data presented in this 
thesis. 
1. In the Balb / c mouse model of oral tolerance to OVA, feeding 20 mg OVA 
prior to priming with OVA or the major immunogenic, I-Ad-restricted peptide 
323-339 of OVA reduced specific in vitro lymphocyte proliferation in response to 
OVA or OVA 323-339 by 40-80% compared to PBS-fed controls. Transfer 
experiments with spleen cells or serum from OVA-fed donors under conditions 
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previously shown to suppress DTH responses in recipients, could not substitute 
for direct OVA feeding to achieve this effect. However, oral administration of 
OVA 323-339 alone did not reduce subsequent T cell proliferation, as might have 
been expected, if a direct epitope-specific mechanisms such as T cell anergy 
alone could account for the downregulation of proliferative T cell responses. The 
inhibition of both IgGl and IgG2a levels after OVA feeding argues against 
immune deviation towards TH2 responses as a relevant mechanism in this 
model. 
To understand the mechanism by which oral administration of OVA accounts 
for the in vitro phenomenon of reduced T cell proliferation, further studies need 
to address the requirements for distinct OVA epitopes and regulatory cells in 
more detail. These experiments should involve selective depletion and transfer 
of CD4 + and CDS+ T cells as well as oral administration of both MHC class II 
and class I-restricted peptides under various conditions. 
2. In contrast to oral tolerance to OVA, there was no evidence for oral 
tolerance in the H-2u mouse model of EAE when either whole porcine MBP, 
mouse myelin, or the dominant epitope of MBP Acl-11, and the higher affinity 
analogue 4A were fed prior to EAE induction. The time frame for feeding and 
the effective doses relative to the body weight were comparable with previously 
applied protocols for oral tolerance in the Lewis rat model of EAE and EAU, 
showing both T cell-mediated suppression and suppressor-independent 
mechanisms of nonresponsiveness. Complete abrogation of in vitro T cell 
proliferation and EAE after oral administration of 3 mg of the-4Y peptide 
showed, however, that encephalitogenic T cells could be tolerized by peptide 
feeding, most probably independently of CDs+ T cells. These studies need to be 
extended to cover a wider range of antigen doses and timing for feeding 
(preferably pure recombinant murine) MBP, Acl-9, and both higher affinity 
analogues 4A and 4Y. 
3. Unlike oral administration, a single intranasal 100 µg dose of Acl-9 (or 
Acl-11) and the higher affinity analogues 4A and 4Y inhibited EAE induced 
with Acl-9 alone or whole SCH. The ability to induce nonresponsiveness with 
this I-Au-restricted peptide alone and the positive correlation between peptide-
MHC class II affinity and the degree of protection argue against a role for CDS+ 
T regulator cells. Instead, the data are consistent with a direct epitope-specific 
mechanism favoured by high avidity TCR-MHC-peptide complexes. Although 
peptide inhalation also protected against SCH-induced EAE, co-immunization 
experiments using Acl-9 and 35-47 of MBP provided no evidence for bystander 
regulation in this model. However, other data not presented here suggest that 
immunization with whole myelin (rather than a mixture of peptides) after 
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inhalation of the dominant epitope Acl-9 may reveal downregulation of the 
response to the subdominant epitope 35-47 in a bystander fashion. Clearly, 
intranasally administered peptides can also modulate the functions of 
encephalitogenic T cells after the induction of EAE with SCH. Under these 
conditions, however, the effect of inhaled peptide is not yet predictable, but 
appears to depend on the activation state of T cells and perhaps also varying 
precursor frequencies. Significantly, however, data from several experiments 
suggest that inhalation of the 4Y peptide, and, to some extent also the 4A 
analogue, may render mice refractory to relapses. 
Further studies need to address three major issues. 1) The significance of the 
respiratory tract for the induction of tolerance after intranasal administration of 
peptide. Experiments using labelled 4Y peptide are planned to identify relevant 
APC populations for peptide presentation. T cell stimulation experiments in 
vitro and transfer studies with DC and macrophages purified from the 
respiratory tract will address the relevance of these APC for tolerance induction. 
Additionally, the transgenic model will enable us to locate T cells upon peptide 
inhalation under various conditions. 2) The potential to induce bystander 
inhibition to subdominant epitopes upon inhalation of a dominant epitope has 
to be investigated in more detail. Active bystander regulation mediated by 
(presumably CD4+) regulator T cells may be revealed in transfer studies with 
cells from peptide-treated donors. It may be possible to demonstrate lack of 
bystander help if MBP or Acl-9 could be modified so as to abrogate processing 
and presentation and/ or T cell recognition of this dominant epitope. 3) On a 
cellular level, the effect of peptide on the activation state of T cells should be 
studied. This will be crucial to predict an effective application of peptide after 
EAE induction, and will also provide information about the mechanism by 
which peptide acts upon naive T cells (i.e. before EAE induction) at a 
biochemical level. This issue as well as the questions of epitope specificity and 
the potential for bystander regulation should be investigated in a chronic-
relapsing model · of EAE such as in BIOZZI mice which probably provides a 
more faithful representation of the human autoimmune condition in multiple· 
sclerosis. Here, peptide inhalation between two phases of disease should 
demonstrate whether previously activated T cells' can be prevented from 
inducing relapses and, furthermore, whether spreading to epitopes other than 
the dominant initial disease-inducing autoantigenic fragment can be prevented 
by intranasal administration of the immunodominant peptide alone. 
Once detailed knowledge of the mechanism allows us to predict the effect of 
inhaled antigens on the immune system, this method of antigen-specific immune 
intervention might prove a convenient and efficient strategy to enforce an 
129 
interpretation of those antigens as being innocuous that were erroneously 
attacked as detrimental. 
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